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Spinal cord injury (SCI) results from a mechanical primary injury that is 
followed by a multifactorial secondary injury which worsens the clinical 
course. Persistent inflammation is a crucial event during the secondary 
injury. Indeed, microglia/macrophage respond to traumatic stimuli by 
adopting an activated phenotype, which has a dual role. An M1 
phenotype, associated with harmful effects, is expressed very early and 
persists for a long time in the injured site, whereas M2, associated with 
a beneficial phenotype, has only a transient expression in a subacute 
phase of the trauma. This suggests that microglia/macrophage 
mediated inflammation is a crucial therapeutic target.  
Nanoparticles (NPs) are selectively engulfed by microglia/macrophage 
as part of their endocytic/phagocytic activity in removing foreign bodies. 
Microglia assume phagocytic activity after traumatic stimuli and this 
makes NPs an excellent tool for carrying drug to these cells. So, in 
order to counteract this deleterious pro-inflammatory response, we 
decided to maximize the efficacy of a well-known anti-inflammatory 
drug, minocycline, through a NPs delivery tool selectively targeted to 
microglia/macrophage. We developed and tested a new drug delivery 
nanocarrier (minocycline loaded in poly-ε-caprolactone NPs, PCL Mino) 
in vitro and in vivo. Specifically, we demonstrated a reduced activation 
of microglia/macrophage after PCL Mino treatment in vitro and a 
reduction of cells with phagocytic-like phenotype, up to 15 days tested 
in vivo. To clarify the involvement of the inflammatory response 
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associated to microglia/macrophage in SCI progression, we treated SCI 
mice in acute and subacute phase. PCL Mino treatment, only when 
administered acutely after the damage, was able to ameliorate the 
locomotor activity up to 63 days post injury. Furthermore, we 
demonstrated that this treatment reduced M1 macrophages recruitment 
orchestrated by activated microglial cells via CCL2 chemokine in the 
damaged site, suggesting a deleterious effect in the early phase of the 
injury of these cells.  
In conclusion, this delivery tool represents a new hope for SCI 
treatment by showing several advantages compared to conventionally 
administered anti-inflammatory therapy, such as maximization of 
therapeutic efficiency and reduction of side effects. Furthermore, the 
potential of transfer to clinical practice is aided by the large clinical use 
of minocycline and the high biocompatibility of the proposed NPs. 
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GENERAL INTRODUCTION 
 
Spinal Cord Injury (SCI) represents the most frequent disabling injury 
between the diseases of the spine. An estimated 2.5 million people 
worldwide live with SCI and more than 180,000 new injuries are 
reported each year (Lee et al.; 2014). As a consequence of the injury, 
severe impairments or loss of motor and sensory function arise leading 
to tetraplegia or paraplegia (Becker et al.; 2003). Therefore, SCI has a 
great impact on the quality of life of the affected persons and also 
represents a heavy burden for the society in terms of loss of income 
and healthcare costs. Specifically, the devastating consequences 
following SCI are the outcome of a two-step process that initiates with a 
mechanical insult to the spinal cord (primary injury) and is followed by 
a wide spectrum of different events (extending from massive 
neuroinﬂammation reactions to the formation of a glial scar that inhibits 
axonal regeneration) that is called secondary injury (Borgens et al.; 
2012). Because of the different neuropathological aspects that 
characterize secondary injury, SCI is classified as a multifactorial 
disease. To the present, high dose methylprednisolone (MP) 
administration is still the only recommended neuroprotective route to 
prevent further secondary injury damage (Sayer et al.; 2006). 
Unfortunately, the systemic high dose of MP also seriously aggravates 
adverse side effects such as wound infections, pneumonia and acute 
corticosteroid myopathy (Baptiste et al.; 2007) limiting the drug’s 
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neuroprotective potential. Furthermore, it is demonstrated that MP 
shows only modest overall improvements in the neurological functions 
(Chvatal et al.; 2008). So, new therapies are still required to treat 
efficaciously the SCI pathology. 
Much evidence shows that acute and chronic inﬂammation is implicated 
in the development and exacerbation of the secondary injury phase 
contributing negatively on outcome in SCI 
Specifically, activation of microglia/macrophages and the associated 
inﬂammatory response appears to be a self-propelling mechanism that 
leads to progressive neurodegeneration. Therefore, microglia/ 
macrophages are considered a crucial therapeutic target after SCI and a 
selective treatment of this cell population could represent an interesting 
strategy to counteract the spreading of the secondary injury. 
Contextually, targeted drug delivery nanoparticles (NPs) could be a 
promising approach in term of selectivity, improved drug efficacy and 
reduced side effects. Indeed, NPs for biomedical applications has 
acquired a great importance in recent years representing a primary 
vehicle for drug delivery into phagocytic cells, such as activated 
microglia/macrophages. 
In the present study, it will be characterized the use of a nanovector 
drug delivery system able to modulate the inflammatory reaction. In 
particular, a nanoparticle system composed of poly-ε-caprolactone and 
polyethylene glycol (PCL) will be loaded with a well-known anti-
inflammatory drug, minocycline, to perform a targeted anti-
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inflammatory therapy addressed to modulate microglia and 
macrophages activation. The proposed treatment will be also useful to 
clarify the involvement of the inflammatory response related to the 
activated microglia/macrophages during SCI progression
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1. SPINAL CORD ANATOMY 
 
The central nervous system is composed of the brain and the spinal 
cord (SC).  
SC is the seat of recruitment, processing and transmission of 
information and provides a means of communication between the brain 
and the peripheral nerves. 
The SC is made of a thick bundle of neurons and resides in the vertebral 
column, the latest composed of individual vertebrae, which acts as a 
protective barrier. SC has a cylindrical shape, with an average diameter 
of 8-10 mm, and extends from the foramen magnum at the base of the 
skull, seat of the first cervical vertebra (atlas), proceeding from the 
medulla oblongata up to the first lumbar vertebra (L1) (human) or the 
fourth (L4)(mice). Indeed, SC does not occupy the vertebral canal for 
its entire length, even though at the level of the sacrum there is the 
sacral cord, with a similar structure. At that level, the SC is cone-
shaped (medullary cone) and continues caudally as a thin fibrovascular 
structure surrounded by the nerves of the cauda equina, anchoring the 
coccyx. SC is divided into several regions: cervical, thoracic, lumbar, 
sacral and coccygeal. Sensory information, carried by afferent axons of 
peripheral nerves, penetrates into the spinal cord via the dorsal roots. 
The motor functions, conveyed by the efferent axons, leave the SC 
through the ventral roots. Once the roots are joined, the sensory and 
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motor axons travel along and combine to form the spinal nerves, 
which exit the spine through the intervertebral holes. 
The spinal nerves innervate most of the body and emerge from the 
spinal cord in the form of 31 pairs (34 pairs in mice), one on each side 
of the SC. In Table 1 is schematically shown the subdivision of the 
nerves depending on the regions of the SC. 
 
 
 
 
 
 
 
 
 
 
Table 1. Subdivision of peripheral nerves 
 
The spinal cord is surrounded by the meningeal shrine, composed of 
three protective tissue membranes, which extends along the brainstem 
and the brain. Taken together, the three membranes are called 
meninges: the most outer layer of the meninges is called the dura 
mater, for its thickness and its consistency; the intermediate layer, 
arachnoid, is characterized by extensions branched off to reach the 
SC region Number of Nerves 
(human/mouse) 
Innervation 
cervical 8 Shoulder, hand, neck, 
arms 
thoracic 12/13 Thorax 
lumbar 5/6 Legs, hip 
sacral 5/4 Legs, glutex, anus 
coccygeal 1/3 Viscera, small basin 
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underlying layer; the third layer, the pia mater, is a thin and delicate 
layer of cells which envelop the entire surface of the bone marrow. The 
space between the arachnoid membrane and the pia mater is full of 
cerebrospinal fluid that helps protect the marrow. As the pia mater 
adheres strictly to the cord, the arachnoid membrane has some points 
of dilation, called cisterns. 
The main arteries that supply blood to the tissue run through the 
subarachnoid space, which for this reason is the bleeding site in case of 
trauma.  
Observing a coronal section of spinal cord, it is possible to detect the 
provision of the gray matter, inside, and white matter, outside. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Internal organization of spinal cord 
 
The white matter is organized in columns, called dorsal (or posterior), 
lateral and ventral (or anterior), each of which contains bundles of 
INTRODUCTION 
26 
 
myelinated axons with specific functions. The lateral columns are made 
up of axons which extend from the cerebral cortex until they contact the 
spinal motor neurons. The dorsal columns carry the ascending 
sensitivity information from the somatic mechanoreceptors. The ventral 
columns carry both ascendants information about the thermal 
sensitivity and descending motor information. 
The gray matter of the spinal cord, divided into dorsal and ventral 
horns, is constituted by neurons carrying signals capable of putting in 
connection neurons localized in different levels of the spinal cord and 
the brain. The dorsal horn neurons receive sensory information through 
dorsal roots of the spinal nerves. The preganglionic neurons of the 
visceral nervous system are located in an intermediate region between 
the dorsal horn and the ventral horn. 
The ventral horn contains the cell bodies of motor neurons that send 
axons to ventral roots reaching the striated muscles which are able to 
contract. The gray matter of the SC is divided into ten large groups of 
cells known as Rexed’s laminaes. Laminae I-VI are located in the dorsal 
horn, lamina VII is in the intermediate horn, and laminae VIII-X are in 
the anterior horn. 
Laminae I-IV are delegated to the reception of stimuli from the skin, 
lamina V receives axons from the skin, muscles and viscera, and lamina 
VI receives proprioceptive fibers. The extensions of afferent fiber 
entering the spinal cord are divided into ascending and descending 
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axons that are located in the Lissauer tract that divides the apex of the 
dorsal  horn from the back seam. 
 
Spinal circuits    
Motor activity is regulated by different groups of neurons, mutually 
linked by multiple synapses (Fig.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Organization of the nervous structures involved in mobility 
regulation (from Silva et al.; 2014) 
 
The first group of nerve circuits is located in the gray matter of the SC, 
which cells include α motor neurons that innervate the skeletal muscle 
fibers and interneurons of the SC. All motor commands are transmitted 
to the muscles only through the α motor neurons. The interneurons 
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receive both sensory afferents and descendants projections from the 
upper centers and provide much of the reflex coordination among the 
different muscle groups. 
The second group consists of descending pathways including the upper 
motor neurons, located in the brainstem and cerebral cortex, and able 
to connect interneurons and/or the α motor neurons. The descending 
pathways integrate the information necessary for the execution of 
elementary movements of the body government and postural 
adjustment. 
The third group consists of the cerebellum, having the main function of 
coordinating the activity of motor centers able to carry out complex 
movements. 
The other subset consists of the basal ganglia, important in the 
initiation of voluntary movements. The axons of motor neurons induce 
muscle contraction via neuromuscular junctions positioned between the 
muscle fibers and the motor neuron terminations. The release of the 
neurotransmitter acetylcholine stimulates the shortening of the muscle 
fiber. 
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2.  SPINAL CORD INJURY (SCI) 
 
Spinal cord injury is a disabling condition that affects sensory and motor 
functions and leads to devastating neurological deficits and impairment. 
SCI provokes the partial or total loss of sensory/motor capacity, leading 
to paraplegia or tetraplegia and other common problems such as 
frequent infections, cardiac and respiratory problems, vesical and bowel 
malfunction (Watson et al.; 2009). 
All of these problems have an enormous impact on the life of SCI 
patients and represent also a heavy burden for society in term of 
health-care cost. 
SCI affects about 180.000 new individuals each year for a total of 1,3 
million persons worldwide (Lee et al.; 2014). In Italy there are about 
70,000 people with spinal cord injury, of which 2/3 are younger than 60 
years, with incidence between 1,500 and 1,200 cases per year. The 
therapies available today only bring modest benefits to the quality of 
patients life, and are not able to completely restore the motor 
functionality. It is therefore crucial to find new therapeutic strategies for 
the treatment of SCI. 
 
2.1 Etiology 
SCI can be caused by traumatic or non traumatic events. 
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Trauma can break, displace or collapse one or more vertebrae. The 
bleeding, inflammation and accumulation of cellular infiltrates create 
further damage, complicating the clinical picture. Non-traumatic events 
which may cause a spinal cord injury are: arthritis, cancer, 
inflammation, infection or degeneration of the intervertebral discs. 
The most common causes of spinal cord injuries are accidents of various 
types (motor vehicle accidents, everyday falls, sports, work), as well as 
injuries from assaults (firearm wounds or scuffles). 
 
 
 
 
 
 
 
 
 
Figure 3. Causes of traumatic SCI 
 
 
2.2 Outcomes and symptoms of SCI 
Very often SCI leads to permanent paralysis and loss of sensibility 
below the lesion site, resulting in four main clinical pictures: paraplegia, 
quadriplegia, paraparesis, quadriparesis. 
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Paraplegia means a sensorimotor syndrome with lower limb paralysis 
and sphincter disturbances, while in quadriplegia are also added upper 
limb paralysis and neurodegenerative disorders; paraparesis and 
quadriparesis are respectively incomplete paralysis of the lower limbs 
and incomplete paralysis of four limbs. 
The degree of disability after SCI depends primarily on two factors: the 
level of neurological lesion and the completeness of the lesion. 
The neurological level of injury refers to the segment of the spinal cord 
caudal to the injury which preserves normal motor and sensory 
functions on both sides of the cord. If a patient, for example, has a 
normal sensibility at the C3 level, but the absence of sensibility at level 
C4, the neurological level is at C3. 
SCI can be classified as complete or partial: complete lesion describes a 
total loss, and usually permanent, of the ability to send sensory nerve 
impulses and start a movement and a complete loss of function below 
the level of the lesion. This causes complete paraplegia or quadriplegia. 
Partial SCI refers instead to partial spinal cord damage: in this situation 
some motor and sensory functions are maintained. 
The main symptoms resulting from a partial or complete SCI are: 
- Loss of motor functions. In addition to paralysis, people with SCI have 
muscle tone changes: spasticity can cause spontaneous contractions, 
while the flaccidity makes the muscles weak and soft, without muscle 
tone. 
- Loss of sensitivity, including the ability to feel heat, cold and touch. 
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Below the neurological level of the lesion, there is the loss of sensitivity 
of a part or all the skin. 
- Loss of bladder control that increases the risk of urinary tract 
infections and it can even cause urinary infections or the formation of 
kidney or bladder stones. 
- Loss of bowel control. The nervous system is no longer able to control 
the muscles that open and close the anus, causing fecal incontinence. 
- Exaggerated reflex activity or spasms. 
- Disorders of sexual activity and fertility. 
- Pain or a sensation of intense burning caused by damage to the nerve 
fibers in the spinal cord; allodynia is a type of neuropathic pain where a 
higher sensitivity to normally harmless stimuli is manifested. 
- Difficulty in breathing, coughing, or lungs secretion. There is also 
frequent involvement of abdominal muscles and chest. The neurological 
level of the lesion determines which type of respiratory problem the 
patient presents. Cervical and thoracic lesions present greater risks. 
- Circulatory problems. Injury increases the risk of blood clots, such as 
deep venous thrombi or lung emboli and, in some cases, can cause a 
permanent increase in blood pressure (autonomous hyperreflexia). 
 
The most common tool used by physicians to classify the neurological 
deficit and the extent of the injury is the ASIA scale, initially developed 
by Spinal Injury Association (ASIA) (Fig. 5). 
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The ASIA classification is based on a careful assessment which maps 
any sensory and motor function and includes five degrees that describe 
the severity of SCI: 
A = Complete: no motor-sensory function is preserved (below the 
level of injury, including the sacral segments S4-S5). 
B = Incomplete: the sensory function, but not the motor is kept below 
the level of injury (including the sacral segments S4-S5). 
C = Incomplete: motor function is preserved below the level of injury, 
and more than half of key muscles below this level have a muscle 
degree less 3. 
D = Incomplete: motor function is preserved below the level of injury, 
and at least half of the key muscles below this level have a muscle 
degree of 3 or more. 
E = Normal: motor and sensory functions are normal. 
 
The evaluation should be performed 72 hours after the lesion, as at this 
time prognostic values seem to be more accurate than those obtained 
in shorter times (Herbison and Theodosis, 1991). 
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Figure 4. ASIA scale 
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3. SCI IN EXPERIMENTAL ANIMAL MODELS  
Animal models offer the possibility to study the pathophysiological 
mechanisms of SCI and to test in vivo experimental therapeutic 
strategies, a fundamental step that precedes clinic application. Up to 
now, the use of animals is the only preclinical approach able to have a 
translational potential to the clinic. 
Rodents are by far the most widely used animal model as they have a 
number of clear advantages: reproducibility of the disease, low cost, 
easy to care for and ability to conduct large number studies, post-
surgical infections are rare. Well-established functional analysis 
methods, rodents are moderate size that allows one to easily perform 
behavioral and histological tests. 
In experimental animal models, three general classes of injury are 
frequently used: transection, contusion and compression 
(Rosenzweig and McDonald, 2004). 
Transection is induced by cutting the spinal cord following 
laminectomy. Because all the nerve fibers are severed, this model offers 
the advantage of easier evaluation of the therapeutic efficacy of 
treatments that promote axonal regeneration. The main disadvantages 
are that it reproduces a type of injury, complete transection, of rare 
clinical occurrence and, above all, the post-surgical care of transected 
animals is very difficult. 
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Incomplete transection (e.g. hemisection) is used for the evaluation of 
treatments aimed to re-grow and regenerate spared axons and for 
evaluating the correlation between anatomical changes and specific 
behavioral improvements. Hemisection preserves the integrity and 
function of one side of the cord, which reduces the need for 
postoperative care and provides an internal control on the side of the 
cord not damaged. At the same time, it makes it rather difficult to 
distinguish the benefits resulting from the therapeutic procedure being 
tested and those due instead to physiological reorganization (Zorner et 
al.; 2010). However, incomplete transection such as those produced by 
hemisection are rarely seen in human patients, so many researchers 
prefer to use compression and contusion injury models. 
The contusion and compression models present a neuropathological 
course and histological characteristics that reproduce those present in 
humans following trauma. In fact they trigger a series of biochemical 
processes that lead to a cell necrosis confined primarily within the SC, 
which correlates with the loss of mobility. 
Contusion is induced by hitting the exposed spinal cord with a blunt 
contusion force. The first contusion animal model was proposed in 1911 
by Allen: it was a weight dropped on the spinal cord of a dog previously 
submitted to laminectomy (Anderson, 1982). 
Subsequently, a wide range of methods have been developed over the 
years to induce injury into the SC via external contusion, in order to 
optimize the intensity, the duration and the accuracy of biomechanical 
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forces applied to obtain a reproducible lesion. Now this model is often 
obtained using an impactor, which consists of a device that delivers a 
weight (New York University impactor, Gruner et al.; 1992) or a 
solenoid (Ohio State University impactor, Behrmann et al.; 1992) to the 
SC, with a computer monitoring the impact. 
A recent computer-controlled contusion device is the Infinite Horizon 
(IH), which uses force instead of tissue displacement and is the first 
able to inflict reproducible injuries without touching the SC before the 
hit. 
The compression model was introduced by Rivlin and Tator in 1978, 
inducing injury by compressing the SC with a modified aneurysm clip 
(Rivlin and Tator, 1978). 
The compression model can create different degrees of SCI adjusting 
the compression strength and/or time. This model also mimics the 
human neuropathology. It begins with a spreading of hemorrhagic 
necrosis and edema, progressing to a phase of partial repair and 
reorganization up to a chronic phase with axonal atrophy and the 
formation of a glial scar. The clip compression model has provided 
valuable knowledge about the pathophysiology of SCI (Fehlings et al.; 
1989), and neuroprotective agents (Schwartz and Fehlings, 2001). 
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3.1 Assessment of recovery 
Behavioral analysis (motor and sensory), histological staining and 
electrophysiology are the most used techniques to evaluate functional 
and anatomical recovery. 
 
Behavioral evaluation: The most commonly used test to assess motor 
function after SCI is the Basso Mouse Scale (BMS) for mice or the 
Basso, Beattie and Bresnahan (BBB) locomotor scale for rats. Note that 
the locomotor recovery indices are not comparable between the two 
models. BMS consists of a 9-point scale divided into 3 main phases of 
motor recovery: an early phase based on ankle movement (0-2), an 
intermediate phase with plantar placing and stepping (3-5) and a late 
phase of recovery based on fine movements details (coordination, paw 
placement, stability, 5-9) (Basso et al.; 2006). 
BBB locomotor scale is a 21-point scale where 0 corresponds to no 
apparent movement and 21 represents a normal coordinated 
movement. Scores from 0 to 7 are related with recovery of isolated 
movements in the hip, knee and ankle. Scores from 8 to 16 are 
associated with plantar placement and coordination of forelimbs; from 
14 to 21 are evaluated paw and tail position, toe clearance and trunk 
stability (Basso et al.; 1995). 
In order to decrease the subjectivity of both tests, they should be 
performed by two independent researchers. 
Other tests able to evaluate the locomotor recovery after SCI are: 
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CatWalk: computer-assisted gait analysis useful to measure different 
dynamic parameters such as limb base of support, stride length, 
velocity, interlimb coordination (Hamers et al.; 2001). The major 
limitation is that animals must be capable of at least occasional plantar 
stepping. 
Horizontal ladder walking test: in this test the animal walks along a 
horizontal ladder with variable rung spacing. The frequency of mis-steps 
is calculated as the number of foot slips by each limb divided by the 
total number of steps. Also this test cannot be used in complete 
paralyzed animals (Metz and Whishaw, 2002). 
3D Analysis of musculoskeletal movement: with the use of several 
video cameras and reflective markers attached to the animal skin, it is 
possible to obtain a precise geometric locomotor profile of the animal 
and to detect fine motor improvements. Some disadvantages of this 
technique are costs, time and the lack of standardization (Zorner et al.; 
2010). 
 
The assessment of sensory function in rodents is usually performed with 
the hot plate test and Von Frey filaments test. 
The first evaluates the hind paw withdrawal latency from a radiant heat 
source, which is increased in the case of thermal hyperalgesia after SCI 
(altered perception of temperature) (Woolf and Thompson, 1991). 
The second test is used to evaluate the mechanical allodynia (increased 
sensitivity to innocuous stimuli caused by neuropathic pain). Filaments 
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are sequentially applied to the plantar surface of the limbs, with a 
pressure that causes a slight bend of the filament, until the withdrawal 
response is obtained. A positive reaction occurs when the paw is quickly 
removed away from the filament. This response may be associated with 
vocalization, flinching and/or abnormal aggressive behavior (Gris et al., 
2004). It is important to note that sensory tests are usually difficult to 
interpret as they virtually all depend on a motor end point that could, of 
course, be compromised by SCI. 
 
Anatomical analyses: immunohistochemistry provides knowledge 
about anatomic changes, pathophysiology and axonal regeneration. 
Specific markers are associated to specific hypothesis to be tested. 
Examples of biomarkers associated to SCI-related experiments are 
summarized in table 2. 
Marker Information about References 
NF  Axonal organization Kaneko 2006 
CD11b/OX42 Microglia Detloff 2008 
GFAP Astrocytes Liu 2010 
APC Mature Oligodendrocytes Karimi-Abdolrezaee 
2006 
MBP Myelin sheath Woerly 2001 
5HT Serotonergic Neurons Kaneko 2006 
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Table 2. Most popular biomarkers employed in SCI experiments (adapted 
from Silva et al.; 2014) 
 
Another helpful tool for identifying cellular populations involved in 
inflammation or regenerative mechanisms are transgenic mice 
expressing fluorescent labeling in specific CNS cells, such as neurons, 
microglia, and astrocytes. Indeed, the most definitive way of verifying 
axon regeneration is to document the process while it is happening. Live 
images of an axon re-growing from its injured tip could be considered 
as possible evidence of axon regeneration. In vivo imaging of single 
axons in the spinal cord requires animal models with appropriate 
fluorescent labeling. A widely used transgenic mouse line has been 
developed by Feng et al., in which different fluorescent markers are 
expressed under the Thy1 promoter in specific subsets of neurons. 
Using the GFP-S line of these transgenic mice, Kerschensteiner et al. 
described the response of lesioned ascending dorsal sensory axons 
through repetitive imaging in vivo (Kerschensteiner et al.; 2008). 
Again, by using CX3CR1-GFP mice expressing Enhanced Green 
Fluorescent Protein (EGFP) in brain and SC microglia under control of 
the endogenous Cx3cr1 locus, it is possible to evaluate the 
inflammatory response after SCI. 
 
NeuN Neuronal Nuclei  
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4. PATHOPHYSIOLOGY OF SCI 
 
The pathological events following acute SCI are divided into two broad 
chronological events: the primary injury and the secondary injury, 
due to the additional damaging processes initiated by the primary injury 
(Taoka et al.; 1998; Dumont et al.; 2001; Priestley et al.; 2012).  
The pathophysiological mechanism of SCI is more than a simple 
mechanical disruption of nerve transmission following injury. In addition 
to the primary lesion of the spinal cord, a multi-step cascade results in 
progressive enlargement of the injury, due to factors that include an 
inflammatory reaction, ischaemia, oedema, haemorrhage and 
cytotoxicity (Ronsyn et al.; 2008). Although there is little or no loss of 
interneurons and motor neurons in several segments beyond the injury, 
there are significant changes in their biochemical, and consequently 
physiological, properties (Petruska et al.; 2007; Button et al.; 2008; 
Roy et al.; 2012). Various studies indicate that there are strong 
correlations between human and rodent spinal injuries (Metz et al.; 
2000; Cheriyan et al.; 2014). The similarities between the human and 
rodent inflammatory response (Fleming et al.; 2006) and the 
morphological response (Norenberg et al.; 2004) after SCI permit useful 
translation to clinical use of treatments developed in animals. 
Experimental rat SCI models are also similar to the human SCI with 
respect to motor function recovery related to electrophysiological 
changes, such as motor evoked potentials and somatosensory evoked 
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potentials, and lesion size assessed using MRI examination (Metz et al.; 
2000). Thus, it is essential to use reliable animal models to assess the 
pathophysiological mechanisms of SCI and to investigate neuroplasticity 
in the intact spinal cord caudal to the lesion site.  
 
4.1 Primary injury  
 
The primary injury is represented by an immediate mechanical damage 
to the SC (contusion, compression, or laceration) that leads to a 
hemorrhagic zone of necrosis in the grey matter. Neurons and their 
axons become permeabilized acutely following injury due to 
compressive and shear forces. Animal studies have demonstrated that 
neurological impairment increases relative to the force of trauma and 
the duration of compression. Clinically, there are several types of 
primary injury. The most common mechanism involves impact with 
persistent compression (Tator, 1996). This happens in burst fracture 
with bone fragment compression of the SC, fracture-dislocation or disc 
rupture following injury. Another mechanism of primary injury is caused 
by flexion, extension, rotation or dislocation, producing shearing or 
stretching of the SC. This type of injury may be present without obvious 
radiological evidence of trauma, but it is common in adults with 
underlying degenerative spine disease (Tator, 1996). Sharp knife 
cutting and severe distraction leads to laceration and transection injury, 
which is another type of mechanism. This type of injury may occur to 
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varying degrees in SCI, from minor injury to complete transection. The 
primary mechanical injury is the starting point for additional secondary 
mechanisms of injury extend. Consequently, the damage can spread 
from the lesion epicenter to caudal and rostral segments. 
 
4.2 Secondary injury  
 
The mechanical injury leads to a cascade of neuropathological events 
and the secondary phase of the injury begins. This response of SCI can 
be divided into three phases, an acute phase, subacute phase and a 
chronic phase (Tator, 1995; Bareyre et al.; 2003).  
 
The acute phase represents the first 48 hours after injury and is a 
direct result of physical trauma to the nervous tissue that causes death 
of cells near the site of injury. The main cells involved are neurons, 
astrocytes, oligodendrocytes and endothelial cells. The death of the 
endothelial cells of local blood vessels causes bleeding, which alters the 
supply of oxygen and nutrients to the tissue, causing additional necrotic 
cell death. During the acute phase of the injury the body responds by 
activating the complement cascade and inducing a massive infiltration 
of neutrophils into the damaged site and in the adjacent parenchyma 
(Donnelly and Popovich, 2008). As a consequence, there is edema at 
the site of the SC lesion. The hemorrhagic area, initially confined to the 
gray level of the substance which is very vascularized, extends at a 
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later time (from minutes to hours) at the level of the white matter in 
the rostro-caudal direction. This event continues in the sub-acute phase 
and sometimes even for months during the chronic phase.  
The subacute phase develops within minutes and can last several 
weeks following injury, up to 6 months in humans. During this phase we 
are witnessing a worsening of the initial damage mainly due to the local 
inflammatory response. In addition, the cell death due to trauma 
increases the levels of amino acids, such as glutamate, the 
excitotoxicity contributing extra-cellular fluid, while high levels of 
calcium activate enzymes that damage cellular structures 
(phospholipase, protease). The microglial cells are activated and remain 
in this state for up to four months after injury. The lipid peroxidation 
and the formation of free radicals contribute to the necrosis of the 
tissue. There is also the infiltration of neutrophils (6-24 hours), 
macrophages (24 hours – 2 weeks) and T lymphocytes in the damaged 
tissue during the first week after injury (Bethea et al.; 2002). 
Oligodendrocytes and vulnerable neurons undergo apoptosis (Liu et al.; 
1997).  
The chronic phase, which persists throughout life, is characterized by 
the stabilization of the lesion through the formation of the scar that has 
the function of confining and separating the lesion from the damaged 
tissue. However, at the same time this prevents the regeneration of 
nerves. The scar is surrounded by fibroblasts, activated macrophages 
and glial cells and often surrounds a cyst or cavity (Bruce et al., 2000). 
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A progressive expansion of the lesion in more than one segment, a 
process called syringomyelia, can occur for months or years after the 
lesion, increasing the severity of the lesion and causing death in some 
cases. 
 
5. SPONTANEOUS FUNCTIONAL RECOVERY AFTER SCI  
 
The neuroplasticity of the CNS allows some degree of functional 
recovery after SCI. The process of learning, skill acquisition and in 
particular the response to an injury leads to neuronal reorganization, 
synaptic rearrangements, changes in neuronal activation pattern and 
axon collateral sprouting. Many studies show that functional recovery 
occurs in both humans and rodents, particularly after incomplete 
injuries (Weidner et al.; 2001; Tetzlaff et al.; 2009). This finding 
indicates that reorganization throughout the neuraxis can compensate 
for the disrupted pathways and rebuild a circuit for control of motion. 
Although this neuroplasticity has been related to spontaneous functional 
recovery (Onifer et al.; 2011), the underlying mechanisms are still 
largely unknown.  
 
5.1 Neuroplasticity following SCI  
Following injury, neurons are capable of mounting a transient 
regenerative response, as evidenced by the expression of regeneration 
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associated proteins and genes (Kruse et al.; 2011). The most commonly 
upregulated genes and transcription factors that are found to be 
associated with regeneration are: c-jun, activating transcription factor 3 
(ATF-3), heat shock protein 27 (HSP-27), growth associated protein–43 
(Gap-43), signal transducer and activator of transcription–3 (STAT3) 
(Sun et al.; 2010). Again the upregulation of molecules that contribute 
to axonal regrowth, such as neuronal calcium sensor-1 (NCS-1) (Yip et 
al.; 2010) and mammalian target of rapamycin (mTOR) (Liu et al.; 
2010), can induce compensatory sprouting from unlesioned nerve 
pathways. Furthermore, a number of the molecules that can guide 
growing axons in the developing nervous system are also present in the 
injured spinal cord (Jacobi et al.; 2014). These factors can support 
growing collaterals and initiate synaptogenesis during circuit 
remodeling. This indicates that the intrinsic growth program inherent to 
neurons is activated in response to injury; however, it is not sustained. 
 
5.2 Reorganization of descending pathways after SCI  
Recently, it has been recognized that spontaneous and treatment-
induced functional recovery is correlated with spared descending axons 
and myelin (Fouad et al.; 2001; Weidner et al.; 2001). It has been 
demonstrated by using electrophysiology and retrograde neurotracing 
(Bareyre et al.; 2004), that the new neuronal circuits make functional 
connections. Adult neurons in the CNS cannot regenerate over long 
distances, but axotomized neurons can form short sprouts from their 
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damaged axons (Fawcett et al.; 1998). The injury provides a stimulus 
for intact interneurons, white matter tracts and sensory neurons to 
replace inputs to the spinal neurons that have lost synapses. Collateral 
or regenerative sprouting of intraspinal axons after SCI may provide an 
opportunity to make new connections or to strengthen existing 
synapses on denervated spinal neurons (Brown et al.; 2012). A 
probable mechanism that leads to collateral formation is the 
upregulation of diffusible attracting factors by the denervated tissue. 
One study showed that the reorganization of corticospinal tract (CST) 
circuits is guided by brain derived neurotrophic factor (BDNF) secretion 
by the target interneurons. Furthermore, knockdown of BDNF in spinal 
neurons diminished the formation of new CST pathways (Ueno et al.; 
2012).   
 
5.3 Modulation of the synaptic transmission  
There are three different mechanisms able to alter neural activity: (1) 
modifying synaptic transmission at pre-existing synapses, (2) eliciting 
the growth of new synaptic connections or the pruning away of existing 
ones, or (3) modulating the excitability properties of individual neurons 
(Crupi et al.; 2013). SCI denervates spinal neurons by disrupting 
ascending and descending pathways to and from the brain as well as 
output to lower motor neurons. The loss of part or all synaptic inputs 
results in structural modifications in the number, size, and distribution 
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of synaptic contacts on interneurons and motor neurons (Raineteau et 
al.; 2001). One way that synaptic changes after SCI have been 
detected is by comparing the synaptophysin level in intact versus 
lesioned spinal tissues. (Nacimiento et al.; 1995). Synaptophysin is a 
protein within synaptic vesicles in the presynaptic terminal. The 
expression of synaptophysin is decreased after a spinal cord lesion, but 
the level recovers to normal after a few weeks. This finding suggests 
that new synapses form on motor neurons following SCI, and this 
formation could arise from interneurons or sensory afferents 
transmitting tactile and proprioceptive signals. The mechanism with 
strongest evidence in mediating changes within neuronal networks is 
the removal of GABAergic inhibition in excitatory synapses. Gamma-
aminobutyric acid (GABA) is the most important inhibitory 
neurotransmitter in the CNS and plays a “counter balance” role against 
enhanced synaptic transmission as a result of glutamate-mediated 
excitation of neurons following SCI. GABA has a presynaptic inhibitory 
action on primary afferents on postsynaptic membranes of interneurons 
and motor neurons (Alvarez et al.; 1996). After complete SCI, Roy and 
collaborators demonstrated that the GABAergic intracortical inhibitory 
circuit is reduced, resulting in altered inhibition during the post-lesion 
period (Roy et al.; 2011). These changes in synaptic efficiency and 
neurotransmission may be important during the period of post-lesion 
recovery and addressing these changes may be important for a 
successful therapy after SCI. 
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5.4 Reorganization of cortical areas  
Following traumatic SCI, axonal architecture is disturbed and the brain 
grey matter becomes atrophic (Jurkiewicz et al.; 2006; Freund et al.; 
2011; Henderson et al.; 2011; Rao et al.; 2013). Furthermore, in 
response to SCI, the sensorimotor cortex can undergo a dramatic 
reorganization. Remodeling of the S1 map correlates with tactile 
discrimination performance (Xerri et al.; 2005; Rao et al.; 2013), while 
different populations of cortical neurons in M1 cortex selectively 
contribute to the execution and regulation of movements during 
locomotion in cats (Drew et al.; 2002). This cortical reorganization is 
sometimes found to be compatible with functional recovery (Schmidlin 
et al.; 2004; Rao et al.; 2013). It was previously described that cortical 
territories controlling intact body parts tend to enlarge and invade 
cortical areas that have lost their peripheral targets (Qi et al.; 2000). 
Although the underlying mechanism of cortical reorganization is not well 
clarified, some studies have suggested that these events are partly due 
to changes in neuronal circuits, such as axonal sprouting (Bareyre et 
al.; 2004; Schmidlin et al.; 2004; Martinez et al.; 2010). 
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6. OVERCOMING THE LIMITED REGENERATION OF 
THE CENTRAL NERVOUS SYSTEM 
 
Unlike the peripheral nervous system (PNS), in which axons are able to 
regenerate after a lesion, in the CNS there is an almost total absence of 
nerve regeneration. In the literature it has been shown that neurons 
from PNS, able to regenerate in their district of residence, are not able 
to do equally well in the CNS lesion site level, while neurons from the 
CNS are able to regenerate at the lesion site in the PNS (Chong et al.; 
1996; Yiu and He; 2006), suggesting that an enabling environment is 
necessary for axon regeneration. 
In particular, the causes of this deficit appear to be: 
- an inhibitory external environment, characterized by the presence 
of inhibitory molecules produced by myelin and the glial scar; 
- a repression of intrinsic regenerative pathways (neurons), which 
is due to an adjustment of the RAG (Regeneration Associated Genes) 
and a lack of trophic factor production. 
 
6.1 Myelin Inhibition 
A specific inhibition of CNS regeneration has been related mainly to 
white matter rather than to grey matter (Savio et al.; 1989) and, in 
particular, to myelin associated-inhibitors (MAIs). The expression of 
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specific inhibitory proteins causes cytoskeletal rearrangements leading 
to growth cone collapse and inhibition of neurite growth.  
The first MAI discovered was the Myelin-associated glycoprotein (MAG) 
in 1994, from two different groups (McKerracher et al.; 1994; 
Mukhopadhyay et al.; 1994). However, myelin derived from MAG-
deficient mice is already inhibitory for axonal regeneration (Ng et al.; 
1996; Bartsch et al.; 1995), suggesting that other inhibitory proteins 
are produced.  
Other inhibitory proteins are produced by the Nogo gene (Chen et al.; 
2000). It encodes for three different splice variants: Nogo-A that is the 
inhibitory molecule expressed by oligodendrocytes (the long isoform), 
Nogo-B (intermediate isoform) and Nogo-C (short isoform) that are 
expressed outside the CNS. A conserved domain present in all the Nogo 
proteins is Nogo-66, a C-terminal domain exposed to the extracellular 
space that possesses the inhibitory effect on axonal regeneration 
(GrandPre et al.; 2000). Nogo is expressed only by oligodendrocytes, 
not by Schwann cells, and this could, at least in part, explain the 
different permissive environment for axonal regeneration between CNS 
and PNS. Experiments in mice lacking one of three Nogo isoforms led to 
inconsistent results (Simonen et al.; 2003; Zheng et al.;  2003; Kim et 
al.; 2003), maybe due to the compensatory effect by MAG and other 
MAIs. Another confounding factor could be also the differential 
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expression of Nogo A levels by mice having a different genetic 
background (Dimou et al.; 2006). 
Oligodendrocyte myelin glycoprotein (OMgp) is the third MAI identified 
and expressed on CNS myelin (Wang et al.; 2002; Kottis et al.; 2002). 
OMgp is a GPI-anchored CNS myelin protein expressed not only by 
oligodendrocytes but also by neurons (Habib et al,; 1998). After 
Knocking down OMgp, a less inhibitory environment is obtained, 
although with no improvement of axonal sprouting or motor function (Ji 
et al.; 2008). 
All MAIs mentioned above (MAG, Nogo66 and OMgp) act on a single 
neuronal receptor, called Nogo receptor (NgR1) (Fournier et al.; 2002; 
Domeniconi et al.; 2002; Wang et al.; 2002; Borrie et al.; 2012). These 
MAIs bind to the same NgR1 domain (N-terminal leucine-rich repeat 
(LRR) domain), indicating a redundant ligand model. Since NgR is a 
GPI-linked protein, it lacks the intracellular domain necessary to 
transduce signals inside the cells. Thus, efforts have been made to 
identify co-receptors of NgR. The first NgR co-receptor identified is p75, 
which mediates the downstream signaling of all three MAIs (Yamashita 
et al.; 2002; Wang et al.; 2002). The pre-incubation of neurons with 
neurotrophins could prevent the inhibition mediated by MAIs, but, after 
injury, they could not interfere anymore (Cai et al.; 1999). Results of 
knock-out mice for NgR are inconsistent and controversial regarding the 
axonal regeneration (Zheng et al.; 2005; Kim et al.; 2004) maybe 
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suggesting the involvement of other receptors for the MAIs action on 
regeneration inhibition. Once activated, NgR co-receptors transmit the 
intracellular signal through RhoA, a small GTPase protein which 
activates ROCK (Rho-A associated kinase) and PKC (Protein kinase C). 
These are regulators of the actin cytoskeleton and cause a stiffening of 
the cytoskeleton leading to an inhibition of the axons elongation and to 
a growth cone collapse, as is well explained by Yiu review (Yiu et al.; 
2006). 
MAIs are not the only inhibitors of neurite growth. Other proteins that 
could be both chemorepellants and chemoattractants are Semaphorin 
family (Moreau-Fauvarque et al.; 2003), Ephrins (Benson et al.; 2005), 
Netrins (expressed by oligodendrocytes, cells of the central canal and 
the meninges) (Culotti et al.; 1996), Repulsive guidance molecule a 
(RGMa) (Schwab et al.; 2005), Wnt proteins (expressed during 
development to guide axons and upregulated in adult only after injury) 
(Liu et al.; 2008) and Lynx1 (Morishita et al.; 2010). 
In order to counteract the axon’s regeneration inhibition by MAIs, 
different approaches have been tested.  In general, we can distinguish 
two main strategies: I) blocking the recognition between inhibitory 
ligands and their receptors, II) blocking the intracellular common 
pathways. 
Regarding the first approach, the most studied is the counteracting of 
Nogo-A ligands. Indeed, the use of drugs anti-Nogo is the longest 
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studied approach for SCI (Kwon et al.; 2011) that stared in 1990 with 
the IN-1 monoclonal antibody against Nogo-A, reviewed by (Buchli et 
al.; 2005). This approach was able to enhance regeneration and 
compensatory sprouting, together with functional improvement. Also 
the humanized anti-Nogo antibody (ATI-355) is able to enhance 
sprouting and functional recovery in primates (Freund et al.; 2006).  
Other approaches have been used on soluble receptors of NgR (Fournier 
et al.; 2002) which demonstrated functional improvements (Li et al.; 
2004) also with a 3 day delay from the primary injury (Wang et al.; 
2006). Moreover, recently, a lentiviral mediated expression of a soluble 
NgR in the intracellular space has been achieved, leading to an 
increased axon regeneration (Zhang et al.; 2013). 
Regarding the other inhibitory molecules produces by myelin debris, 
different strategies have been used to block Semaphorins. These 
include Sema3A antagonists (SM-216289), which show some results in 
regeneration and functional improvements (Yamashita et al.; 2003), 
anti-Sema3A peptide (Montolio et al.; 2009) and Xanthofulvin (SM-
216289) to inhibit Sema3A, which promotes regeneration and functional 
recovery (Kaneko et al.; 2006). An anti EphA4 peptide has been also 
utilized and the authors reported increased CST sprouting and an 
improved recovery (Fabes et al.; 2007). 
The second strategy aims to inhibit more than one MAI at the same 
time, acting on common intracellular pathways. Different inhibitors have 
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been used, such as ROCK inhibitors, (Fournier et al.; 2003), RhoA 
inhibitors (Dillon et al.; 1995) or PKC inhibitors (Sivasankaran et al.; 
2004). However, negative effects associated with Rho/ROCK inhibition 
have also been reported. Although McKerracher’s group documented 
corticospinal tract regeneration in mice (Dergham et al.; 2002) and 
neuroprotection in both rat and mice (Dubreuil et al.; 2003) with acute 
C3 treatment, others have found increased spinal cord tissue atrophy 
(Fournier et al.; 2003) and detrimental health effects (Sung et al.; 
2003) in rats. Again, for Y27632, certain dosages of this drug actually 
decreased axonal sprouting/regeneration, and impaired functional 
recovery (Chan et al.; 2005, Sung et al.; 2003).  
Another strategy to block the inhibition of axonal regeneration is to 
modify the cAMP levels. Indeed, it has been demonstrated that some 
myelin associated proteins are able to decrease cAMP neuronal levels 
limiting the axonal re-growth (Hannila et al.; 2008). Hence, cAMP 
depletion is an important pharmacological target for a neuronal 
regeneration approach, because the increase of cAMP overcomes the 
inhibition by MAG and myelin. A promising drug able to act on the cAMP 
levels is Rolipram. This drug inhibits phosphodiesterase 4, thereby 
raising the level of cAMP. 
It is now clearly demonstrated that the deletion of inhibitory proteins is 
able to enhance sprouting, but it does not affect motor behavior. This 
may suggest that these inhibitors are more involved in the sprouting 
INTRODUCTION 
57 
 
than in CNS regeneration failure (Lee et al.; 2010). Moreover, there is a 
redundant biochemical pathway both for inhibitory molecules produced 
by myelin and for inhibitory receptors present in neurons. For this 
reason, the deletion or the suppression of only one signal is not 
sufficient to promote plasticity and subsequent functional recovery after 
SCI. 
 
6.2 Glial Scar 
 
The initial insult causing spinal cord injury is followed by numerous 
barriers that counteract successful axon regeneration, including the 
development of a glial scar. Indeed, several days after SCI, astrocytes 
surrounding the injury site begin to show hypertrophy with 
morphological and molecular changes. They accumulate, extend and 
overlap their processes forming tight junctions that constitute the scar 
around the injury site (Reier et al.; 1983, Fawcett et al.; 1999, Silver et 
al.; 2004). The scar also contains oligodendrocytes and microglia. The 
glial scar has a role in re-establishing the physical and chemical 
integrity of the CNS and for closing the blood brain barrier, reducing 
infiltration from the periphery, minimizing infections and the spread of 
cellular damage (Reier et al.; 1983, Faulkner et al.; 2004, Sofroniew et 
al.; 2009). 
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On the other hand, the glial scar produces chemical signals inhibiting 
axonal sprouting. In fact, between the factors involved in the lack of 
repair after SCI, glial scar-associated inhibitors such as tenascin, 
Semaphorin 3, keratin and chondroitin sulfate proteoglycans (KSPGs, 
CSPGs) play an important role (Silver et al.; 2004, Carulli et al., 2005). 
CSPGs are extracellular matrix molecules consisting of a protein core 
with one or more covalently attached chondroitin sulphate 
glycosaminoglycan (CS-GAG) chain. Chondroitin sulphate readily 
interacts with proteins in the extracellular matrix due to its negative 
charges and these interactions are important for regulating a diverse 
array of cellular activities, such as pathfinding and guidance during 
development and limitation of neuronal plasticity in the adult CNS 
(Corvetti et al.; 2005; Fukuda et al.; 1997). The CSPG family includes 
aggrecan, neurocan, versican, brevican, NG2 and phosphacan/DSD-1. 
Following SCI, CSPGs are upregulated around injury sites (Asher et al.; 
2000, 2002; Jones et al.; 2003; Tang et al.; 2003) and it has been 
demonstrated that this upregulation can inhibit neurite outgrowth in 
vitro (Snow et al.; 1990; Smith-Thomas et al.; 1994, 1995; Dou and 
Levine, 1994, 1997) and in vivo (Davies et al.; 1997). Therefore, its 
degradation has become a key therapeutic goal in the field of CNS 
regeneration. Evidence that the GAG sugar chains are a major inhibitory 
component of CSPG molecules have come from studies which have 
utilized the bacterial enzyme chondroitinase ABC (ChABC), that is able 
to digest chondroitin sulfate glycosaminoglycans (CS-GAGs) of CSPGs. 
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There is robust pre-clinical evidence demonstrating beneficial effects of 
ChABC treatment following SCI. Furthermore, these effects have been 
replicated in a number of different injury models providing an important 
validation of ChABC as a promising therapeutic strategy. In particular, it 
has been demonstrated that in vivo ChABC treatment can render 
inhibitory substrates more permissive to growth (McKeon et al.; 1995; 
Zuo et al.; 1998; Yu and Bellamkonda, 2001; Grimpe et al.; 2005) and 
enhance axon regeneration after injury (Moon et al.; 2001; Bradbury et 
al.; 2002; Yick et al.; 2003, 2004; Chau et al.; 2004; Fouad et al.; 
2005; Ikegami et al.; 2005; Houle et al.; 2006). 
Mechanisms underlying these effects have been investigated. ChABC-
mediated repair occurs partly through the digestion of the CS-GAG side 
chains, which are able to interact with PTPσ, a neuronal transmembrane 
receptor that mediates inhibition of axonal growth after interaction with 
CSPGs (Shen et al.; 2009, Fry et al.; 2010). Moreover, CSPGs are able 
to activate calcium dependent pathways, perturbing growth inhibitory 
responses in neurons (Sivasankaran et al.; 2004, Koprivica et al.; 2005, 
Monnier et al.; 2003). 
In addition, CSPGs may hinder the growth-promoting potential of 
molecules expressed in the glial scar (such as laminin). Consequently, 
degrading CSPGs with ChABC may unmask this potential and allow 
growth to occur (Zuo et al.; 1998). 
According to these studies, the abundant de novo synthesis of CSPGs in 
response to injury has also led to the hypothesis that CSPGs play also a 
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beneficial role in the repair process. In their works, A. Rolls et al. 
argued that CSPGs can control spatially and temporally the activity of 
infiltrating blood-borne monocytes and resident microglia, distinguishing 
between the beneficial role of CSPGs during the acute stage and its 
deleterious effect at later stages (Rolls et al.; 2008, 2009). These 
observations arise from the need to retain the endogenous potential of 
this molecule in repair by controlling its levels at different stages of 
post-injury repair. 
In addition to ChABC treatment, two works showed different approaches 
to inhibit glial scar formation in mice models of SCI. The first 
demonstrates that it is possible to inhibit glial scar formation and 
facilitate regeneration after SCI using bioactive three-dimensional 
nanostructures, displaying high densities of neuroactive epitopes on 
their surfaces (Tysseling-Mattiace et al.; 2008). 
In addition, a recent work shows how conditional Sox9 ablation reduces 
CSPG levels and improves motor function following spinal cord injury in 
mice (Mckillop et al.; 2013), suggesting a new molecular and 
pharmacological target. 
 
6.3 Regeneration associated proteins (RAGs) 
Following SCI, one of the main factors involved in the absence of axonal 
regeneration is the lack of an appropriate cell body response in terms of 
activating a proper pro-survival gene expression. In fact, regeneration 
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in the adult CNS of mammals is unsuccessful as a result of the 
decreased intrinsic regenerative capacity of affected neurons (Silver et 
al.; 2004).  
A great contribution to the understanding of the regenerative 
mechanisms after injury, comes from the observation of neurons 
projecting into the peripheral nervous system (PNS), which are able to 
regenerate their axons after insult, in contrast to those confined to the 
CNS. In particular, the analysis of the differential gene expression 
response to axotomy in PNS and CNS neurons reveals that CNS neurons 
fail to up-regulate the expression of regeneration-associated proteins 
(RAGs), due also to the lack of trophic factors and their receptors 
(Fernandes and Tezlaff; 2000, Goldberg and Barres; 2000). 
A strategy to stimulate the intrinsic machinery for neuronal 
regeneration is to lesion the neuronal peripheral axons before 
performing the central lesion or just after the injury. These phenomena 
are known as pre-conditioning and conditioning, respectively (McQuarrie 
et al.; 1973, Richardson et al.; 1984). An interesting issue arises from 
the observation that a pre-conditioning stimulus is more efficient in 
activating regenerative pathways if compared to conditioning after CNS 
injury, because the composition of a pro-regenerative environment is 
achieved before injury and CNS neurons are able to activate 
regenerative pathways before the glial scar formation.  
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Moreover, it has been shown that neurons within the CNS can be 
conditioned. Indeed, a regeneration-enhancing effect has been 
stimulated in adult mammalian retinal ganglion cells by lens injury or by 
an inflammatory agent placed within the vitreous body (Yin et al.; 
2003). Again, a peripheral conditioning lesion stimulates axonal 
regeneration after a CNS lesion, activating a retrograde signaling 
pathway, setting neurons in a growth-competent state within 2 days 
(Yudin et al.; 2008, Hanz et al.; 2003). Among the various effects of 
such conditioning lesions, the most important appears to be the 
renewed activation of RAGs, such as GAP-43 (Plunet et al.; 2002, Ylera 
et al.; 2009). GAP-43 is required for neurite growth since it regulates 
the actin cytoskeleton. Its expression in injured CNS neurons is only 
transient and it decreases depending on the distance from the lesion to 
the cellular body (Fernandes et al.; 1999). However, increasing the 
expression of only one RAGs, such as GAP-43, seems to be not 
sufficient to increase neuronal regeneration (Buffo et al.; 1997, Mason 
et al.; 2000). Probably, the simultaneous expression of other RAGs is 
necessary, such as c-jun, Tα-tubulin, CAP-43 or NCAM (Bomze et al.; 
2001, Plunet et al.; 2002, Kwon et al.; 2011). 
Since a pre-conditioning stimulus has no translational potential for 
clinical use. Many efforts have been tried in order to mimic the 
stimulated responses of such stimuli in the neuronal cell body. Trying to 
act directly on the expression of RAGs, one proposed strategy is the 
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exogenous application of trophic support (BDNF or NT-4/5) directly to 
the neuronal cell body or by genetically modified cell lines. Trophic 
factors, indeed, are able to stimulate the neuronal expression of a large 
number of RAGs. This approach and the use of trophic factors in the SCI 
is discussed further later in this thesis. 
To activate neuron-intrinsic growth it has also been proposed to use a 
gene transfer approach. In particular, gene transfer of transcription 
factors such as CREB, ATF3 or STAT3 are able to enhance axonal 
growth, even though in vivo effects are limited to short distance 
sprouting around the lesion site. This kind of therapy and its limitation 
are presented and discussed in the work of Franz and collaborators 
(Franz et al.; 2012).  
On this basis, future research is needed to develop less invasive ways of 
stimulating RAGs expression, and also to evaluate these techniques in 
combination with strategies such as cellular bridging and/or glial 
inhibition, to overcome the obstacles imposed by the inhibitory 
environment. 
 
6.4 Growth factors 
The toxic environment produced after a lesion in the SC is characterized 
by a lack of trophic factors that fail to promote the axonal survival and 
guide  axonal regeneration. This represents a further difference 
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between CNS and PNS, where Schwann cells produce spatially and 
temporally defined trophic factors, necessary to achieve a biologically 
active concentration that chemotactically guides axons (McCall et al.; 
2012).  
In a SCI context, neurotrophic factors could be used to prolong survival 
of injured neurons, to promote regeneration, to improve axons 
sprouting, to drive axonal growth, passing through the lesion, to 
influence glial development and in general to modify the environment 
making it more permissive for axonal growth. Trophic factors can be 
released by grafted cells or cells genetically modified to release a 
greater amount of a specific trophic factor, or by osmotic pumps, that 
deliver the trophic factors systemically or in situ, or by other polymeric 
delivery systems such as collagens and hydrogels (Katz et al.; 2009; 
Rossi et al.; 2013).  
However, when used in single dose administration, neurotrophic factors 
revealed limited improvements, due to the impossibility of maintaining 
in vivo a constant biological effect. Indeed, ideally, the biological effect 
should be maintained until the regenerative processes finish, thus 
requiring multiple administrations or invasive therapies (Peleshok et al.; 
2006).  
For these reasons, gene therapy has been used to increase the amount 
of factors available for neurons and glia. Two kinds of therapy have 
been proposed in this field: a direct application of viral vectors to the 
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spinal cord, able to target a specific cell population (in vivo delivery), or 
a neurotrophin delivery by scaffolds or infected stem cells, which can 
provide also a growth substrate for axons (ex vivo delivery) (Bo et al.; 
2011). 
However, one concern about the use of artificial substrates is that they 
could trigger, once implanted in the injured spinal cord, a further 
inflammation response (Ronsyn et al.; 2008). For this reason, the use 
of cellular transplantation could provide an alternative method for the 
release of a great amount of trophic factors in the site of injury. Indeed, 
even though the real mechanism of action of stem cells is not yet 
known, one hypothesis is that they act through the release of trophic 
factors. It has been proved that bone marrow derived MSC (BM-MSCs) 
are able to secrete a great amount of neurotrophic factors, including, 
BDNF, NGF, VEGF and HGF (Chen et al.; 2002, Lin et al.; 2013, 
Quertainmont et al.; 2012). The advantages associated with BM-MSCs 
are their low immunogenicity, the possibility to be autologously 
transplanted and their immunomodulatory properties (Mothe et al.; 
2012). This cell type has been tested also in several completed or 
ongoing clinical trials, demonstrating their safety and tolerability in SCI 
patients (Pal et al.; 2009; Yoon et al.; 2007; Sahni et al.; 2010). 
Overall, they reported favorable effects of MSCs on SCI patients due to 
the release of trophic factors and the recruitment of protective cells 
(Mothe et al.; 2012). Again, fetal stem cells are thought to act primarily 
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through the release of trophic factors (Coumans et al.; 2001), rather 
than to the cells themselves (Ronsyn et al.; 2008). The neurotrophic 
factor release seems to play a key role in the efficacy of neural stem 
cells, as well, after a SCI (Lu et al.; 2003; Gu et al.; 2012; Hawryluk et 
al.; 2012). 
Independently from the route of administration, different neurotrophic 
factors have been used to date in SCI, each having specific function and 
peculiarities (Rosner et al.; 2012).  
Nerve growth factor (NGF) is a trophic factor able to promote axonal 
regeneration and sprouting, primarily of nociceptive sensory axons 
(Hollis et al.; 2011). Fibroblasts genetically modified to produce NGF 
and inserted into the lesion cavity promote axonal regeneration of 
sensory axons (Grill et al.; 1997; Nakahara et al.; 1996) and local 
motor axons. However, NGF has no effect on the CST, and consequently 
promotes no functional improvement (Tuszynski et al.; 1997).  An 
important feature of this trophic factor is that activity has been obtained 
in a wide therapeutic window in acute and chronic SCI (Grill et al.; 
1997). However, it must be taken into account that NGF could have also 
deleterious effects, such as the development of neuropathic pain and 
cell death (Beattie et al.; 2002). 
Brain-derived neurotrophic factor (BDNF) is one of the most studied 
trophic factors for the therapy of SCI. It suppresses the apoptosis of 
neurons and oligodendrocytes (Uchida et al.; 2012) and it is able to 
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reduce the necrotic zone and to promote neuronal survival (Novikova et 
al.; 1996; Namiki et al.; 2000), but its effects are restricted to CNS 
(Hiebert et al.; 2002). It has been demonstrated that BDNF is able to 
increase the number of contacts with propriospinal interneurons (Vavrek 
et al.; 2006). Indeed, it increases the growth of local motor, sensory, 
and coerulospinal axons. However, even though it is able to protect CST 
neurons (Hiebert et al.; 2002; Zhou et al.; 2003), it has no effect on 
their growth because its receptors are present only on the somata and 
dendrites but not on CST axons (Lu et al.; 2001). Overall, BDNF seems 
to be able to promote survival of axotomized axons, the regeneration of 
injured fibres and their re-myelination (a complete review could be 
found, Weishaupt et al.; 2012). Like NGF, neurons show responsiveness 
to BDNF also after a delayed administration (Koda et al.; 2002). 
Neurotrophin 3 (NT-3) is a potent neurotrophic factor for ascending 
sensory axons (Taylor et al.; 2006; Bradbury et al.; 1999) and CST 
axons (Grill et al.; 1997; Schnell et al.; 1994). Adeno-associated vector 
secreting NT-3 (Fortun et al.; 2009) resulted in an increased number 
and sprouting of CST axons around the lesion, together with a 
decreased astrogliosis.  
Glial cell line-derived neurotrophic factor (GDNF) is a member of the 
transforming growth factor-β (TGF-β) family. It is able to enhance 
axonal sprouting, synaptic connectivity and GABAergic 
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neurotransmission in SC after injury, resulting in an improved functional 
outcome (Koelsch et al.; 2010).  
Vascular endothelial trophic factor (VEGF) has been reported to 
decrease CST degeneration and to decrease apoptosis (Facchiano et al.; 
2002) after SCI. However, an increased secondary damage has also 
been reported after VEGF treatment, due to the increased angiogenesis 
and subsequent increased influx of inflammatory cells (Benton et al.; 
2003). 
Insulin growth factor (IGF-1), like BDNF, seems to be able to promote 
corticospinal neuron survival, but not their regeneration (Hollis et al.; 
2009). 
However, continuous trophic factor expression in the SCI site, even if 
necessary to stimulate the entry of axons into the graft, does not 
promote axonal growth toward the inhibitory environment beyond the 
lesion. This goal has been achieved by changing the temporal 
expression of growth factors, for example through the tetracycline-
inducible expression of BDNF in modified fibroblasts (Blesch et al.; 
2007). The authors demonstrated that transient growth factor delivery 
is sufficient to sustain long-term axonal projections. Whatever the 
method, the goal is to create a gradient of trophic factors, in order to 
guide axons, not only to regenerate into the graft, but also to grow out 
of it into the CNS environment. 
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7. SPINAL CORD INJURY – STATE OF THE ART 
An important goal in the treatment of SCI is the development of 
effective treatments to prevent tissue damage and promote neuron 
survival. Indeed, up to now there are no efficient clinical treatments for 
SCI patients. The usual procedure provides stabilization and 
decompression of SC combined with high dose of methylprednisolone, 
the only approved treatment (Bracken and Holford et al.; 2002). 
However, there is no consensus about the true beneficial effects of 
these therapies so there is always the constant search for new 
treatments.   
 
7.1 Surgical interventions 
Following the lesion, the medical objective is to protect the traumatized 
region to reduce the possible compression, whose persistence is a 
source of neuronal tissue degeneration. This requires a well-timed 
treatment. In the medical-scientific context there is a general consensus 
that surgical decompression of the SC, compressed or bruised, is often 
necessary (Fehlings and Perrin.; 2005). This can be achieved mainly 
through the spinal traction and stabilization of the spine. The spinal 
traction is based on the manual or mechanical application of a force 
(usually a weight) along the longitudinal axis of the spine. The fracture 
of the spine vertebrae may be stabilized by the insertion of rods and 
screws to align correctly the spine. In addition, it may be necessary to 
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remove bone fragments or foreign objects in the SC with a surgical 
intervention. At a physiological level, surgical decompression has the 
ability to reduce the intradural pressure thus increasing the blood flow 
to the spinal cord, reducing ischemia and edema, and preventing 
secondary damage (Li et al., 2014). 
Another surgical technique is intramedullary decompression: it has the 
potential to improve damaged vessels and prevent further cell death, 
but it is still under study (Li et al., 2014). 
 
It is known that if the surgery is performed within 24 hours after the 
trauma, the chances of functional recovery increase significantly 
(Fehlings et al.; 2012). However, the optimal timing of surgical 
intervention generates considerable debate and remains unanswered. 
Although previously cases of post-operative complications were 
common, now they are much decreased thanks to centers specialized in 
the treatment of SCI (Cristante et al.; 2012).  
Also in animal models, decompression of the spinal cord improves 
functional recovery and minimizes secondary injury after SCI (Carlson 
et al.; 1997, Dimar et al.; 1999).  
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7.2 Pharmacological interventions 
Methylprednisolone 
The only pharmacological treatment for the SCI acute phase so far 
accepted by the US Food and Drug Administration (FDA) is the systemic 
use of a cortisone based-drug, methylprednisolone (MP) (Bracken et al.; 
1984, 1990, 1997). Its neuroprotective effects are due to its anti-
oxidant activity, to the improvement of the blood flow of the spinal 
cord, to the reduction of calcium influx, to the decrease of the axonal 
retrograde degeneration and the reduction of lipid peroxidation. In a 
few years the North American Spinal Cord Injury Study (NASCIS) 
carried out 3 different studies of MP: the results showed that the 
neuroprotective activity, even though limited, is present only if high 
doses of MP are administered within 3-8 hours after the injury. 
However, high doses of MP were associated with pneumonia, infection, 
pulmonary embolism and death (Fehlings and Baptiste, 2005). Another 
two prospective clinical trials on the administration of MP in spinal 
injuries have been published (Pointillart et al.; 2000) in which some 
benefits were seen, but both of these studies involve a small number of 
patients and therefore the results are difficult to interpret (Hawryluk et 
al.; 2008). The data obtained led to a huge controversy about the use 
of MP in the acute phase of injury, which had a climax in 2002 with the 
conclusion of the American Association of Neurological Surgeons 
Congress on Neurological Surgery that the treatment with MP is 
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recommended for 24 or 48 hours in the treatment of patients with acute 
spinal cord injury.  
A possible alternative approach could be the use of nanoparticles (NPs) 
as delivery tool for MP, in situ administered, to enhance the 
effectiveness of MP therapy and avoid the side-effects arising from high 
dose corticosteroid therapy. This treatment significantly decreases 
secondary injury-related inflammation, resulting in significantly reduced 
lesion volume and improved behavioral recovery (Kim et al.; 2009, 
Chvatal et al.; 2008, Cerqueira et al.; 2012).  
 
Minocycline 
Minocycline is a broad spectrum tetracycline antibiotic which shows also 
neuroprotective effects through the inhibition of M1 
microglia/macrophages (Festoff et al.; 2006; Kobayashi et al.; 2013). 
Minocycline decreases also the formation of ROS, reduces matrix 
metalloproteinase activity and inhibits apoptotic cell death (Yong et al.; 
2004). Minocycline is an attractive drug for clinicians because it is 
known to be well tolerated in human, where it has been used for acne 
treatment for decades.  
A randomized Phase II trial has demonstrated that treatment with 
minocycline leads to improvement in functional outcome in patients with 
cervical motor-incomplete injury, although the improvement was not 
statistically significantly. The study also showed no serious adverse 
events in patients receiving treatment (Casha et al.; 2012). At present, 
INTRODUCTION 
73 
 
two Phase III clinical trials are in progress for patients with acute SCI 
(NCT01828203, NCT01813240 identified in ClinicalTrials.gov). 
 
Additional pharmacological therapies that have been explored in human 
SCI trials, but have not demonstrated significant clinical efficacy 
include: naloxone (Bracken et al.; 1990), thyrotropin releasing hormone 
(Pitts et al.; 1995), trilazad mesylate (Bracken et al.; 1997), nimodipine 
(Pointillart et al.; 2000) GM-1 ganglioside (Geisler et al.; 2001), 
gacyclidine (Lepeintre et al.; 2004), and granulocyte colony stimulating 
factor (Yoon et al.; 2007). 
 
Chronic treatments 
Therapies in the chronic phase after a spinal cord traumatic event 
include drugs, rehabilitation, medical devices and functional electrical 
stimulation (FES).  Drugs are used to control pain and spasticity, to 
improve bladder control and bowel and sexual functions. For example, 
gabapentin is used as an analgesic drug to reduce neuropathic pain in 
chronic patients with complete lesion. 
Rehabilitation can be active, in which case  it involves the SCI  
individual and volunteers making efforts to improve motor performance, 
or it can be passive, performed from massages and movements induced 
by the physiotherapist. Passive rehabilitation is a fundamental and 
essential part of any treatment protocol, but alone is not sufficient to 
maximize functional outcomes after injury. To date, however, no active 
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rehabilitation therapy has been completely validated as essential or 
effective for functional recovery following the various types of spinal 
lesion, although there is evidence that the effort may encourage the 
formation of new local connections in the CNS. Several computerized 
devices are used to help patients to become independent. Also 
functional electrical stimulation (FES) can be used to allow patients to 
control the muscles and organs. 
 
7.3 Cell therapy 
The cell transplantation therapy is one of the most promising strategies 
for the treatment of SCI and this is a focal point of some preclinical 
research. Recruited cell types are olfactory ensheathing cells (OECs), 
Schwann cells (SCs), mesenchymal stem cells (MSCs), neural stem cells 
(NSCs), oligodendroglial progenitor cells and embryonic stem (ES) cells. 
The beneficial effects of these therapies are multifactorial, because 
these cells are able to secrete several trophic factors with 
neuroprotective effect or promote  neuronal plasticity. 
Most transplants are performed directly in the wound site or in the 
areas adjacent to the lesion, through the injection of a few microliters of 
cell suspension. When the treatment is carried out in sub-acute or acute 
phase (transplantation takes place respectively immediately after the 
trauma or a few days after the injury) a poor outcome is obtained 
because the SCI site is a toxic and inhospitable environment for the 
transplanted cells. 
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The properties, advantages and disadvantages of each of these cells are 
further reviewed by Silva and collaborators (Silva et al.; 2014). 
 
7.4 Molecular therapy 
The remarkable advances in molecular biology in the past decades have 
led to a better understanding of the mechanisms implicated in the 
pathophysiology of SCI as well as mechanisms that control axonal 
growth and sprouting. This knowledge has raised the hope of 
developing new therapies that can attenuate secondary damage and 
maximize regeneration after a SCI. Molecular therapy usually focuses 
on the modulation of inflammatory response, administration of growth-
stimulating factors and/or blocking the inhibitory nature of the injured 
adult CNS tissue. 
Non-steroidal anti-inflammatory drugs (NSAIDs): The most 
studied among the NSAIDs for SCI is Indomethacin which produced a 
reduction of edema and tissue damage. Others NSAIDs tested are 
BW755C, NS-398, naproxen, aspirin, ibuprofen, administered a few 
minutes before or after the injury. Among them, ibuprofen appears to 
promote both histological and behavioral improvements following 
administration up to 3 and 7 days after injury (Wang et al.; 2009). 
Ibuprofen is able to reduce the RhoA activity by promoting axonal 
regeneration, as well as to alleviate the inflammation. 
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It has been long understood that neuronal damage is mediated by 
disproportionate intracellular accumulation of sodium and calcium ions. 
This accumulation is mediated by overstimulation of NMDA receptors 
(due to high glutamate levels after injury) in a process known as 
“excitotoxicity” (Agrawal and Fehlings, 1996; Faden et al.; 1989). In 
order to protect neural tissue several researchers explored the 
therapeutic potential of either sodium channel blockers, such as 
riluzole, or NMDA antagonists, such as magnesium. 
Riluzole is a drug approved by the FDA for the treatment of 
amyotrophic lateral sclerosis (ALS) that can be administered orally. For 
years it has been known that damage to the white matter can be 
mediated by an influx of sodium ions through sodium channels and 
voltage-dependent block of these channels has been shown to 
significantly prevent the loss of white matter (Rosenberg and Wrathall, 
2001). Riluzole appears to act by blocking voltage-dependent sodium 
channels, with a consequent decrease in the pre-synaptic release of 
glutamate. Its neuroprotective action is strongly linked to the time from 
injury to administration. It has proven effective if the dose is 
administered after 15 minutes or 30 minutes from the lesion 
(Stutzmann et al.; 1996). These studies report a significant reduction of 
secondary damage around the lesion and an improvement in the 
recovery of motor function. Having already been demonstrated as safe 
for humans and having achieved encouraging results in preclinical 
studies, riluzole is now being tested clinically. Currently, a prospective, 
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randomized, multicenter Phase II/III trial is ongoing in patients with 
acute C4-C8 SCI (NCT01597518 identified in ClinicalTrials.gov).  
Magnesium has been investigated in animals as a neuroprotective 
agent for traumatic brain injury (TBI) and SCI (Suzer et al.; 1999; 
Kaptanoglu et al.; 2003; Gok et al.; 2007; Hoane et al.; 2007; 
Wiseman et al.; 2009). The biological rationale for magnesium in SCI 
includes the attenuation of excitotoxicity through a voltage-dependent 
blockade of NMDA receptors (Zhang et al.; 1996), and the replacement 
of depleted magnesium levels following injury (Vink et al.; 2000). In 
acute SCI animal models, magnesium sulfate administration has been 
shown to decrease membrane damage, protect axonal function and 
improve electrophysiology and behavioural outcome (Suzer et al.; 
1999; Kaptanoglu et al.; 2003). However, the neuroprotective effect 
was achieved with extremely high doses of magnesium that far exceed 
the tolerable human dose. More recently, magnesium chloride 
formulated within polyethylene glycerol (PEG) has been developed, and 
the dose of magnesium is similar to the clinically-acceptable dose. This 
formula has been investigated as a potential neuroprotective agent for 
SCI in thoracic and cervical SCI animal models (Kwon et al.; 2009; Lee 
et al.; 2010). A clinical trial of a proprietary form of PEG with 
magnesium chloride, AC105 (NCT01750684 identified in 
ClinicalTrials.gov), is currently underway to determine the efficacy of 
the drug in patients who have a SCI. 
 
INTRODUCTION 
78 
 
7.5 Physical approaches 
To minimize secondary damage to the spinal cord physical approaches 
may be possible among which the most studied are hypothermia, 
hyperbaric oxygen and training. The first technique involves local 
cooling by pouring a low-temperature saline solution. It is based on the 
fact that low temperature protects from phenomena of hypoxia and 
ischemia. However, being poorly reproducible and unreliable, it has a 
high mortality rate (Schwab and Bartholdi, 1996). 
The second technique is characterized by raising the partial pressure of 
oxygen at the injury site, and this is achieved by making the patient 
breath inside a hyperbaric chamber with an oxygen pressure greater 
than that atmospheric (Yeo et al.; 1976). The rationale is that the loss 
of perfusion can be compensated by the partial pressure of oxygen 
(Cristante et al.; 2012) and in the literature there are numerous 
positive results obtained with this therapy (PEC Galvao and RP, 2011). 
Finally, many studies show excellent improvements in coordination and 
in functional recovery by performing different types of exercise 
(Cristante et al.; 2012).  Benefits have also been observed at the level 
of intrinsic neural circuits (AF Ferreira, 2012). 
 
7.6 Combinatorial therapies 
Because of the limited effective treatments for SCI, it is not surprising 
that many pharmacological and non-pharmacological approaches are 
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being investigated to provide better treatment for SCI patients. 
Although therapeutic effects have been observed in preclinical work, we 
have not seen any treatments translated successfully into clinical use. 
One of the reasons for this is the complexity and multi-factorial nature 
of the secondary pathophysiological changes following SCI. Most 
treatments only target one aspect of this response; however, a 
successful approach is likely to depend on a combination of different 
treatments. Single therapies have shown, so far, only limited effects, 
because it remains the need to overcome other toxic or inhibitory 
factors. In order to increase the small effect on behavior seen after a 
single neuroprotective treatment, the most powerful strategy is 
probably the simultaneous treatment of different pathological 
processes, as suggested by other studies (Thuret et al.; 2006). This 
should improve the effects of each therapy. However, in vivo 
combinatorial studies require a great effort, because introducing each 
additional treatment doubles the number of experimental groups and 
the total number of animals necessary to evaluate all the parameters 
singularly (Zhao et al.; 2013). 
An exhaustive overview of studies using combinatorial strategies is in 
the review of Silva and collaborators (Silva et al.; 2014). 
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8. THE ROLE OF INFLAMMATION 
In physiological conditions, the blood-brain barrier (BBB) limits the 
entry into the CNS of patrolling bone marrow (BM)–derived immune 
cells, while resident microglia perform physiological surveillance. In 
response to mechanical injury to spinal cord, microglia become rapidly 
activated, undergoing morphological and molecular changes often 
associated with neurotoxicity and initiating the inflammatory cascade 
that mainly characterizes the secondary injury. The composition and the 
potential effect of the cellular and molecular inflammatory cascade 
changes as a function of time and distance from the lesion. 
The main pathological changes have been arbitrarily categorized into 3 
stages by Shin et al.: (1) an early inflammatory stage, from the injury 
to the first 3 days, (2) a cleaning stage, approximately from 4 days to 
about 2 weeks post-injury and (3) reactive gliosis at 2 weeks post-
injury (Shin et al.; 2013). 
The first stage is characterized by hemorrhage, destruction of myelin, 
cell death, edema, and infiltration of inflammatory cells due to the BBB 
disruption. As residents of the SC, microglia and astrocytes are the first 
cells to respond to tissue damage. These cells are important for re-
establishing tissue homeostasis (Davalos et al.; 2005, Myer et al.; 
2006, Okada et al.; 2006). They are able to release chemokines and 
cytokines, both pro-inflammatory, such as tumor necrosis factor 
(TNF)α, interleukin (IL)-1β, IL-6, interferon (IFN)-γ, and anti-
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inflammatory interleukins such as IL-10 and tumor growth factor (TGF)-
β1, and other vasoactive substances, such as reactive oxygen species, 
kinins, histamines, nitric oxide and elastase, that enhance recruitment 
of peripheral leukocytes (Rice et al.; 2007, Weber et al.; 2007). The 
first circulating leukocytes that infiltrate injured tissue are neutrophils, 
followed by monocyte-derived macrophages (Stirling and Yong; 2008, 
Kigerl et al.; 2006). These cells support recovery processes through 
their ability to phagocytose cellular debris but they are also able to 
enhance the release of cytokines, free radicals, eicosanoids and 
proteases. Unlike neutrophils, macrophages persist in SCI lesions years 
and months respectively for humans and rodents (Kigerl et al.; 2006, 
Chang et al.; 2007). 
Also T and B lymphocytes infiltrate the site of injury, but in fewer 
number and at later time than monocytes, and their functional 
significance remains a controversial issue (Ankeny and Popovich, 2009, 
Popovich and Longbrake, 2008). During the cleaning stage, edema is 
reduced and a massive proliferation of macrophages/activated microglia 
is identified in the site of lesion (Ahn et al.; 2012, Moon et al.; 2004). 
In the lesion core, macrophages remove cells and the myelin debris, 
reducing edema, and inducing the formation of a cavity (Blight et al.; 
1985).  
The third phase is characterized by astrogliosis and/or shrinkage of SC 
volume. Astrocytes become the predominant cell type (Fawcett et al.; 
1999) and form a ‘scar-like’ barrier between the fluid-filled cavitation 
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and normal tissue (Popovich et al.; 1997). These aspects will be deeply 
discussed later in this thesis. 
Recently, a later phase of cellular inflammation was observed persistent 
up to 180 days post injury (DPI), with a peak in the 
microglial/macrophage response at 60 DPI that is double the magnitude 
of the earlier peak. This later peak did not coincide with a change in 
locomotor function, suggesting that this second phase is insufficient to 
affect locomotor recovery (K. D. Beck et al.; 2010). 
It has been demonstrated by previous studies that, despite variations in 
SCI lesions, the main features of neuropathological changes following 
SCI are similar among rodent models (Basso et al.; 1997) and human 
patients (Sala et al.; 1999, Metz et al.; 2000). However, species-
specific differences in the distribution, magnitude, and composition of 
infiltrating leukocytes are present between humans and rodents, 
between rodent species (rat vs. mouse) and between different rat and 
mouse strains. The processes initiated by the pro-inflammatory 
cytokines, especially the activation of macrophages, exacerbate 
secondary tissue damage and promote the formation of an inhibitory 
glial scar (Rostworowski et al.; 1997, Popovich et al.; 2002). However, 
the role of neuroinflammation is still controversial, being both beneficial 
and detrimental for recovery after the trauma. Indeed, the immune 
response may facilitate the recovery from injury by reducing the size of 
the lesion, facilitating wound repair and stimulating axonal regeneration 
(Elkabes et al.; 1996, Bomstein et al.; 2003) (Streit et al.; 1998, 
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Klusman et al.; 1997). Moreover, further discussion concerning 
microglia/macrophages phenotypes, including classically activated M1 
and alternatively activated M2 macrophages should be considered. Even 
though the M1 phenotype is usually associated with a neurotoxic effect, 
it is also involved in the axonal regeneration. In contrast, while the M2 
phenotype is associated with neuroprotective effects, it lacks the 
necessary environmental signals to maintain the phenotype (Aguzzi et 
al.; 2013). It has also been reported that M1 phenotype shows an early 
and persistent activation after injury, while M2 protective phenotype 
has a transient expression and is significant only in a subacute phase of 
injury (David and Kroner, 2011, Kigerl et al.; 2009). The current view is 
that the inflammatory response after injury is a ‘double-edged sword’, 
having both neuroprotective and neurotoxic properties, and that the 
detrimental phases of inflammation are interspersed with 
neuroprotective events (Kwon et al.; 2004). From this perspective, a 
promising therapeutic strategy should limit the neurotoxic potential and 
enhance the reparative mechanisms. 
To present, several attempts have been made to try and counteract the 
harmful effects of the inflammatory cascade, following different 
approaches, the main of which are: cellular, molecular, general 
immunosuppression and therapeutic vaccination. 
Cellular approaches – These therapies target specific cell types which 
are involved in the spreading of injury. The selective depletion of 
neutrophils and/or monocytes leads to an improvement of functional 
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recovery and to a tissue sparing in rat models of SCI (Popovich et al.; 
1999, Taoka et al.; 1997).  
The blocking of leukocyte entry into the lesion site is achieved through 
the inhibition of leukocyte binding molecules, including selectins and 
integrins (Gris et al.; 2004, Mabon et al.; 2000, Bao et al.; 2004), or by 
the inhibition of chemokines or cytokines that enhance recruitment of 
leukocytes. MIP-II is a broad-spectrum chemokine receptor antagonist 
which is able to reduce leukocyte infiltration in rat models of SCI 
(Ghirnikar et al., 2000, 2001). Antibody to CXCL10 treatment decreases 
the number of macrophages, CD4+ and CD8+ T-cells and B-cells, with 
relevant effects on promoting axon sprouting and functional recovery in 
mice models (Gonzales et al.; 2007). Inhibition of pro-inflammatory 
cytokines, such as TNF-α with infliximab or genetic deletion, or IL-1 and 
IL-6 with receptor antagonist IL-1ra and IL-6ra, confer neuroprotection 
and ameliorate neuropathic pain, reduce apoptosis and inhibit p-38 
MAP-kinase activation in rodents (Kim et al.; 2001, Vogel et al.; 2006, 
Okada et al.; 2004). In three different laboratories, selective 
cyclooxygenase (COX)-2 inhibitors, systemically adminstered, have 
demonstrated significant improvements in both behavioral and 
neuroprotective outcome measures (Hains et al.; 2001, Resnick et al.; 
1998) in SCI rodent models. 
On the other hand, Schwartz’s laboratory has published numerous 
studies documenting the beneficial effects of enhancing inflammation, in 
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a carefully controlled way, after CNS injury. They demonstrated that, 
when pre-activated macrophages were implanted into the transected rat 
spinal cord, there was enhanced axonal regeneration and functional 
recovery (Rapalino et al.; 1998) even though the degree of 
regeneration was not better than using transplants of other cell types. 
Schwartz’s group also showed that the macrophages were fundamental 
in the clearance of debris and this allowed axonal regrowth in 
transected rat optic nerves (Lazarov-Spiegler et al.; 1996, 1998). 
Other researchers have called for caution in applying activated 
macrophage transplantation in a clinical setting. Moreover, Popovich’s 
group identified different populations of macrophages - bone marrow-
derived, resident peritoneal, and thioglycollate-elicited - that 
differentially contribute to secondary damage (Popovich et al.; 1999, 
Longbrake et al.; 2007). 
In addition, it has been observed that the timing of intervention can 
significantly affect microglia/macrophage activation and change the 
functional outcome in mice models of SCI (Klusman et al.; 1997), 
raising the questions of which cell type is neuroprotective and when the 
best time of intervention is. 
 
Molecular approaches - This kind of approach targets intracellular 
signaling pathways. After SCI, activated (phosphorylated) p38 MAP-
kinase is rapidly increased. Some preclinical studies showed that a 
single dose of SB203580 inhibits phosphorylation of p38 MAP-kinase, 
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and reduces apoptosis and iNOS gene expression (Wang et al.; 2005, 
Xu et al.; 2006). More controversial are the effects after continuous 
intrathecal delivery (Horiuchi et al.; 2003, Stirling and Yong, 2008). 
Initially, the Rho GTPase and its downstream effector, Rho kinase 
(ROCK) have become attractive targets because they were able to 
stimulate axonal regeneration, as will be discussed subsequently in this 
thesis. Surprisingly, inhibition of ROCK using Y27632 (Chan et al.; 
2005) or fasudil (Nishio et al.; 2006, Sung et al.; 2003) came out to 
have also anti-inflammatory effects in models of SCI. Indeed, inhibition 
of this pathway may contribute to neuroprotection via suppression of 
immune cell migration and infiltration into the injury site. In vitro, the 
Y27632 decreased the number of macrophages that migrate in a three 
dimensional assay (Nakayama et al.; 2005) and impaired lymphocyte (T 
cell) proliferation (Tharaux et al.; 2003). In vivo, ROCK inhibition 
decreased leukocyte infiltration into the injured SC (Hara et al.; 2000) 
and decreased the cytokine production (Angkachatchai et al.; 1999). 
However, negative effects associated with ROCK inhibition have also 
been reported, because certain dosages of Y27632 actually decreased 
axonal sprouting/regeneration and impaired functional recovery (Chan 
et al.; 2005, Sung et al.; 2003).  
Another attempted approach has been the selective inactivation of 
astroglial transcription factor nuclear factor (NF)-κB, which is highly 
activated after trauma, and leads to both protective and detrimental 
effects. Brambilla et al. demonstrated in their work that transgenic mice 
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expressing an inhibitor of NF-κBα, under the control of an astrocyte-
specific promoter, leads to a dramatic improvement of functional 
behavior, suggesting that selective inhibition of NF-κB signaling in 
astrocytes results in protective effects after SCI (Brambilla et al.; 
2005). 
 
General immunosuppression - Immunosuppressive approaches have 
been carried out by using inhibitors of calcineurin, such as cyclosporine 
A (CsA) and FK506 (Tacrolimus), that have proved to reduce 
neuroinflammation and to improve recovery (Guzmàn-Lenis et al.; 
2008, Kaymaz et al.; 2005, Hayashi et al.; 2005). 
Intravenous application of an antiangiogenic compound CM101, one 
hour after SCI in mice, with the intent of preventing inflammatory 
angiogenesis and inhibiting gliosis, demonstrated an improvement of 
locomotion and appeared to be neuroprotective (Wamil et al.; 1998). 
Other immunosuppressants, like minocycline or methotrexate, have 
been  showed to be neuroprotective and to ameliorate neuropathic pain, 
basically suppressing macrophages/microglia activation, in addition to 
their antiapoptotic properties (Festoff et al.; 2006, Scholz et al.; 2008). 
The promising preclinical results about minocycline treatments have led 
to two clinical trials, one is currently recruiting participants 
(ClinicalTrials.gov Identifier: NCT01828203, NCT01813240).  
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Therapeutic vaccination - In the perspective of the dual role of 
inflammation, to find an effective way to boost the spontaneous 
neuroprotection, the effectiveness of therapeutic vaccination has been 
tested. Schwartz’s group reported beneficial results. They showed that 
injection of anti-myelin basic protein (MBP) T cells (T-MBP) was 
neuroprotective in a model of SCI. Since this approach could provoke an 
autoimmune reaction, they tested a synthetic four amino acid peptide, 
copolymer-1 (Cop-1), which mimicked the MBP molecule but was non-
encephalitogenic. This peptide was able to induce a T cell response 
against MBP, reporting neuroprotective effects (Hauben et al.; 2000). A 
patent for the use of Cop-1 and related peptides and T cells treated with 
these peptides was obtained by this group in 2005 and the treatment is 
expected to enter Phase II clinical trial, even if this approach is still 
controversial (reviewed in Chan et al.; 2008). Other groups reported 
that implantation of activated macrophages or T-lymphocytes activated 
against modified myelin self-antigens, achieved by either adoptive 
transfer or active immunization in rats (Hauben et al.; 2000, 2001, 
Moalem et al.; 2000), enhances recovery in SCI by conferring 
neuroprotection or regeneration. Although the intriguing concept of 
neuroprotective autoimmunity is growing in popularity, to date there is 
no definitive mechanism that explains its efficacy. 
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 9. DRUG DELIVERY TO THE SPINAL CORD 
 
 
Common practice methods to administer pharmacological compound in 
CNS are based on oral, intravenous (IV) and intraarterial (IA) delivery. 
However, many limitations drastically reduce the applicability of the 
above mentioned route of administrations: i) limited access to the SC 
environment for the physical obstruction due to the blood spinal cord 
barrier (BSCB), ii) the half-life of the drug in the plasma and iii) 
potential unacceptable side effects of prolonged treatments. 
Consequently, new efforts are directed to develop innovative strategies 
and drug delivery tools to overcome BSCB or perform effective drug 
delivery in either cerebrospinal fluid (CSF) or SC parenchyma. 
 
9.1 Intrathecal drug delivery: catheters and minipumps 
 
Intrathecal (IT) drug delivery by catheters and implanted minipumps 
has been clinically used as an alternative route of drug administration to 
the systemic and oral ways, expanding the medical options to treat the 
SC (Simpson et al.; 2003). IT delivery is proposed as way to release 
compounds with a single or continuous infusion directly into the CSF. 
Indeed, a direct injection of drug is clinically possible into the spinal 
space corresponding to the interstice between the pia mater and the 
arachnoid membrane, without great iatrogenic exacerbation of the 
patient’s medical condition (Lawson et al.; 2012). IT delivery shows 
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various additional therapeutic advantages compared to conventional 
routes: a more localized immediate pharmacological activity, a greater 
control of drug delivery, rapid reversibility and reduced side effects 
(Smith et al.; 2008). However, a direct injection or infusion in the CSF 
shows a poor distribution of therapeutic compounds into the SC 
parenchyma, reaching only the outer part of it. Furthermore, CSF is 
produced in the choroid plexus in the brain and moves in a pulsatile 
manner to the SC; CSF then returns to the vascular system by venous 
sinuses via the arachnoid granulations (Pardridge et al.; 1997). CSF is 
produced at a rate of 0.2 - 0.7 mL/min and it is renewed within 5h. For 
these reasons the injected therapeutic compounds return quickly in the 
bloodstream and the BSCB again represents a strong limitation to a 
diffuse pharmacological treatment of the SC. 
In addition, some side effects regarding the placement of the catheters 
were described, such as obstruction, leakage, breakage, dislodgment, 
side effects of the surgery required for the placement and pump 
refilling. Hemorrhage, CSF leaks and infections, such as granulomas, 
were observed too (Belverud et al.; 2008). 
 
 
9.2 Nanoparticles  
In recent years, nanomedicine has provided many innovations and has 
been increasingly applied in drug delivery, underlining the importance of 
NPs in biomedical applications.  
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The science involved in their synthesis is nanotechnology, defined as 
“the engineering and manufacturing of materials at the atomic and 
molecular scale”. In its strictest definition from the National 
Nanotechnology Initiative, nanotechnology refers to structures roughly 
in the 1−100 nm size regime in at least one dimension. Despite this size 
restriction, nanotechnology commonly refers to structures that are up 
to several hundred nanometers in size. Recently, significant 
achievements have been obtained in developing NPs as new smart tools 
able to deliver in situ a wide range of molecules (drugs, antibodies and 
neurotrophins). Indeed, due to their versatility in terms of size, 
potential surface and hydrophilic or lipophilic characteristics, polymeric 
NPs lead relevant advantages in drug delivery by increasing the 
selectivity of drugs and by controlling their release overtime (Cho et al.; 
2008, Kohane et al.; 2007, Mout et al.; 2012). Furthermore, to obtain 
NPs able to pass biological barriers, various materials and synthetic 
approaches are being investigated. Several cell-penetrating peptides, 
such as transactivating – transduction peptide, were found to be 
capable of penetrating the barrier, and their attachments to the surface 
of liposomes and NPs were used to facilitate internalization of these 
nanostructures into the CNS (Begley et al.; 2004, Liu et al.; 2010). 
Moreover, poly(butyl cyanoacrylate) NPs can penetrate the barrier via 
apolipoprotein-mediated transport, showing neuroprotective efficacy 
once functionalized with enzymes (superoxide dismutase) and 
antibodies (N-methyl D-aspartate receptor 1) (Reukov.; 2011). 
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Furthermore, NPs are considered a primary vehicle for targeted 
therapies because of their ability to enter and distribute within cells by 
energy-dependent pathways. So far, many studies have shown that NP 
properties, such as size and surface, can influence how cells internalize 
and take them up. Once taken up, NPs may act as a drug depot within 
cells and could be useful in achieving therapeutic dosing via targeted 
therapies. Furthermore, NPs can sustain drug release profile overtime 
and protect therapeutic compounds from efflux or degradation 
(Cerqueira et al.; 2012). Receptor mediated endocytosis could be the 
potential filter for greater selectivity in cellular targeting. The cellular 
membrane is dotted with a myriad of receptors, which extracellularly 
interact with their respective ligands (or with NPs whose surface is 
functionalized with ligands) transducing a signal to the intracellular 
space. This signal can trigger a multitude of biochemical pathways and, 
furthermore, it may also cause internalization of the ligand and its 
appended NPs via endocytosis. 
However, NPs sometimes limit their therapeutic efficacy because of no 
specific uptake by macrophages (Lunov et al.; 2011). 
One attractive alternative, to reduce the uptake kinetics, is to 
functionalize NPs with synthetic polymers creating covalent bonds: 
polyethylene glycol (PEG) is the most widely used polymer for this 
purpose. The attachment of PEG chains to NPs can sterically hinder its 
access to macrophages surface receptors and subsequently delay their 
uptake: PEGylated NPs have an increased half-life in the bloodstream. 
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Further, in vivo paradigms showed that PEGylated NPs also significantly 
reduced the formation of reactive oxygen species and the process of 
lipid peroxidation of the cell membrane. Moreover, the use of NPs can 
also optimize the delivery of MP, the only FDA approved drug for SCI 
treatment, providing a diffusive barrier and enhancing its 
neuroprotective properties (Kim et al.; 2009). The use of NPs as 
carriers for neuroprotective agents was also considered for 
prostaglandin E1: its sustained delivery significantly prevented cell 
death, induced angiogenesis and improved blood flow, thereby 
preserving the remaining cells and recruiting them in spinal diseases. In 
addition, hepatocyte growth factor released through NPs contributes to 
neuroprotection, anti-apoptosis and angiogenesis around a SCI lesion 
site. Furthermore, NPs can be used to deliver drugs selectively into 
specific cells of the spinal cord, paving the base for a cell-targeted 
therapy. In addition, nanostructured materials could be the right answer 
to the multitherapeutic clinical needs. Indeed, a therapeutic 
combinatorial treatment is a new challenge in the pharmacological 
management of SCI and simultaneous drug delivery through 
nanovectors could represent a considerable opportunity to synergy the 
efficacy of therapeutics against the multifactorial mechanisms of the 
secondary injury.  
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9.2.1 Nanoparticles and SCI 
Different preclinical studies have demonstrated that NPs represent a 
promising drug delivery alternative for SCI treatment. Chemically 
conjugated NPs composed of ferulic acid and glycol chitosan, 
systemically administered in SCI rat model, were able to reach the 
lesioned spinal cord showing neuroprotection and functional restoration 
(Wu et al.; 2014). Furthermore, intravenously injected NPs containing 
prostaglandin E(1) were able to reduce the lesion cavity volume and 
promote the recovery of motor dysfunction (Takenaga et al.; 2010). A 
preclinical study using GDNF loaded in poly-lactic-co-glycolic acid 
(PLGA) NPs, directly injected into the damaged spinal cord to target 
neural and glial cells, demonstrated an increase of neuronal survival 
and an improvement of motor locomotion (Wang et al.; 2008). In 
addition, nanovectors were used to optimize the delivery of anti-
inflammatory drugs. This is the case of MP loaded in PLGA and 
administered in situ (Kim et al.; 2009).  
It showed a higher pharmacological efficacy compared with the 
conventional systemic administration, reducing tissue damaging and 
inflammation, and improving behavioral outcome in an SCI rat model 
(Kim et al.; 2009). Furthermore, a micellar structure of poly(ethylene 
oxide)–poly(propylene oxide)–poly(ethylene oxide) has been used as a 
delivery vehicle able to increase the bioavailability of MP in the injured 
SC (Chen et al.; 2008). Also the delivery of cerebrolysin (a mixture of 
different neurotrophic factors such as BDNF, GDNF, NGF, and ciliary 
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neurotrophic factor) was able to reduce spinal cord water content, 
leakage of plasma proteins, and neuroprotection when carried by NPs 
(Menon et al.; 2012). The direct injection of NP suspension into the 
injury site is one attractive alternative compared with systemic 
administration. Indeed, intravenous administration of NPs could have 
different contraindications for the treatment of the SCI, such as limited 
or unequal distribution of NPs in the target tissues (owing to BSCB 
restriction) (Rossi et al.; 2013), and relevant NPs uptake by circulating 
macrophages in the liver and/or spleen. Furthermore, NPs intrathecally 
injected without any support very often leave the zone of injection. 
According to these critical issues, several studies suggested to associate 
hydrogels with NPs, providing a localized targeted therapy able to 
maximize the efficacy of neuroprotective agents (Kang et al.; 2013, 
Baumann et al.; 2010). 
Kang et al showed that NGF-2 encapsulated in PLGA NPs and embedded 
in a biopolymer blend of hyaluronan and methylcellulose was able to 
enhance the endogenous angiogenic response once implanted into the 
damaged spinal cord (Kang et al.; 2013). Moreover, in situ delivery was 
optimized by encapsulating MP in PLGA-based NPs subsequently 
embedded in an agarose hydrogel and implanted into the site of the 
contusion. This showed a significant reduction of the early inflammation 
(Chvatal et al.; 2008). Interestingly, nanomaterials themselves have 
been recently recognized as having a neuroprotective efficacy. 
Intravenously injected micelles composed of self-assembled 
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monomethoxy poly(ethylene glycol)–poly(d,l-lactic acid) diblock 
copolymer effectively recovered locomotor function and reduced both 
the lesion volume and the inflammatory reaction in SCI rats (Shi et al.; 
2010). Moreover, local administration of poly(ethylene glycol) reduced 
oxidative stress and repaired nerve membranes, leading to the 
restoration of the nerve potential conduction and increasing behavioral 
outcome in SCI models in guinea pigs (Borgens et al.; 2002). A superior 
neuroprotective efficacy has also been demonstrated using nanowired 
material as a delivery tool in SCI. Tian et al. showed that TiO2 
nanowires were able to increase the bioavailability of neuroprotective 
and anti-inflammatory compounds (Acure Pharma synthesized 
compounds), improving their efficacy. This was likely due to the higher 
concentration of drugs available in the injured tissue (Tian et al.; 2012). 
NPs thus appear to be a very interesting delivery tool also for a cell-
targeted therapy given their ability to enter in specific cells, exploiting 
specific receptors or permissive pathways. Once internalized, NPs may 
act as a drug depot within cells, protecting therapeutic compounds from 
degradation or efflux and delivering therapeutic doses with a sustained-
release drug profile. An interesting application of this innovative cell-
targeted delivery regards the pharmacological modulation of 
microglia/macrophages. New evidence both in vitro and in vivo suggests 
that NPs can be selectively internalized by a specific 
endocytotic/phagocytic activity of macrophages after different insults, 
exploiting them as Trojan horses (Jain et al.; 2013). It is well known 
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that microglia/macrophages assume phagocytic activity after traumatic 
stimuli and this makes NPs a potential tool for drug targeting. Recently, 
this approach has been used by Cerqueira et al. They demonstrated 
that surface-engineered carboxymethyl chitosan/ polyamidoamine 
dendrimer NPs were able to deliver MP into glial cells, specifically 
microglial cells, allowing a controlled and selective release of MP in the 
injury site. However, a critical issue in using NPs is the safety of the 
nanostructured material proposed as biomedical tools. Indeed, 
biocompatibility and efficacy can be influenced by minor variation in 
different parameters that characterize the nanomaterial, such as size, 
shape, chemistry, solubility and surface area (El-Ansary et al.; 2013), 
suggesting that a deeper investigation is mandatory in these 
characteristics before being translated into clinical trials and medical 
practice. 
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10. OVERALL OBJECTIVES AND SPECIFIC AIMS 
Spinal cord injury is characterized by a primary event, due to a 
mechanical insult to the spinal cord, followed by the so called 
“secondary injury”, that exacerbates the clinical outcome. Secondary 
injury includes a wide spectrum of neuropathological events, resulting in 
motor dysfunction below the level of lesion. Much evidence shows that 
persistent inflammation, represented by immune cell infiltration and 
release of inflammatory mediators, is a crucial event involved in 
worsening of the secondary injury. In particular, microglia/macrophage 
related inflammation appears to be a self-propelling mechanism which 
leads to progressive neurodegeneration and development of persisting 
pain state in SCI.  
So far, the challenge has been to find ways to selectively modulate the 
microglia/macrophages activation after SCI, in order to understand the 
real involvement of these cells in the inflammatory response occurring 
during and after the trauma. Indeed, the role (beneficial or detrimental) 
of the inflammatory response associated with the activation of 
microglia/macrophages during SCI repair remains unclear. The 
magnitude of SCI pathology and related functional loss correlates with a 
robust microglia/macrophages response and the blockade of their own 
related inflammatory signaling often confers neuroprotection (Festoff et 
al.; 2006, Donnelly et al.; 2011). Contrarily, different studies showed 
that activated microglia/macrophages in particular conditions could 
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ameliorate the progression of SCI (Shechter et al.; 2013, Shechter et 
al.; 2009). Different reasons could explain the difficult interpretation of 
these inflammatory events: 1) high difficulty to target experimentally 
microglia/macrophages; 2) beneficial or detrimental effects are spatially 
and temporally defined; 3) different subsets of microglia/macrophages 
are involved (M1 and M2 phenotype). 
Growing interest in the improvement of in situ drug delivery system to 
treat SCI was demonstrated in the last years (Perale et al.; 2011) and 
the development of new tools for enhancing drug delivery in specific 
target cells is one of the most promising challenges. Recent advances in 
polymer science have provided a huge amount of innovations, 
underlining the increasing importance of NPs in this field (Perale et al.; 
2011, Mout et al.; 2012). NPs are considered a primary vehicle for 
targeted therapies because they can pass biological barriers and enter 
and distribute within cells. New evidence in vitro and in vivo suggests 
that NPs can be selectively internalized by a specific phagocytic activity 
of macrophages after insults, exploiting them as Trojan horses to 
selectively treat them.  Many anti-inflammatory treatments have been 
proposed to modulate microglia/macrophages in SCI, but no one is able 
to do that in a selective way (Festoff et al.; 2006, Loane et al.; 2010, 
Wells et al.; 2003, Gwak 2012) and this may give rise to potential 
effects associated with other cells of the central nervous system, 
leading to misinterpretation. 
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The innovative selective delivery of minocycline using polymeric NPs as 
carriers, could represent a new promising strategy to gain new insights 
into cellular inflammation of SCI.  
In order to increase the efficacy of potential drugs (e.g. minocycline) in 
modulating macrophage/microglia mediated inflammation and deeply 
understand the role of these cells in the inflammatory process after SCI, 
the aim of this project is to develop a new drug delivery system for a 
selective pharmacological treatment of activated macrophage/microglia 
and to evaluate its efficacy. 
 
SPECIFIC AIMS 
The characterization of this new drug delivery tool will be achieved 
through the development of the following points: 
• The first part of the work aims to characterize a new nanoparticle 
tool able to treat selectively activated microglia/macrophages. 
Different polymeric nanoparticles will be tested in vitro and in vivo 
to define the most suitable biocompatible and biodegradable NPs, 
able to release loaded drugs within cells, after their uptake.  
 
• In the second part of the work, polymeric NPs characterized 
previously will be loaded with a well-known anti-inflammatory 
drug, minocycline. Minocycline-loaded NPs will be used in vitro 
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and in vivo to evaluate the ability of this treatment in modulating 
microglia/macrophages activation. 
 
 
• The third part of this work aims at understanding whether the 
specific inflammatory response related to microglia/macrophage 
activation could lead to an amelioration of the behavioral outcome 
of SCI in a mouse model at different times of investigation 
(subacute and acute phase) by means of a selective modulation of 
this cellular response. In addition, the molecular mechanisms 
related to the inflammatory activation of microglia/macrophages 
will be investigated after their selective modulation. 
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1. BIOMATERIALS SYNTHESIS 
1.1 NPs SYNTHESIS (Provided by Politecnico di Milano) 
The macromonomer used for the NPs synthesis was 
synthesized through a ring opening polymerization 
reaction (ROP) using a procedure reported in literature 
(Ferrari et al.; 2013). PCL based NPs were synthesized 
through free radical emulsion polymerization, by using 
KPS as initiators and Tween80 as surfactant. RhB was 
used as fluorescent dye to detect NPs, it was covalently 
bonded to HEMA (2-hydroxyethyl methacrylate), an FDA 
approved molecule, through an esterification reaction 
and then copolymerized with other monomers obtaining 
NPs with RhB covalently linked to the polymer matrix. 
 
1.2 LOADING OF MINOCYCLINE IN PCL NPS (provided 
by Politecnico di Milano) Since NP synthesis has been 
carried out using an emulsion polymerization process, 
the drug loading step could not take place during NP 
formation because of the presence of both high 
temperature and radicals; therefore, a postsynthesis 
process has been set up. First NPs latex concentration 
was increased up to 5% w/w under a vacuum; the 
absence of NPs coalescence during this step was 
confirmed by Dynamic Light Scattering measurements. 
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Minocycline-base was preliminarily obtained from 
minocycline hydrochloride (Sigma-Aldrich, CAS 13614-
98-7) in order to increase its hydrophobicity and 
consequently the loading efficiency. Minocycline 
hydrochloride was converted into its free base before 
being loaded within NPs to increase its hydrophobicity 
and consequently the percentage of loading. Briefly, 
minocycline hydrochloride (10 mg) was dissolved in a 
saturated solution of sodium bicarbonate (2 mL). Then 
the aqueous solution was extracted four times with 
dichloromethane (4±2 mL). The organic phase was 
separated and then dried over sodium sulfate, filtered, 
and concentrated under reduced pressure. The resulting 
powder (8 mg, 80% yield) was then dissolved in 
Dimethyl sulfoxide at a concentration of 2 mg/mL. The 
drug loading procedure is facilitated since the NPs are 
naturally constituted of a hydrophobic core and a 
hydrophilic shell constituted of PEG chains. The drug was 
entrapped in the partially swollen preformed NPs in the 
following way: a Polytetrafluoroethylene cylinder of 1 cm 
of diameter and 1 cm of length with an axial perforation 
of 1 mm diameter and a radial one of 500 μm was used 
as a mixing device for the drug loading procedure. The 
NP latex (300 mg in 6 mL of deionized water, 
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concentration of 50 mgNPs/mLwater) and the dissolved 
drug (2 mg of minocycline in 1 mL of DMSO) were loaded 
in syringe pumps and injected radially in the device at a 
flow rate of 30 and 5 mL/min, respectively. Four-hour 
dialysis was employed to remove free minocycline. The 
amount of minocycline present in PLC based NPs at the 
end of the dialysis period was determined by HPLC-
MS/MS. For that, aliquots were added with IS and 10 
volumes of chloroform:isopropanol (1:1), shaken for 5 
min and centrifuged at 13.000 rpm for 10 min. 
Supernatants were dried under a gentle nitrogen stream 
at room temperature, and samples were finally 
reconstituted in acetonitrile (ACN, Sigma-Aldrich) 
containing 0.1% formic acid to be injected in the 
HPLC_MS/MS system maintained at 6°C. Stock solutions 
of minocycline hydrochloride (Sigma-Aldrich) and 
demeclocycline hydrochloride (Sigma-Aldrich), used as 
internal standard (IS), were prepared in methanol and 
kept at -20°C until use. All chemicals (formic acid, 
isopropanol, and chloroform, Carlo Erba) used were of 
analytical or HPLC-MS grade. The HPLC system consisted 
of an Alliance separation module 2695 coupled with a 
Micromass Quattro Micro triple quadrupole mass 
spectrometer (Waters) controlled by Mass Lynx software 
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4.1. The mass spectrometer operated in positive ion and 
multiple reaction monitoring (MRM) mode, measuring the 
fragmentation products of molecular ions of substances. 
The instrument is equipped with an electrospray 
ionization interface and uses argon as collision gas. 
Source and desolvation temperatures were set at 100 
and 300°C, respectively. Samples were analyzed with the 
ion spray needle operating at 4.8 kV, the cone voltage at 
25 V, and the collision energy at 15 eV. The principal ion 
transition 458.1 > 441.2 was selected for minocycline 
quantification, while the transition 465.0 > 448.3 was 
selected for IS. Chromatographic separation was 
achieved on a Waters XTerra MS C18 column (100±2.1 
mm, 3.5 μm) coupled with an XTerra C18 cartridge, held 
at 30°C. The mobile phases consisted of water (MP-A) 
and ACN (MP-B), both containing 0.1% formic acid. The 
HPLC system was set up to operate at a flow rate of 0.2 
mL/min at a the following linear gradient: from 2 to 98% 
MP-B in 15 min, at 98% MP-B for 3 min, from 98 to 2% 
MP-B in 1 min (total run time 30 min). The retention 
times were 9.9 min for minocycline and 11.3 min for IS. 
 
1.3 HYDROGEL SYNTHESIS (provided by Politecnico di 
Milano) Hydrogels (AC) were prepared by blocking 
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polymerization in PBS at about 80°C, where polymeric 
solution (carbomer 974P 0.5 wt.%, agarose 0.5 wt.%) 
was achieved by mixing polymer powders into the 
selected solvent, adding a mixture of cross-linking agents 
primarily made of propylene glycol (30 wt.%) and 
glycerol (1.2 wt.%). Reaction pH was indeed kept 
neutral. Gelation start was achieved by means of 
microwave (EM) stimulation. Effective gelation and 
reticulation were achieved by microwave heating for 1 
min per 10 mL of polymeric solution. 
 
2 IN VITRO EXPERIMENTS 
 
Procedures involving animals and their care were conducted in 
conformity with the institutional guidelines that comply with national 
(D.L. n. 116,G.U., suppl. 40, Feb. 18, 1992, Circolare No. 8, G.U., July 
14, 1994) and international laws and policies (EEC Council Directive 
86/609, OJL 358, 1, December 12, 1987; Guide for the Care and Use of 
Laboratory Animals, U.S. National Research Council, 1996). 
 
2.1 PRIMARY CELL CULTURES Primary cultures of 
microglia or neuron/glia co-cultures were obtained from 
the spinal cord of  C57BL/6J (Charles River Laboratories 
International, Inc.) and B6.129P-Cx3cr1tm1Litt/J (The 
Jackson Laboratory) mouse embryos (E13). Spinal cords 
were dissected, exposed to DNase and trypsin (Sigma-
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Aldrich, Milan, Italy), and centrifuged through a BSA 
cushion. Cells obtained at this step were a mixed 
neuron/glia population and underwent centrifugation 
through a 6% iodixanol (OptiPrep, Sigma-Aldrich) 
cushion to separate large neurons from glial cells. The 
glial feeder layer was prepared by plating the glial 
fraction at a density of 25 000 cells/cm2 into 12-well 
plates or into flasks, both previously pre-coated with 
poly-L-lysine (Sigma-Aldrich). Purified microglia were 
obtained from flasks containing confluent mixed glial 
cultures after overnight shaking at 275 rpm in 
incubators. The supernatants (containing microglia) were 
collected and seeded at a density of 20.000 cells/cm2. 
Astrocyte cultures were obtained by treating the glial 
cultures, from which microglia had been previously 
harvested, with 60 mM L-leucine methyl ester (Sigma-
Aldrich) for 90 min. To establish neuron/glia co-cultures, 
the neuron-enriched fraction (obtained from the 
iodixanol-based separation) was seeded at a density of 
10.000 cells/cm2 onto a mature astrocyte layer, and 
microglia were added (10% of the astrocyte number) on 
the third day in vitro. 
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2.2 CULTURE TREATMENTS Microglia activation was 
induced by exposing purified microglia cultures or 
neuron/glia co-cultures to 1 μg/mL of LPS (from 
Escherichia coli 0111:B4; Sigma-Aldrich) for 18 h. 
Cultures maintained with normal medium served as the 
control condition. PCL NPs were then added to untreated 
or LPS-stimulated cultures. For the chlorpromazine 
hydrochloride (CPZ; Sigma-Aldrich) treatments, different 
solutions of CPZ (final concentrations: 30, 40, or 50 μM) 
were added to the culture medium 2 h before NPs 
exposure. CPZ did not show neurotoxicity up to 40 μM. 
 
2.3 CELL VIABILITY ASSAY The CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (MTT; Promega, 
Italy) was used according to the manufacturer’s 
instruction to determine cell viability in NPs treated 
microglia cultures. 
 
2.4 IMMUNOCYTOCHEMISTRY Cells were fixed with 4% 
paraformaldehyde and permeabilized by 0.2% Triton X-
100 (Sigma-Aldrich). Staining was carried out by 
overnight incubation with the primary antibodies, 
followed by incubation with an appropriate fluorescent 
secondary antibody. Cell nuclei were labeled with 
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Hoechst 33258 (Invitrogen) by incubation with a 250 
ng/mL solution. The following primary antibodies were 
used: anti-NeuroFilament 200 (rabbit, 1:500; Sigma-
Aldrich); anti-GFAP (rabbit, 1:500; Millipore); anti-
CD11b (rat, 1:1,000; eBioscience Inc.). Appropriate 
fluorescent secondary antibodies (Dy-light; Rockland 
Immunochemicals Inc.) conjugated to different 
fluorochromes were used at 1:1.000 dilution. For 
lysosomal activity analyses, a lysosensor dye (1:20.000 
diluition, Life technologies) was used. For the membrane 
staining, we used the Wheat germ agglutinin (WGA) 
Alexa fluor 350 conjugated (5 μ g/ml, Life technologies). 
 
2.5 TRANSMISSION ELECTRON MICROSCOPY A 5 μL 
drop of purified PCL in PBS were placed on a 100 mesh 
formvar/carbon coated copper grid (EMS, Hatfield, PA, 
USA) and observed with an Energy Filter Transmission 
Electron Microscope (EFTEM, Zeiss Libra® 120) equipped 
with YAG scintillator slow scan CCD camera. Microglia 
cells were plated on glass coverslips and exposed to 
PMMA for 1 and 6 days. After incubation, cells were pre-
fixed with 4% paraformaldehyde and 1% glutaraldehyde 
in Hepes 0,2M (pH 7.4) and fixed at 4°C in 1% 
glutaraldehyde in Hepes 0.2M, pH 7.4 until use. After 30 
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minutes incubation with osmium 1% in 0.12M phosphate 
buffer pH 7.4 on ice, cells were incubated with a 
saturated solution of thiocarbohydrazide followed by 
1.5% ferrocianide and 1% osmium for 30 minutes. 
Microglial cells were then counterstained with 0.5 % 
uranyl acetate after dehydration in graded series of 
ethanol and embedded in Epoxy medium (Epon 812 
Fluka, Sigma Aldrich). Thereafter, coverslip was removed 
from the well of multiwell plate and, to allow the transfer 
of cells from coverslip to resin block, was placed on 
disposable flat embedding mold (Electron Microscopy 
Sciences) pre-filled with Epoxy resin and polymerized at 
60°C for 72 h. After removing the glass coverslip using 
40% fluorhydric acid, resin block with neurons on the top 
was trimmed to obtain a small pyramid suitable for 
ultrathin (55-60 nm thick) sectioning with a Leica EM 
UC6 ultramicrotome. Sections were then collected on 100 
mesh formvar carbon coated grids and examined with an 
EFTEM equipped with a YAG scintillator slow scan CCD 
camera (Zeiss). 
2.6 CHEMOTAXIS  ASSAY Conditioned media (CM) were 
collected from purified microglia cultures treated with 1 
mg/mL LPS (from Escherichia coli 0111:B4; 
SigmaeAldrich) for 18 h to induce microglia activation, 
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and then exposed to empty NPs (PCL, NPs 0.25 gr 
polymer/mL) or minocycline loaded NPs (PCL-mino, 0.25 
mg of minocycline within 0.25 gr of polymer/mL) for 72 
h. CM were analyzed to detect the levels of CCL2 release 
by solid-phase sandwich enzyme-linked immunosorbent 
assay (ELISA, sensitivity of the kit: 15 pg/mL; 
eBioscience) following the manufacturer's instructions 
and stored at -8°C for macrophage treatments. 
Macrophages plated into a small slit of the m-Slide 
Chemotaxis 2D (IBIDI) were exposed to CM on the first 
day in vitro for 18 h. CM (final dilution 1:2.5) was added 
into the reservoir specifically used to test the 
chemoattractant properties of compounds, as described 
by Zengel et al. [34]. Each m-slide contains three 
independent experimental set up: control condition, 
where both reservoirs were filled with unconditioned 
medium (UM) and two testing conditions, where one 
reservoir was filled with CM (from LPS-activated 
microglia treated with empty PCL or PCL-mino) and the 
other one with UM. The evaluation of macrophages 
migration was performed using live cell imaging 
techniques. Time-lapse video microscopy was performed 
using a Cell^R imaging station (Olympus) coupled to an 
inverted microscope (Olympus IX 81) and equipped with 
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an incubator to keep constant temperature (37 °C) and 
CO2 (5%). Images were acquired with a 4X objective 1 
frame/30 min for a total of 18 h. Quantification of 
chemotaxis was performed by evaluating M1 
macrophages migration, expressed by COM (Chemotaxis 
and Migration Tool, IBIDI) a strong parameter for 
evaluating chemotaxis that represents the spatial 
averaged migration of all cell endpoints. 
 
 
3 IN VIVO EXPERIMENTS 
 
 
3.1 SURGERY C57BL/6J mice (Charles River Laboratories 
International, Inc.) or B6.129P-Cx3cr1tm1Litt/J mice 
(The Jackson Laboratory) were used for in vivo studies. 
Before surgery, the animals received an antibiotic and 
analgesic treatment, respectively with a subcutaneous 
injection of ampicillin (50 mg/kg) and buprenorphine 
(0.15 mg/Kg). Entire surgical procedure was carried out 
in deep anesthesia by ketamine hydrochloride 
(IMALGENE, 100mg/kg) and medetomidine hydrochloride 
(DOMITOR, 1mg/kg) intraperitoneally. Animals were 
placed on a Cunningham Spinal Cord Adaptor (Stoelting, 
Dublin, Ireland) mounted on a stereotaxic frame, and 
laminectomy of T12 vertebra was done to uncover the 
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lumbar spinal cord. For the induction of a localized 
inflammatory reaction, using a glass capillary (40±2 μm 
diameter) the hydrogel AC solution (0.5 μL/site) was 
injected in the spinal cord with a flow rate of 0.2 μL/min. 
Stereotaxic coordinates were referred to the midline of 
the dorsal horn of the spinal cord. The needle was 
positioned at +0.5 mm aside from the midline, then it 
was deepened into the parenchyma to 0.7 mm below the 
pia mater. The injector was left in place for 1 min and 
then retracted for 0.2 mm before starting the delivery. 
After gel injection, the needle was left in place for an 
additional 3 min and then gently withdrawn. Mechanical 
trauma of the Spinal Cord at T12 vertebral level was 
achieved using an aneurysm clip with a closing force of 
60g (left in place for 1 min and then removed). After 
spinal cord compression, dorsal muscles were juxtaposed 
using absorbable sutures and the skin sutured. Manual 
compression of the bladder was also performed twice 
daily for two days after SCI induction. At several time 
points mice were treated with intraparenchymal 
injections of minocycline loaded NPs (PCL-mino, 0.25 mg 
of minocycline within 0.25 gr of polymer/mL), empty NPs 
(PCL, NPs 0.25 gr polymer), free delivered minocycline 
(mino free, 0.25 mg in addition to PCL) or phosphate 
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buffered saline, PBS (Saline). Using a glass capillary (40 
± 2 mm diameter) the solutions (0.250 mL/site) were 
injected in the injured area of spinal cord with a flow rate 
of 0.2 mL/min. Six injections were performed in order to 
cover the whole injured area. The capillary was 
positioned at ±0.5 mm aside from the midline, then it 
was deepened into the parenchyma to 0.6mm below the 
pia mater. After treatment, dorsal muscles were 
juxtaposed using absorbable sutures and the skin 
sutured and disinfected. During the experiment, mice 
were housed one per cage with facilitated access to food 
and water. To compare the efficacy of the 
intraparenchymal minocycline treatment with the most 
commonly used intraperitoneal (IP) administration, a 
group of mice (mino-IP) was treated with intraperitoneal 
injection of 50 mg/kg minocycline 1 h after surgery. This 
was followed 24 h later by a second injection of 50 
mg/kg. Subsequently, treated mice were injected with a 
25 mg/kg dose every 24 h for the next 5 days (Wells et 
al.; 2003). 
 
3.2 BEHAVIORAL EVALUATIONS All treated mice were 
evaluated by testing hind-limb locomotor performances 
using Basso Mouse Scale (BMS) once a week from day 7 
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e 63 DPI. The BMS is a 10-points scale (9 = normal 
locomotion; 0 = complete hind limb paralysis). Video 
acquisition of the locomotor performances (5 min) was 
performed by camera (ICD-49E, Ikegami) and the 
evaluation was carried out by two independent 
observers, blinded to the treatment. Individual hind limb 
scores were averaged for each animal at each time point. 
 
3.3 TRANSCARDIAL PERFUSION At selected time mice 
were deeply anesthetized with ketamine hydrochloride 
(IMALGENE, 100 mg/kg) and medetomidine 
hydrochloride (DOMITOR, 1 mg/kg) and transcardially 
perfused with 40 mL of PBS, 0.1 mol/liter, pH 7.4, 
followed by 50 mL of sodium phosphate buffered 4% 
paraformaldehyde solution. Spinal cords were rapidly 
removed, post-fixed for 2 h, transferred to 30% sucrose 
in PBS at 4°C overnight for cryoprotection and stored at 
4°C until use. 
 
3.4 PREPARATION OF SPINAL CORD SECTIONS Spinal 
cords area around the site of injection (±5 mm from the 
epicenter) was embedded in OCT compound and frozen 
by immersion in N-pentane. Frozen tissues were 
sectioned in 30 μm coronal sections on a cryostat at −20 
°C. 
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3.5 IMMUNOFLUORESCENCE Imunofluorescence was 
performed on 30 μm coronal spinal cord sections. 
Sections were incubated with different primary antibodies 
dissolved in PBS, 1% normal goat serum and 0.1% 
Triton X-100 and incubated overnight at 4°C under 
constant shaking. Astrocytes were stained with a mouse 
monoclonal antibody directed to GFAP (Glial Fibrillary 
Acidic Protein; 1:2500 dilution, Millipore). Microglia were 
revealed using a rat monoclonal antibody anti-CD11b. To 
label neuronal cells, spinal cord sections were stained 
with NeuroTrace Fluorescent Nissl Stain (1:500 dilution, 
Life technologies, fluorescence excitation/emission 
maxima 640-660 nm). Oligodendrocytes were detected 
with MBP (Myelin Basic Protein; 1:100 diluition; Abcam). 
Sections were then processed with specific secondary 
antibodies conjugated to Alexa Fluor (1:500 dilution, Life 
technologies). Finally, spinal cord sections were mounted 
on slides and coverslipped with a 50% glycerol solution 
in PBS to proceed with acquisition by confocal 
microscope. 
 
3.6 IMMUNOFLUORESCENCE QUANTIFICATION 
Fluorescent signal was quantified thanks to the free 
software Fiji (http://fiji.sc/Downloads). Single cells were 
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surrounded with the “free hand” selection and the 
integrated density of the signal was taken into 
consideration, as a representative value of both signal 
intensity and area of the staining. For the evaluation of 
the cell sphericity, considered an index of microglial cells 
activation, single cells (about 200) were surrounded, and 
the “shape descriptors” were calculated through the 
software Fiji. For each cell, the software gives a value of 
sphericity ranging from 0 to 1, the last representing a 
perfect sphere. For the quantification of the CD11b 
staining in the area around the lesion, a specific plugin of 
Fiji was used (radial profile plot, 
http://rsbweb.nih.gov/ij/plugins/radial-profile.html). This 
plugin produces concentric circles around the epicenter of 
the lesion and gives a graph of the integrated density of 
the pixel values around each circle. We evaluated up to 
100 μm of distance outside the epicenter of the lesion. 
For the correlation between CD68 expression and cellular 
uptake of NPs (about 200 cells evaluated), the integrated 
density of each staining was plotted on a graph, and 
Person's correlation analysis was taken into account. 
 
3.7 QUANTITATIVE ENZYME-LINKED IMMUNOSORBENT 
ASSAYS (ELISA) TNFα, IL-6, IL-1β and CCL2 
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concentrations for both cell culture supernatant and 
homogenate of spinal cord tissues were quantified by 
solid phase sandwich ELISA (eBioscience, Inc.). Samples 
from each experiment were tested in triplicate, according 
to the manufacturer's instructions. To obtain 
homogenate of spinal cord tissues, at selected time point 
mice were transcardially perfused with 40 mL of PBS, 0.1 
mol/L, pH 7.4. Spinal cords were rapidly removed, frozen 
on dry ice and then homogenized in 4 volumes of 5X 
assay diluent provided in the Mouse TNFα ELISA Ready- 
SET-Go! Kit (eBioscence). For each animal the spinal 
cord area encompassed the injury or treatment site (6 
mm) and a cervical part of the cord (internal control) 
were removed and analyzed. 96 wells microplates with 
MaxiSorp surface (NalgeNunc International) were coated 
with Capture Antibody. After blocking for at least 1 h, 
100 mL of either sample or standard mouse TNFα 
(provided by ELISA kit) was added to each well and 
incubated for 2 h at room temperature. After washing, 
Detection Antibody (200 ng/mL) was added and 
incubated for 2 h at room temperature. Following the 
addition of peroxidase substrate solution, the enzyme 
reaction color product was detected by a microplate 
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reader set to 450 nm, with wavelength correction set to 
540 nm. 
 
 
3.8 FLOW CYTOMETRIC ANALYSIS At selected time 
points, B6.129P-Cx3cr1tm1Litt/J mice were deeply 
anesthetized with ketamine hydrochloride (Imalgene, 
100 mg/kg) and medetomidine hydrochloride (Domitor, 1 
mg/kg). After a brief perfusion with PBS, spinal cords 
were rapidly flushed out by the column and the region 
around the lesion epicenter was passed through a cell 
strainer (40 mm-nylon mesh) by pressing with the 
plunger of a 10 mL syringe, and a cell suspension was 
obtained by washing the strainer with 5 mL of GKN 
solution pH 7.4 (8.00 g/L NaCl, 0.40 g/L KCl, 0.93 g/L 
NaH2PO4, 1.42 g/L Na2HPO4, 2.00 g/L Dglucose, 0.02% 
BSA). For each specimen, 1.5 mL of cell suspension was 
centrifuged at 2000 rpm for 5 min and pellets were 
resuspended in 500 mL of FACS blocking (1% BSA and 
5% FBS in PBS). After 20 min of incubation in FACS 
blocking at 4°C, selected primary antibodies (APC-780 
conjugated CD11b, eBioscence, 1:100 dilution; APC-
conjugated CD45, BD-Bioscences, 1:100 dilution; APC-
conjugated Ly6C, BD-Bioscences, 1:400 dilution) were 
added and incubated for 20 min at 4°C in the dark. One 
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mL of PBS was then added and specimens were 
centrifuged at 2000 rpm for 5 min. Pellets were 
resuspended in 1 mL of FACS blocking before proceeding 
to the cytometer analysis. In addition, a specific isotype 
antibody staining was performed as negative control. 
Immunophenotyping analyses were performed on at 
least 1.500.000 cells for each sample by using MoFlo 
Astrios instruments (Beckman Coulter) equipped with 
488, 546 and 640 nm lasers. Fluorescence pulses were 
detected using a band pass filter 531/26 nm for GFP, 
576/21 for RhB, 671/20 for CD45 and Ly6C, 795/70 for 
CD11b Results were analyzed using Kaluza software 
(Beckman Coulter). Data are expressed as percentage of 
positive cells per gated event. 
 
3.9 REAL-TIME REVERSE TRANSCRIPTION 
POLYMERASE CHAIN REACTION (Real Time RT-
PCR) At different time points of analysis, spinal cord 
regions encompassing the epicenter of the lesion were 
dissected out, rapidly frozen on dry ice and stored at -
80°C until use. Total RNA was obtained from tissues 
using miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). 
Briefly, spinal cord segments were suspended in QIAzol 
Lysis Reagent and homogenized with a tissue grinder. 
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Chloroform was added to the homogenate and a phase 
extraction performed. A small volume (0.3 mL) of the 
aqueous phase was added to 450 mL of ethanol and 
loaded onto an RNeasy column. The column was washed 
and RNA eluted following the manufacturer's 
recommendations. RNA was quantified by a 
spectrophotometer at 260 nm for all samples. Samples of 
total RNA were treated with DNAse (Applied Biosystems) 
and reverse-transcribed with random hexamer primers 
using Multi-Scribe Reverse Transcriptase (Taq-Man 
Reverse transcription reagents; Applied Biosystems). 
Realtime RT-PCR was performed using 2 ng of cDNA, 200 
nmol of each primer and SYBR Green master mix 
(Applied Biosystems) in a total volume of 20 mL. Levels 
of PCR product were measured using SYBR Green 
fluorescence collected during Real-Time RT-PCR on an 
Applied Biosystems 7300 system. The expression of the 
following genes was analysed: YM1 (FW: 
TCTGGTGAAGGAAATGCGTAAA; REV: 
GCAGCCTTGGAATGTCTTTCTC); Arg-I (FW: 
CATGGGCAACCTGTGTCCTT; REV: TCCTGGTACA 
TCTGGGAACTTTC); IL1β (FW: 
AGTTGACGGACCCCAAAAGA; REV: 
GGACAGCCCAGGTCAAAGG); TNFα (FW: 
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AGACCCTCACACTCAGATCATCTTC; REV: TTGCTACG 
ACGTGGGCTACA); CCL2 (FW: GCCTGCTGTTCACAGTTGC; 
REV: ATTGGGATC ATCTTGCTGGT); β-Actin (FW: 
CGCGAGCACAGCTTCTTT; REV: 
GCAGCGATATCGTCATCCAT). β-Actin was used as the 
reference gene and relative gene expression levels were 
determined according to the manufacturer's DDCt 
method (Applied Biosystems). Data are expressed as fold 
change from uninjured spinal cord samples (healthy 
condition). 
 
 
3.10 LIGHT SHEET FLUORESCENCE MICROSCOPY (LSFM) 
Spinal cords from perfused and fixed mice have been 
processed for Light Sheet Fluorescence Microscopy 
(LSFM). We performed a whole mount staining of myelin 
with green Fluoromyelin (#F34651, Life technologies). 
Briefly, specimens were permeabilized through a 4-day-
long procedure. In the first day, specimens were 
immersed in Dent's solution (4 parts Methanol, 1 part 
DMSO) for 8 h at 4°C and then transferred in Dent's 
bleach (1 part H2O2 30%, 2 parts Dent's solution) o.n. at 
R.T. Subsequently, spinal cords were placed in methanol 
and permeabilized through several passages at -80°C 
(45 min at -80°C and then thaw at R.T.). In the third 
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day, tissues were rehydrated by methanol, treated with 
Proteinase K (10 μg/mL in PBS) for 5 min and then 
transferred in a blocking solution containing 0.5% Triton 
X-100, 4 parts FBS, 1 part DMSO. In the fourth day 
spinal cords were then transferred in the staining 
solution containing Fluoromyelin (1:200), 0.5% Triton X-
100, 4 parts PBS and 1 part DMSO for 4 days. After the 
staining, spinal cords were washed in PBS and Triton X-
100 0.5% to remove the excess of staining. Then, spinal 
cords were clarified and imaged through the 3DISCO 
technique (Ertuk et al.; 2012). Specimens were 
dehydrated through a crescent series of tetrahydrofuran 
(THF) (300 in THF 50%, 300 in THF 70%, 300 in THF 
80%, 450 in THF 100% x2), lipids were then removed 
with dichloromethane (DCM) for 200. Tissues were then 
clarified with a solution of benzyl alcohol and benzyl 
benzoate (1:1, BABB) and conserved until acquisition in 
this clearing solution. LSFM was performed using a 
custom made microscope, whose optical scheme is 
similar to the system proposed by Dodt et al. (Dodt et 
al.; 2007). The illumination is provided by two laser 
beams that are focused with two cylindrical lenses on the 
sample from two opposite sides, in order to create an 
illumination plane. A 4x objective (Olympus UPLFLN 
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4x/0.13 with 17 mm working distance) was used for 
fluorescence detection. The sample was automatically 
scanned through the illumination plane while the 
fluorescence signal was imaged by an Hamamatsu 
camera (Digital camera ORCA-ER-1394), acquiring about 
400 images for each sample. The field of view of the 
camera was 2.2 mm x 1.6 mm and, in order to image a 
large volume of the spinal cord, the samples were 
translated vertically and several regions of interest 
(typically 7) were acquired. Fluoromyelin Green signal 
was acquired using a 488 nm laser for excitation, with an 
emission filter of 525/50 nm (Omega). The regions of 
interest were stitched by XuvTools software 
(www.xuvtools.org) and the images were then 
reconstructed and analyzed using Imaris software 
(Bitplane). A region of interest (ROI) was applied to 
measure the fluoromyelin signal of the preserved tissue. 
 
3.11 MICROSCOPY Fluorescent signal was acquired by using 
a 40X objective magnification, BX81 microscope and 
Fluoview II camera (Olympus). Colocalization studies 
were carried out by confocal microscope by using 40X 
objective magnification, BX81 microscope, FV1000 
confocal (Olympus). Time lapse analysis was performed 
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by using 60X objective magnification, Cell R station 
(Olympus), ORCA camera (Hamamatsu). 
 
 
3.12 STATISTICAL ANALYSIS Data were processed using 
Prism 6 software (Graphpad). Values are reported as 
mean ± SEM or mean ±SD. Mann−Whitney rank sum 
test was performed to test the significance among groups 
for in vitro NPs uptake assessment, in vivo evaluation of 
CD11B staining at 15DPI, in vivo evaluation of CD68 
staining at both 3 and 15 DPI, in vivo FACS analyses. 
Kruskal-Wallis and Post hoc analysis (Dunn’s test) was 
performed to test the significance among groups for in 
vitro NPs uptake assessment after CPZ treatment and in 
vitro ELISA assay, in vitro evaluation of cell sphericity, in 
vivo evaluation of CD11b staining at 3 DPI, whereas a 
two-way ANOVA and post hoc analysis (Tukey's test) 
were performed to test the significance among groups for 
in vivo ELISA assay and behavioral analysis. P<0.05 
were considered as statistically significant for all analysis.  
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1. INTRODUCTION 
 
Among the physiopathological mechanisms involved in the progression 
of SCI, inflammation is one of the most relevant. Indeed, recent 
discoveries demonstrated that acute and chronic inflammation, 
represented by microglia and cellular infiltration (neutrophils, 
macrophages and lymphocytes), which subsequently induce the release 
of inflammatory mediators (cytokines and chemokines), results in the 
spreading and exacerbation of tissue injury. The strong inflammatory 
response that occurs after SCI is triggered by the immediate activation 
of resident microglial cells, able to rapidly respond to insults by 
changing their own phenotype toward a phagocytic activated shape, 
and by the subsequent recruitment of monocyte-derived macrophages, 
that reach the lesion site via the blood stream. Within the lesion, these 
myeloid cell populations acquire a unique molecular phenotype and 
share comparable neuromodulatory functions, so in a pathological 
context they are referred to as microglia/macrophages. Activated 
microglia and macrophages dominate sites of SCI soon after the trauma 
and persist in the tissue for several weeks (Sierra et al.; 2013, Loane et 
al.; 2010). Recently, a dual role (harmful or beneficial) has been 
associated to different activated microglia/macrophage phenotypes (M1 
and M2) during the progression of the traumatic event (Kigerl et al.; 
2009, Shechter et al.; 2013). The M1 phenotype is associated with the 
release of reactive oxidizing species and inflammatory mediators; much 
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evidence show that the chronic or uncontrolled M1 activation results in 
neurotoxicity and pro-inflammatory response (Kigerl et al.; 2009, Beck 
et al.; 2010). Conversely, M2 microglia/macrophages support tissue 
repair, intrinsic growth and resolution of inflammation. The mechanisms 
responsible for this functional diversity in microglia/macrophages are 
not well understood, but are surely conditioned by differential signaling 
pathways mediated by chemokines and cytokines and other 
components present in the lesion microenvironment. They appear to be 
able to activate specific intracellular signaling pathways with opposite 
results. In a SCI inflammatory context, the dynamic equilibrium of 
M1/M2 expression has been extensively studied and shows a prevalence 
of M1 polarization of resident microglia immediately after injury with a 
subsequent recruitment of M1 macrophages, and an only transient 
appearance of M2 microglia/macrophages few days after injury. (David 
and Kroner, 2011; Raposo and Schwartz, 2014; Cohen et al., 2014; 
Shechter and Schwartz, 2013; Thawer et al., 2013). Unfortunately, this 
pattern of expression, with a prevalent M1 phenotype acquisition, 
impairs and limits the recovery and the behavioural outcome after SCI. 
This suggests that microglia/macrophage associated inflammation could 
be a persistent deleterious event during the chronic phase of 
neurodegeneration, representing a crucial therapeutic target for SCI 
treatment (Cerqueira et al.; 2013, Sato et al.; 2012). In this view, a 
pharmacological approach specifically tailored to modulate microglia/ 
macrophage activation would provide better chances to interfere with 
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inflammatory events. Different strategies aimed to selectively modulate 
microglia/macrophages have already been proposed in preclinical 
paradigms, such as specific viral carriers, able to transfer genetic 
sequences and modulate their own expression (Chen et al.; 2005) or 
various anti-inflammatory treatments (Loane et al.; 2010, Festoff et al.; 
2006). However, they showed many limitations. Some safety concerns 
are associated with gene therapy approaches. Moreover, the short half-
life of genes delivered in dividing cells through non-integrative vectors 
and the possibility that the viral vector is inactivated due to recognition 
by the immune system, restricts the range of possible applications of 
gene therapy (Nayerossadat et al.; 2012). On the other hand, anti-
inflammatory drugs are not selective for a specific cell type and may 
give rise to potential side effects associated with systemic 
administration.  
Among the drugs with a direct active effect on microglial cells, 
minocycline is one of the most promising. In fact, in addition to the 
well-known antimicrobial activity, minocycline has been reported to 
have neuroprotective effects in various experimental models such as 
cerebral ischemia, Amyotrophic Lateral Sclerosis, Parkinson's disease, 
Huntington disease, Multiple Sclerosis, Traumatic Brain Injury and SCI. 
Recent studies have demonstrated anti-inflammatory, antiapoptotic and 
antioxidant properties of minocycline in SCI. Anti-inflammatory effects 
are mostly associated with the suppression of the proliferation and 
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activation of the microglial cells and the subsequent release of cytokines 
such as IL-1β, TNFα, IL-6, chemokines, and nitric oxide.  
However, it has been reported that a prolonged systemic administration 
of minocycline causes a significant incidence of vestibular effects 
(dizziness, nausea and vomiting) and pigmentation accumulating in skin 
and sclera of the eyes (Zemke et al.; 2004). 
Recently, a new approach using nanoparticles (NPs)-based tool has 
been proposed as a selective carrier to deliver compounds directly in 
microglial cells, namely Qdot nanocrystal (Minami et al.; 2012). This 
approach exploits the phagocytic activity of activated 
microglia/macrophages to obtain a selective uptake of NPs by these cell 
populations. However, a great limitation associated with the capability 
of these NPs to link chemically to compounds restricts this approach to 
a scanty number of drugs. As an alternative, polymeric NPs represent a 
promising pharmacological delivery tool, thanks to their biocompatibility 
and their ability to sustain the release of drugs. In the first part of this 
work a new selective delivery tool will be characterized in vitro, namely: 
biodegradable polymeric NPs (100 nm size), obtained through a two-
step process, both solvent-free, with a peculiar comb-like structure 
composed of a poly-(2-hydroxy-ethyl methacrylate) backbone grafted 
with poly-ε-caprolactone (PCL) and PEG chains both controllable in 
terms of length and composition. These NPs (hereafter termed PCL NPs) 
present unique properties such as biocompatibility and the possibility to 
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sustain the release of drugs. Moreover, their high versatility allows 
control of their degradation rates depending on medical needs.  
A selective delivery of minocycline in microglia/macrophages by PCL 
NPs could enhance drug targeting and concentration at the injury site, 
reduce side effects, limit drug catabolism and slow down the release of 
drugs over time. 
The selective delivery of drugs through NPs administered in situ 
facilitates also the access of drug to SC. Indeed, conventional drug 
delivery directed to the damaged spinal cord is limited by the partial 
physical obstruction due to the BSCB. Most therapeutic compounds are 
not able to cross the BSCB when administered by oral intake or 
intravenous infusion. Alternatively, intrathecal delivery by catheters and 
implanted minipumps has been proposed. However, several 
disadvantages are associated with the latter delivery techniques, such 
as side effects of the surgery that is required to implant them and pump 
refilling.  
Accordingly, in the second part of this work the efficacy of an in situ 
minocycline-loaded PCL NPs treatment in reducing the activation of 
microglia/macrophages in an inflammatory context will be evaluated in 
an in vivo paradigm.  
This pharmacological tool will also be useful to understand the real 
contribution of microglia/macrophage mediated inflammation during SCI 
progression. Indeed, despite the recent growing effort to characterize 
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the role associated to the innate immunity response, the specific role 
played by activated resident microglia during the inflammatory phase 
remains elusive. Various reasons could explain the difficulties 
encountered to understand the involvement of activated microglia in 
this neuropathology: i) microglial cells are extremely complex to target 
experimentally; ii) their beneficial or detrimental effects are spatially 
related and temporally defined (Shechter et al.; 2013, Thawer et al.; 
2013, Cohen et al.; 2014, Kigerl et al.; 2009); iii) several subsets of 
microglia are involved (Shechter et al.; 2013, Thawer et al.; 2013, 
Cohen et al.; 2014, Kigerl et al.; 2009). This raises the importance to 
understand the functional commitment of inflammatory cells over time 
and space. Given these critical issues, in the third part of the work an in 
situ minocycline-loaded PCL NPs treatment will be performed in SCI 
mice, in order to understand the distinct role played by 
microglia/macrophage in SCI mouse model and to provide a specific 
treatment to counteract their deleterious effects during the progression 
of secondary injury.  
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2.  RESULTS 
 
2.1 DEVELOPMENT AND CHARACTERIZATION OF A 
MICROGLIA/MACROPHAGE  TARGETED 
NANOVECTOR IN VITRO 
 
 
2.1.1 Aims 
 
 
In order to increase the efficacy of potential drugs in modulating 
microglia/macrophage mediated inflammation after SCI, the aim of the 
first part of this work is to develop and characterize in vitro a new 
polymeric NPs drug delivery system for the selective pharmacological 
treatment of activated microglia/macrophage. 
In particular, the distribution and biocompatibility of polymeric NPs 
composed of poly-(2-hydroxy-ethyl methacrylate) and poly-ε-
caprolactone (PCL), conjugated to Rhodamine B (RhB), will be 
evaluated in in vitro co-cultures of microglia, astrocytes and neurons.   
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2.1.2 Evaluation of selective microglia/macrophage 
uptake of PCL nanoparticles 
 
Primary co-cultures of microglia, astrocytes and neurons obtained from 
the spinal cord of mouse embryos (see methods) were used to 
characterize the uptake of PCL NPs previously described. Specific 
antibodies were used to detect astrocytes, microglia and neurons in co-
culture (respectively stained for GFAP, CD11b and NF200). In order to 
mimic an inflammatory environment, cell cultures have been treated for 
18 hours with LPS, a potent immuno-activator of monocytes and 
macrophages, widely used to activate microglia cells in vitro. 
Morphological changes have been verified for LPS-stimulated microglial 
cells, which showed an activated hypertrophic shape 
(amoeboid/phagocytic shape) in comparison to untreated microglial 
cells used as the control condition (Fig. 1.1, A). No relevant 
morphological alterations were found for astrocytes and neuronal cells 
(Fig. 1.1, A) after LPS stimulus. In addition, a cell viability assay in 
neuroglial culture was performed showing a lack of both morphological 
alteration and viability in astrocytes, whereas 30% of neuronal death 
was detected (data not shown). The NPs uptake evaluation was 
performed only in healthy neuroglial cells detected as negative staining 
for Propidium Iodide (cell death marker). Co-cultures were exposed to 
PCL NPs for 48h (1:100 dilution rate) (Fig. 1.1 A). A selective 
internalization in microglial cells of a few NPs has been observed in 
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unstimulated cultures (Fig. 1.1 A, a,b). Noteworthy, a remarkable 
increased uptake of PCL NPs was detected in LPS-stimulated microglial 
cells (Fig. 1 A, c,d) compared to unstimulated condition, as shown by a 
higher diffuse RhB signal in the cytosol of activated microglia. 
Quantification of RhB internalized in microglia after PCL NPs treatment 
confirms this observation, revealing a significant difference between 
unstimulated and LPS stimulated microglia (about 1.7 fold) (Fig. 1.1, 
B). 
The selectivity of PCL NPs uptake by microglial cells was further 
confirmed by the absence of colocalization between red signal of RhB 
and blue signal of NF200 (Neurons, Fig. 1 A, a,c) or GFAP (Astrocytes, 
Fig. 1 A, b,d). 
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Figure 1.1. In vitro characterization of PCL NPs uptake, in primary co-
cultures of microglia, astrocytes and neurons. Accumulation of fluorescent PCL 
NPs (A) is markedly increased in LPS stimulated microglia (c,d arrows) 
compared to control condition (a,b arrows). No uptake is observed for both 
neurons (a,c arrowheads) and astrocytes (b,d arrowheads). Microglia, CD11b 
(green); NPs (RhB), (red); neurons, NF200 (blue) (a,c); astrocytes, GFAP 
(blue) (b,d). Scale bar=15 μm. Uptake quantification of PCL NPs (B) in 
activated microglia (LPS) vs unstimulated cells (CTR). Data are presented as 
mean ± SEM. Statistical significance: (*)p≤0.05. 
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2.1.3 Time lapse analysis of PCL NPs uptake  
 
In order to investigate the PCL NPs uptake kinetics, time-lapse analysis 
was performed on purified cultures of LPS-stimulated microglia. Time-
lapse analysis after PCL NPs uptake showed that NPs uptake was 
detectable already after 24 hours of treatment, reaching a plateau after 
48 hours of incubation (Fig. 1.2 A). After internalization, a cytosolic 
localization of the RhB signal was found in activated microglia, 
progressively evolving in a cytosol-perinuclear intense distribution, as 
revealed at the end of the acquisition (Fig. 1.2 A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Time-lapse analysis of PCL NPs uptake kinetics. (A) RhB red 
signal shows a perinuclear distribution after 48 hours of treatment. (B) 
B 
A 
PCL NPs kinetic 
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Quantitative evaluation of progressive PCL NPs internalization in activated 
microglial cells during time lapse analysis. Data are presented as mean±SEM.  
 
 
2.1.4 Evaluation of cell viability after PCL NPs uptake 
 
 
To evaluate the biocompatibility of PCL NPs after internalization, we 
tested the cell viability in purified LPS-stimulated microglia cultures. PCL 
NPs uptake did not affect microglial cell viability up to 6 days, as 
detected by MTT assay comparing LPS-stimulated cells treated or not 
with PCL NPs (Fig. 1.3 A). Furthermore, we assessed the release of 
three inflammatory cytokines (IL-1β, IL-6 and TNFα) in co-cultures, 
after treatment with NPs, in order to evaluate whether PCL NPs could be 
a further stimulus to release pro-inflammatory cytokines. We removed 
the medium after 18 hours of LPS stimulation and we treated cells with 
NPs for 48 hours (uptake plateau for PCL), detecting the subsequent 
release of pro-inflammatory cytokines from activated microglia. 
Analyzing the medium for IL-1β, TNFα and IL-6 by ELISA assay, we 
found that IL-1β and TNFα were below the detection limit, whereas IL-6 
showed a significantly increased level in the medium of LPS stimulated 
co-cultures (148.6±10.70 mean pg/ml±SD) compared to unstimulated 
cultures (66.8±35.3 mean pg/ml±SD) (Fig. 1.3 B). When we analyzed 
LPS-stimulated microglial cells exposed to NPs, no significant 
differences in the level of IL-6 were detected (169.8±8.5 mean 
pg/ml±SD) compared to LPS-stimulated co-cultures. 
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Figure 1.3. Cell viability and ELISA assay of microglial cells cultures after 
internalization of PCL NPs. (A) MTT assay reveals that viability of LPS 
stimulated microglial cells after 6 days of treatment with PCL NPs is not 
compromised. Data are presented as percentage±SD of viable cells normalized 
to LPS values (no particles exposure), which represents 100% of viability. (B) 
ELISA assay performed on the supernatants of LPS stimulated cells shows that 
after treatment with PCL NPs, the release of pro inflammatory cytokine IL-6 is 
not significantly increased. Data are presented as mean±SD.  
 
 
 
 
2.1.5 Evaluation of PCL NPs uptake mechanism 
 
In order to understand the mechanism underlying PCL NPs 
internalization, we tested the effect of chlorpromazine (CPZ), a clathrin-
mediated endocytosis inhibitor. Different concentrations of CPZ (30-40 
μM) were used in LPS stimulated co-cultures as pre-treatment for 2 
hours, before exposure to NPs. Quantification of RhB signal in 
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stimulated microglia revealed that a significant dose-dependent 
inhibition of PCL NPs uptake was induced by 30 (2.15±0.39 mean 
integrated intensity±SEM) and 40 μM (1.21±0.26 mean integrated 
intensity±SEM) of CPZ (Fig. 1.4 A), compared to cells not pretreated 
with CPZ (LPS), used as control condition (4.90±0.64 mean integrated 
intensity±SEM) (Fig. 1.4 A,B). These data suggest that clathrin-
mediated endocytosis has a determinant role on PCL NPs uptake in 
activated microglia. 
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Figure 1.4. (A) Pre-treatment with CPZ (a-f) is able to inhibit PCL NPs 
uptake in activated microglia in vitro. Microglia, CD11b (green); PCL, (RhB) 
(red). Scale bar=5μm (B) Quantitative analysis of PCL NPs uptake shows that 
uptake inhibition occurs in a dose-dependent manner. Data are presented as 
mean±SD. Statistical significance: (***)p≤0.001. 
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2.1.6 Evaluation of PCL NPs intracellular distribution 
and degradation 
 
In order to investigate the intracellular distribution of NPs, further 
analyses using transmission electron microscopy (TEM) have been 
carried out after the internalization of NPs in activated microglial cells. 
We used not biodegradable- polymeric NPs composed of poly-methyl-
metacrilate (PMMA) as control treatment for this experiment. PCL and 
PMMA NPs were visible by TEM as white dots (Fig. 1.5 A, a) and after 
internalization were stored in a well-defined structure, identified as 
multivesicular bodies (MVBs). In spite of a large amount of NPs 
internalized, no other morphological alterations have been detected in 
the organelles of the cytosol. In fact, a normal structure of 
mitochondria, nucleus, endoplasmic reticulum and Golgi apparatus was 
found in activated microglial cells exposed to NPs, compared to 
microglial cells not exposed to NPs (Fig. 1.5 A, b), confirming the 
biocompatibility of both polymeric NPs. Two days after PCL NPs 
treatment, we observed areas of PCL NPs debris in the intraluminal 
vesicles of MVB digested by the fusion with lysosomes (Fig. 1.5 B, a,b). 
At 6 days after treatment a complete degradation of PCL NPs was 
found, as shown by more diffuse polymeric debris in lysosomes (Fig. 1.5 
B, c,d, arrows). Conversely, PMMA NPs showed an identical white 
spherical shape in MVBs, at both 1 and 6 days after microglial cells 
treatment (Fig. 1.5 C, a-d, arrows). However, at 6 days after treatment 
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NPs resulted more disperse in both cytosol and MVBs (Fig. 1.5 C, c,d). 
In order to verify the lysosomal enzymatic activity after PCL and PMMA 
NPs internalization, a lysosensor, a fluorescent pH indicator that 
measures the activity of acidic organelles, was used to study the 
lysosome function in live cells after NPs treatment. The analysis 
revealed an increased lysosomal enzymatic activity, represented by an 
increased green signal highly colocalized with PCL RhB red signal, at 6 
days after PCL NPs treatment (Fig. 1.5 D, a). This result confirms the 
biodegradability of PCL, which are rapidly sequestered by MVBs at an 
early stage and then completely degraded by lysosomes. 
Conversely, only some green lysosomal spots in the cytosol of microglial 
cells treated with PMMA NPs with a lack of colocalization with RhB 
signal, suggesting a lack of degradation of PMMA NPs by microglia (Fig. 
1.5 D, b). These results underline the biodegradability of PCL NPs, 
compared to PMMA NPs.  
 
 
 
 
 
 
 
 
 
A b 
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Figure 1.5. (A, a) Representative single PMMA NPs in TEM analysis.  (b) 
Organelles of the cytosol don’t show any morphological alteration after PCL or 
control (PMMA) NPs treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. (B) TEM analysis of activated microglia 2 (2D, a, b) or 6 days 
(6D, c, d) after treatment with PCL NPs. NPs are taken up and stored in MVBs 
in the cytosol of activated microglia (b, arrows) and are degraded after 6 days 
(d, arrows). 
 
 
 
 
a 
CTR 
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Figure 1.5 (C) TEM analysis of activated microglia 1 (1D, a, b) or 6 days 
(6D, c, d) after treatment with PMMA NPs. NPs are taken up and stored in 
MVBs in the cytosol of activated microglia without a clear evidence of 
degradation. (D) Lysosomal activity after PCL (a) or PMMA (b) NPs 
internalization. Orthogonal projection of confocal image stack shows that red 
signal of PMMA does not colocalize with lysensor marker, while an increased 
lysosomal enzymatic activity was measured after PCL treatment. PCL or PMMA 
NPs, RhB (red); lysosomes, lysosensor (green); cell membrane, Alexa 
Fluor®350 WGA (blue).  
 
2.1.7 Discussion and Conclusions 
 
 
In this part of the work a new pharmacological approach has been 
validated, based on biodegradable polymeric NPs, that is able to 
selectively target activated microglial cells in vitro. This may represent a 
C 
5 μm 
D 
a 
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potential tool able to modulate selectively microglia/macrophages 
activation in SCI.  
In particular, it has been demonstrated in vitro that: I) PCL NPs are 
internalized selectively by microglial cells in a short time (some hours); 
II) microglia in activated form are able to internalize markedly PCL NPs, 
whereas microglia displaying a resting phenotype are not; III) PCL NPs 
show a complete biocompatibility and degradation when internalized in 
activated microglial cells; IV) PCL NPs internalization in activated 
microglial cells is based on clathrin-dependent endocytosis mechanisms; 
VI) PCL NPs do not induce further proinflammatory stimuli or any 
toxicity. The selective and specific pharmacological tool here 
characterized could provide, compared to the conventional anti-
inflammatory administration tools, some potential advantages for its 
use in in vivo SCI context: I) an improved efficacy of treatment by 
increasing the concentration of the drug in specific target cells in the 
site of injury; II) reduced potential side effects due to the possibility to 
avoid unwanted distribution of the drug to not-target cells or tissues; 
III) time-selective treatment of microglial cells offers the potential to 
modulate the activation of the microglial cells at different stages of the 
secondary injury and the possibility to deepen the understanding of the 
detrimental or beneficial role of the microglia during the progression of 
the disease. 
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2.2 Characterization of PCL NPs cellular uptake 
and evaluation of the pharmacological activity 
of minocycline loaded PCL NPs in vivo 
 
2.2.1 Aims 
PCL NPs are biocompatible and biodegradable polymeric nanoparticles 
that are selectively taken up by activated microglia after an 
inflammatory stimulus in vitro. PCL NPs are able to load drugs and after 
cellular uptake they are able to release their content, allowing a 
targeted therapy to microglia/macrophage, key players in the 
inflammatory cascade. The aim is to evaluate in an in vivo paradigm the 
cellular distribution of PCL NPs in the CNS in an inflammatory milieu and 
to characterize in vitro and in vivo the pharmacological activity of 
minocycline, a well-known anti-inflammatory drug, loaded into PCL NPs, 
and able to modulate selectively the microglia/macrophages activation. 
 
2.2.2 Cellular uptake of polymeric PCL NPs in vivo 
To evaluate and characterize the distribution of PCL NPs in vivo, an 
injection of hydrogel loaded with PCL NPs was performed within the 
parenchyma of mouse SC in order to induce an acute injury and an 
inflammatory response, as described in materials and methods section 
and previously published by our lab (Perale 2011). Early after the 
injection, the hydrogel revealed a spherical enclosure, which physically 
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displaced the tissue in the SC, due to its in situ gelation. To investigate 
the inflammatory response of the nervous tissue to injury induced by 
the injected hydrogel, a double staining with markers for microglia 
(CD11b) and astrocytes (GFAP) or neurons (Neurotrace) was carried 
out. At 3 days post injection (DPI), an inflammatory reaction was 
detected around the hydrogel, identified as a glial scar formation 
composed of phagocytic/ameboid microglia and astrocytes (Figure 2.1 
A). 
A distribution of PCL NPs was found around the injected hydrogel, 
revealing a selective uptake of NPs into the nearest activated-
phagocytic microglia/ macrophages (CD11b) (Figure 2.1 B). The 
selective uptake by microglia/macrophages was confirmed detecting a 
lack of colocalization between NPs (RhB) and GFAP/Neurotrace which 
identifies respectively astrocytes and neurons (Figure 2.1 C, a,b). 
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Figure 2.1. (A) Dashed lines outline representative low magnification 
coronal sections of mouse spinal cord injected, three days before, with PCL 
NPs loaded hydrogel. CD11b staining shows the proliferation/activation of 
microglia/macrophages around injection site. (a) Microglia, CD11b and (b) its 
representation in pseudocolors. Scale bar= 50 µm. (B) (a). High magnification 
of spinal cord section of a mouse injected with PCL NPs loaded hydrogel and 
(b) relative inset representing three-dimensional details of activated 
A 
C 
50 μm 
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microglia/macrophages and PCL NPs uptake around the injection site C. High 
magnification of selective PCL NPs uptake by microglia/macrophages in vivo 
without a clear evident uptake in astrocytes (a, arrows) or neuronal cells (b, 
arrows). 
 
 
2.2.3 Study of the pharmacological activity of 
minocycline selectively delivered in 
microglia/macrophages by PCL NPs in vitro 
 
 
Minocycline was loaded in preformed PCL NPs (PCL Mino) by 
entrapment of the hydrophobic drug in partially swollen NPs, followed 
by 4 h dialysis to remove unloaded drug, as assessed by HPLC_MS/MS 
(see materials and methods section for details). At this dialysis time 
point, PCL NPs retain about 35% of the added minocycline, with a final 
loading of about 1 μg of minocycline/mg of NPs. Microglial cells in vitro 
were analyzed for their morphological criteria by comparing (I) 
unstimulated control cells (CTR); (II) LPS-stimulated cells (LPS); (III) 
LPS stimulated cells treated with free minocycline (LPS+Mino, 0.07 
μg/mL); (IV) LPS-stimulated cells subsequently exposed to PCL 
(LPS+PCL); (V) LPS-stimulated cells subsequently exposed to both PCL 
and free minocycline (LPS+PCL+Mino, 0.07 μg/mL); and (VI) LPS-
stimulated cells treated with minocycline encapsulated in PCL NPs 
(LPS+PCL Mino, 0.07 μg/mL loaded). Unstimulated microglial cells 
showed a small soma with some ramified processes (Figure 2.2 A, a). 
Differently, LPS-stimulated microglial cells displayed a round shape 
typical of fully activated microglia with a macrophage phenotype (Figure 
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2.2 A, b). Evaluating activated microglial cells treated for 96h with PCL 
Mino, a relevant regression toward a quiescent phenotype was found 
(Figure 2.2 A, d). In fact, a reduced round shape phenotype and the 
reappearance of thick processes could be appreciated after PCL Mino 
treatment. This was confirmed also by quantitative evaluation of the 
sphericity (from 0 to 1, respectively, ramified/oval and round shape) as 
a morphological parameter for the evaluation of the activation state of 
the microglial cells. This assessment showed a significantly reduced 
value for LPS+PCL Mino (0.31±0.13 mean sphericity±SD) compared to 
LPS+PCL (0.67±0.17 mean sphericity±SD) (Figure 2.2 C). The 
regression toward a more quiescent phenotype was further 
demonstrated by time lapse analysis on single cells that showed a 
morphologically defined stepwise deactivation up to 96 h (Figure 2.2 B). 
Analyzing LPS+PCL (0.67±0.17 mean sphericity±SD) an increased, but 
not significant, sphericity was detected compared to LPS (0.52±0.09 
mean sphericity±SD), likely due to NPs uptake (Figure 2.2 C). A 
significant reduced sphericity was detected also for cells treated with 
LPS+Mino (0.41±0.12 mean sphericity±SD) and LPS+PCL+Mino 
(0.52±0.10 mean sphericity±SD) when compared respectively to LPS 
(0.51+0.09 mean sphericity±SD) and LPS+PCL (0.67+0.17 mean 
sphericity±SD) stimulated cells (Figure 2.2 A, C), but with a 
significantly lower efficacy compared to activated microglia treated with 
PCL Mino (0.31±0.13 mean sphericity±SD). All groups showed an 
increased significant sphericity compared to CTR group (LPS, LPS+Mino, 
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LPS+PCL, LPS+PCL+Mino p≤0.0001 (****) and LPS+PCL Mino p≤0.05 
(*)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. PCL Mino treatment of activated microglia is able to revert 
activation process in vitro. (A) In primary GFP microglia cultures from CX3CR1 
mouse embryos, LPS treated cells (b) were incubated with PCL (LPS+PCL) (c) 
or with PCL Mino (LPS+PCL-Mino) and analyzed 96 h later (d). Scale bar=10 
μm. (B) Time lapse imaging of a single microglial cell during 96 h of treatment 
with LPS+PCL Mino. At the end of the analysis, microglia show a more ramified 
phenotype. Microglia, GFP (green); NPs, PCL Mino RhB (orange). Scale bar=5 
μm. (C) Evaluation of cell sphericity (index of cells activation) of microglial 
cells after five different treatments. Sphericity of LPS+PCL Mino treated cells is 
C 
LPS+PCL Mino 
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significantly lower than either LPS+PCL or LPS+PCL+Mino treatment. Each dot 
represents the sphericity of a single cell. Statistical significance: (*) p≤0.05; 
(**) p≤0.01; (****) p≤0.0001. 
 
 
2.2.4 Study of the pharmacological activity of 
minocycline selectively delivered in 
microglia/macrophages by PCL NPs in vivo 
 
 
To determine the potential pharmacological activity of drugs delivered 
by PCL NPs previously described, we tested biodegradable PCL NPs 
loaded with minocycline (PCL Mino) in vivo. To do that, an injury 
induced by injected hydrogel was carried out in adult mice (as described 
in materials and methods section). We compared mice injected with 
hydrogel and unloaded PCL NPs (PCL), as control, hydrogel and free 
minocycline (Mino, 35 μg/mL) and hydrogel and minocycline 
encapsulated in PCL NPs (PCL Mino, 35 μg/mL loaded) at two different 
time points, 3 and 15 DPI. Ex vivo analysis revealed a reduced 
proliferation of microglia/macrophages around the injured site in Mino 
mice at 3 DPI (Figure 2.3 A, B, C). Indeed, the quantification of CD11b 
staining around the injection site, detected up to 100 μm from the 
center of the lesion, revealed that Mino treated mice had a significant 
reduction (931±283 mean integrated intensity (SD) compared to 
control mice (PCL) (1630±241 mean integrated intensity (SD) (Figure 
2.3 C)). However, the activated microglia/macrophages around the 
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injection site in Mino treated mice still showed a round shape, 
suggesting a likely reduced proliferation of these cells without a clear 
morphological changing to quiescent phenotype. 
Analyzing PCL Mino mice at 3 DPI, a significant reduction of CD11b 
staining was detected, suggesting a decreased proliferation and 
activation of microglia/ macrophages (767±237 mean integrated 
intensity (SD) (Figure 2.3 A, C). Moreover, an evident morphological 
change toward a more quiescent phenotype (ameboid/resting shape) 
was found in RhB positive microglia/macrophages around the injection 
site (Figure 2.3 A, B) compared to both PCL and Mino mice.  
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Figure 2.3 (A) PCL Mino treatment of activated microglia/macrophages is 
able to revert activation process induced in vivo by hydrogel injection. Dashed 
lines outline representative low magnification coronal sections of mouse spinal 
cord injected, three days before, with PCL loaded hydrogel (a_d, PCL) or PCL 
Mino loaded hydrogel (e_h, PCL-Mino). CD11b staining in PCL Mino treated 
mice shows a reduced proliferation/activation of microglia/macrophages 
around the site of injection compared to PCL mice. Microglia, CD11b (green); 
PCL NPs, RhB (red); CD11b staining pseudocolors image (d_h). Scale bar 150 
μm. 
A 
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Figure 2.3 (B, D) High magnification of spinal cord sections of a mouse 
treated with PCL NPs (B;a) or with PCL Mino NPs (B;b) representing, 
respectively, region 1 and 2 identified by dashed line in panel A. Insets 
represent three-dimensional details of microglia/macrophages around the 
lesion site in both PCL and PCL Mino NPs. PCL Mino NPs induce an evident 
morphological change toward a quiescent phenotype in CD11b positive 
microglia/macrophages that have taken up PCL Mino NPs compared to PCL 
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treatment, and this deactivation is evident up to 15 DPI (D; a,b). Microglia, 
CD11b (green); PCL or PCL Mino, RhB (red); cell nuclei, Hoechst (blue). Scale 
bar=50 μm. (C, E) Evaluation of CD11b staining in a region of tissue up to 
100 μm of distance from the site of injection at 3 DPI for PCL, PCL Mino or free 
Mino loaded and injected with hydrogel (C; a,b) or 15 DPI for PCL and PCL 
Mino loaded and injected with hydrogel (E; a,b). The analysis (Kruskal-Wallis 
test followed by Dunn’s post-hoc analysis) reveals a significant reduced 
microglia/macrophages proliferation/activation in mice treated with 
minocycline, mostly when it was loaded in NPs. Data are presented as 
mean±SD. Statistical significance: (*) p≤0.05.  
 
To further confirm that NPs loaded with minocycline were able to reduce 
the activation state of microglia/macrophages from the 
phagocytic/ameboid to a more quiescent resting state, we investigated 
deeply the activation of the microglia/macrophage cells by studying the 
expression of CD68, a specific marker of activation and phagocytosis. A 
clear decrease of CD68 staining could be appreciated in PCL Mino 
treated mice compared to mice injected with only PCL (Figure 2.4 A). 
Moreover, many cells containing high amount of PCL Mino NPs showed 
low levels of CD68 compared to either cells that did not uptake NPs or 
cells that uptake unloaded NPs (Figure 2.4 B). This was confirmed by 
the correlation analysis between CD68 staining and RhB signal for single 
cells, evaluated around the injury site, comparing PCL versus PCL Mino 
mice (Figure 2.4 C). This analysis highlighted a reduced level of CD68 
staining in cells with a high RhB signal for PCL Mino treated mice (0.08 
Pearson coefficient) compared to PCL treated mice (0.50 Pearson 
coefficient), which showed higher levels of CD68 in highly RhB positive 
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cells. This was confirmed also by a quantitative evaluation of the overall 
CD68 staining comparing PCL Mino to PCL mice around the injury site 
(Figure 2.4 C). 
To assess the duration of deactivation and/or limited proliferation of 
microglia/macrophages, the effect of the treatment here proposed was 
analyzed up to 15 DPI. At this time of analysis, the fluorescent signal of 
PCL NPs is no longer detectable because of their degradation. However, 
a persistent reduced inflammatory state near the lesion site was found. 
In fact, a significant reduced staining of both CD11b and CD68 was 
revealed in PCL Mino compared to PCL mice, the latter used as control. 
This was confirmed by the quantification of CD11b staining, comparing 
an equivalent region of tissue from the epicenter of the lesion in both 
PCL (1590±243 mean integrated intensity±SD) and PCL Mino 
(1081±174 mean integrated intensity±SD) (Figure 2.4 E). In addition, a 
significant persistent reduced activation of microglia/macrophages was 
demonstrated again by evaluation of CD68 staining for PCL Mino 
(141±54 mean integrated intensity±SD) compared to PCL mice 
(721±167 mean integrated intensity±SD) (Figure 2.4 E, b). 
Furthermore, an ELISA assay was carried out on SC tissue homogenates 
at 15 DPI, which showed significantly reduced levels of the 
proinflammatory cytokine IL-6 in the epicenter of the lesion in PCL Mino 
(26.6±5.2 mean pg/mL±SD) compared to PCL mice (69.6±38.4 mean 
pg/mL ±SD) (Figure 2.4 E, a). Conversely, at this time of analysis, IL-
1β and TNFα cytokines did not show any significant difference between 
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the epicenter and a more peripheral portion of tissue in the rostral 
direction used as a control (data not shown), suggesting no relevant 
involvement of these cytokines during the progression of the 
degeneration in the traumatized site in this specific model. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 (A) PCL Mino NPs are able to reduce the pro-inflammatory milieu 
after trauma in vivo. Dashed lines outline representative low magnification of 
coronal sections of mice spinal cord injected with PCL NPs loaded hydrogel 
(a_d) or PCL Mino NPs (e_h). CD68 staining shows a lower signal in PCL Mino 
treated mice (e,f,h) compared to control mice (a,b,d). Activated 
microglia/macrophages cells, CD68 (green); PCL or PCL Mino, RhB (red); 
microglia, Iba-1 (blue). Scale bar=150 μm.  
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Figure 2.4 (B) High magnification of confocal image stack shows that 
microglia/macrophages with high level of PCL Mino NPs internalized exhibits 
low level of CD68 staining after 3 DPI (b, arrows) compared to 
microglia/macrophages that did not uptake NPs (b, arrowheads) or 
microglia/macrophages that uptake PCL (a, arrows). (D) This effect is evident 
up to 15 DPI (a,b) where an increased number of round shape cells with high 
level of CD68 is found in PCL NPs treatment (a, arrows) compared to PCL Mino 
treated mice (b, arrowheads). CD68 (green); PCL or PCL-Mino, RhB (red); 
microglia, Iba-1 (blue). Scale bar=50 μm. (C) (a) Correlation analysis 
between CD68 staining and RhB signal, sampling single cells, at 3 DPI. A 
reduced correlation is evident for PLC Mino treated mice compared to PCL. This 
is represented by different linear regression slope between them suggesting 
an effect of minocycline in reducing the CD68 level in microglia/macrophages 
after PCL Mino uptake. (C, E) Quantitative analyses of CD68 staining 
respectively at 3 (C, b) or 15 DPI (E, b) show that a significant reduced 
staining of CD68 persists up to 15 DPI. (E, a) ELISA assay on spinal cord 
tissue homogenates shows a significant reduced level of cytokine IL-6 in the 
epicenter of the lesion in PCL Mino compared to PCL treated mice at 15 DPI. 
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Data are presented as mean±SD. Statistical significance: (*)p≤0.05, 
(***)p≤0.001. 
 
 
2.2.5 Discussion and Conclusions 
 
In this part of the work we characterized a PCL NPs delivery tool able to 
release, with a cell-specific targeting, a well-known anti-inflammatory 
drug (minocycline) in the activated microglia/macrophages. Specifically, 
the loading of PCL NPs with minocycline is able to reduce, in an 
inflammatory milieu in vivo, the activation and the proliferation of 
microglia/macrophages around the lesion site, turning them from a 
round shape phagocytic-like phenotype with high CD68 level to a more 
arborized resting phenotype with low CD68 staining. 
Round shape phenotype and increased high CD68 level were well 
characterized in different inflammatory milieu as markers for activated 
microglia/ macrophages, and a reduced expression of them is 
considered predictive of the efficacy of anti-inflammatory treatments. In 
addition, the treatment here proposed limits, up to 15 days tested, the 
pro-inflammatory stimuli associated with microglia/macrophages 
activation, as demonstrated by the reduced expression of the pro-
inflammatory cytokine IL-6 in traumatized site. 
Furthermore, the selective and specific treatment of the 
microglia/macrophages here proposed shows different advantages 
compared to the conventional anti-inflammatory administration: (I) a 
drug delivery nanocarrier capable of directly targeting and modulating 
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specific cells characterized by a pro-inflammatory phenotype during the 
subacute progression of the secondary injury in SCI; (II) a targeted 
delivery approach, as here proposed, is able to improve and maximize 
the therapeutic efficacy of anti-inflammatory compounds, by reducing 
the drug dose used in therapy and minimizing potential side effects; 
(III) a selective treatment in such a specific way represents a new 
potential tool able to modulate at different time during the secondary 
injury, with temporally defined NPs administration, the activation of the 
microglial cells, enhancing the beneficial role of the microglia during the 
progression of the disease.  
 
2.3. Evaluation of Minocycline-loaded PCL NPs 
efficacy in SCI mouse model 
 
2.3.1 Aims 
In order to demonstrate the increased efficacy of minocycline loaded in 
PCL NPs and to deeply understand the potential role of the 
inflammatory response related to activated microglia/macrophages and 
its contribution during the progression of SCI, a targeted in situ 
modulation of microglia/macrophages activation in SCI mouse model 
was carried out. In particular, different time points of treatment will be 
evaluated, in order to describe the detailed spatial and temporal 
changes of the pro-inflammatory response associated to 
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microglia/macrophages activation and their implication in injury 
progression. 
 
2.3.2 Behavioral evaluation of SCI mice treated with 
PCL Mino  
 
In order to evaluate the efficacy of the PCL Mino treatment at different 
time points during the inflammatory response, we performed in vivo 
experiments treating mice immediately after SCI (T0), 1 DPI (T1) or 7 
DPI (T7). Specifically, mice were subjected to SCI and randomly divided 
in 8 groups: untreated (INJ), treated with phosphate buffered saline 
(saline) at T0, treated with empty NPs (PCL) at T0, treated with both 
free Minocycline and empty NPs (Mino free) at T0, treated with 
Minocycline administered intraperitoneally (Mino IP) and treated with 
Minocycline loaded NPs (PCL Mino at T0, T1 and T7). Six injections were 
performed in the injury site with a glass capillary to deliver each 
treatment described above (Fig 3.1 A), except Mino IP. Behavioral 
assessment was performed weekly starting from 7 up to 63 DPI. 
Locomotor performance was assessed by Basso Mouse Scale (BMS, 
score 0 represents complete paralysis whereas score 9 complete 
mobility). A physiological recovery up to about 3 BMS score at 63 DPI 
was detected after an initial complete paraplegia (Fig 3.1 B and C). The 
microinjections of saline (saline) or empty NPs treatment (PCL) in the 
injury site did not modify the course of the SCI progression when 
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compared to the untreated (INJ) group up to 63 DPI (Fig. 3.1 B). 
Interestingly, when we analyzed PCL Mino T0 group (28 DPI 3.7±0.4, 
35 DPI 3.8±0.4, 42 DPI 4.2±0.4, 49 DPI 4.3±0.4, 63 DPI 4.3±0.4; 
mean±SEM), we detected a significant behavioral improvement 
compared to untreated INJ (28 DPI 2.3±0.3, 35 DPI 2.6±0.3, 42 DPI 
2.7±0.3, 49 DPI 2.9±0.2, 63 DPI 2.8±0.2; mean±SEM) and Mino free 
groups (28 DPI 2.2±0.4, 35 DPI 2.3±0.3; 42 DPI 2.6±0.3; 49 DPI 
2.7±0.3; 63 DPI 2.8±0.3; mean±SEM), that appears at 28 DPI and 
persists up to 63 DPI evaluated (Fig. 3.1 C). Contrarily, the delayed PCL 
Mino delivery (T1-T7) was not able to significantly improve behavioral 
functions when compared to untreated mice (Fig. 3.1 C). Altogether, 
these data suggest that PCL Mino efficacy following SCI decreases when 
delayed. Of note, the Mino IP treatment did not improve behavioral 
functions compared to the untreated INJ group (Fig. 3.1 C). 
 
 
 
 
 
 
 
 
 
 
A C B 
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Figure 3.1 An early treatment of activated microglia/macrophages with PCL 
Mino NPs ameliorates the behavioral outcome in SCI mouse model. (A) 
Cartoon representing microinjections of PCL Mino NPs encompassing 6 mm 
around the injury site. (B) (C) Different SCI mice were evaluated weekly 
starting from 7 days post treatment by Basso Mouse Scale (score of 0 
represents complete paralysis, score of 9 represents complete mobility 
referred to healthy mice): INJ (untreated), saline (treated with phosphate 
buffered saline), PCL (treated with empty NPs), Mino free (treated with both 
free delivered Minocycline and empty NPs directly injected into the injury site), 
Mino IP (treated with free delivered Minocycline intraperitoneally injected), 
PCL Mino T0 (treated with PCL Mino NPs injected some minutes after the 
mechanical damage), PCL Mino T1 (treated with PCL Mino NPs injected 1 day 
after the mechanical damage), PCL Mino T7 (treated with PCL Mino NPs 
injected 7 days after the mechanical damage). A significant improvement of 
locomotor performances in PCL Mino T0 treated mice is evident starting from 
28 DPI up to 49/63 DPI when compared to INJ (*), Mino free (§) or PCL Mino 
T7 (#) groups. (*, §, #) p≤0.05; (**, §§, ##) p≤0.01. Mean±SEM is 
reported. N=12. 
 
 
2.3.3 Evaluation of PCL Mino selective uptake in SCI 
mice 
 
In order to confirm the selective uptake of PCL Mino NPs in SCI mice, an 
ex vivo staining with markers for astrocytes (glial fibrillary acidic 
protein, GFAP), neurons (neuronal nuclei, NeuN) or oligodendrocytes 
(myelin basic protein, MBP) was performed, while microglia were 
detected by CX3CR1-GFP expression. At 3 DPI, an inflammatory 
reaction was detected in the injury site with an increased microgliosis 
(Fig. 3.2 A, green) compared to healthy mice (data not shown). 
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Furthermore, hypertrophic astrocytes were found around the lesion (Fig. 
3.2 A, c blue). In this inflammatory scenario a distribution of PCL Mino 
was found in and around the injury site, revealing a selective uptake of 
NPs in the nearest activated-phagocytic microglia (Fig. 3.2 A, d,h,l 
merged channels). A lack of colocalization between NPs and GFAP or 
NeuN or MPB was detected (Fig. 3.2 A, merged channels; Fig. 3.2 B). 
The selective uptake of RhB positive NPs by microglia was further 
confirmed by the colocalization analysis demonstrating a significant 
overlap between GFP and RhB signals, as demonstrated by positive 
Pearson's coefficient (range 0-1 from lack to complete merge) for GFP 
and NPs, whereas a lack of colocalization was detected for NPs and 
astrocytes or neurons or oligodendrocytes (Fig. 3.2 B).  
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Figure 3.2 (A) PCL Mino are selectively taken up by activated 
microglia/macrophages in vivo after intraparenchymal injections in the injury 
site. Representative high magnifications of the injury site after injection of PCL 
Mino NPs T0 at 3DPI. Images show a colocalization between PCL Mino NPs 
(RhB, red) (b, f, j, d, h, l) and CX3CR1-GFP positive microglia (GFP, green) 
(a, e, i, d, h, l), but not with astrocytes (GFAP, blue) (c, d) or neurons 
(NeuN, blue) (g, h) or oligodendrocytes (MBP, blue) (k, l), revealing a 
selective PCL NPs uptake by activated microglia. Scale bar=50 µm. 
A 
B 
                                           RESULTS 
169 
 
(B) Representative colocalization analysis by dot blot pixel (A,B,C; a,b) and 
Pearson’s coefficient (A,B,C; c) of spinal cord coronal sections of the injury 
site at 3DPI after injection of PCL Mino NPs T0. Pictures show a colocalization 
of NPs (RhB, red) (A,B,C; a, b, c) only with CX3CR1-GFP positive microglia 
(GFP, green, A,B,C; a, c), but not with astrocytes (GFAP, blue) (A; b,c) or 
neurons (NeuN, blue) (B, b,c) or oligodendrocytes (MBP, blue) (C, b,c). 
Mean±SD is reported. 
 
In order to further investigate the selective uptake of NPs by myeloid 
cells, we specifically evaluated both microglia and recruited 
macrophages capability to capture PCL at different time points after 
SCI. Six injections of PCL Mino were performed (Fig. 3.1 A) immediately 
after SCI (corresponding to the time point showing therapeutic effects) 
and both microglia and recruited macrophages were evaluated by FACS 
analysis at 1 and 7 DPI. To distinguish between the two cell 
populations, we performed a double labeling with CD11b and CD45 
antibodies, identifying microglia by a CD11bpos/CD45low signal and 
recruited macrophages by a CD11bpos/CD45high signal, according to the 
literature (Shechter 2013, Alexander 2009). In response to SCI, the 
amount of resident microglia increased very early at 1 DPI up to 7 DPI 
(data not shown). At variance, recruited macrophages were barely 
detected in the injury site at 1 DPI and peaked at 7 DPI (data not 
shown). Interestingly, PCL Mino uptake at 1 DPI was high in microglia 
cells while very low in recruited macrophages (Fig. 3.3 a). At 7 DPI PCL 
Mino (Fig. 3.3 b) were absent in microglial cells, due to the degradation 
as previously demonstrated both in vitro and in vivo, and still very low 
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in recruited macrophages (Fig. 3.3 b). Quantitative evaluation 
expressed as NPs uptake ratio between microglia and recruited 
macrophages confirmed the predominant RhB signal in microglial cells 
at 1 DPI (Fig. 3.3 c). 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 PCL Mino T0 NPs are taken up early by activated resident 
microglial cells in SCI mouse model. Representative biparametric flow 
cytometric analysis of spinal cord resident microglial cells (CD11bpos/CD45low) 
and monocytes/macrophages (CD11bpos/CD45high) evaluated at 1 (a) or 7 (b) 
DPI. Black dots represent the overall population of microglia and recruited 
macrophages positive for CD11b and CD45 markers. Red and blue dots 
represent, respectively, microglia or recruited macrophages that uptake PCL 
Mino NPs (RhB). (c) Quantitative evaluation of PCL Mino NPs uptake at 1 DPI, 
expressed as ratio of RhB positive microglia/RhB positive recruited 
macrophages at 1DPI. Mean±SD is reported.  
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2.3.4 Evaluation of microgliosis and macrophages 
recruitment after PCL Mino treatment in SCI mice 
 
 
We assessed by FACS analysis whether the administration of PCL Mino 
was able to modulate activated resident microglia and recruited 
macrophages in the injury site. The amount of CD11b/CD45 positive 
labeled cells was measured by FACS analysis in the injury epicenter. 
Mice treated with PCL Mino T0 and analyzed at 7 DPI (corresponding to 
the peak of microglia activation and recruited macrophages migration in 
the injury site in our model) showed a significant reduced amount of 
both microglia and recruited macrophages in the injury site (Fig. 3.4 b) 
compared to untreated INJ mice (Fig. 3.4 a), as demonstrated by dot 
plots (Fig. 3.4 a, b) and quantitative analyses (Fig. 3.4 c, d). These data 
highlight the ability of PCL Mino T0 treatment in reducing inflammation 
associated to microgliosis and macrophages infiltration. 
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Figure 3.4 An early treatment with PCL Mino inhibits microglia activation and 
macrophages recruitment in the injury site of SCI mice. Representative FACS 
dot plot analysis of spinal cord microglial cells (CD11bpos/CD45low) and 
monocytes/ macrophages (CD11bpos/CD45high) present in SCI epicenter of 
untreated injured (a) or PCL Mino T0 treated injured mice (b) evaluated at 7 
DPI. Quantitative evaluation of the percentage of CD11bpos/CD45low (microglia) 
(c) or CD11bpos/CD45high (recruited macrophages) (d) cells evaluated in 
untreated injured (INJ) or PCL Mino T0 treated injured mice (PCL Mino) at 7 
DPI. Mean±SD is reported. (*) p≤0.05. 
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2.3.5 Evaluation of M1/M2 subsets after PCL Mino 
treatment in SCI mice 
 
To evaluate whether the proposed treatment was able to modulate both 
M1 and M2 subsets in the injury site, FACS analyses were performed to 
detect the expression of the surface markers for M1 
(CD11bpos/CX3CR1low/Ly6Chigh) or M2 (CD11bpos/CX3CR1high/Ly6Clow) 
(Shechter 2013) phenotypes. Quantitative evaluation demonstrated an 
accumulation of both M1 and M2 cells in the epicenter of the lesion 
starting from 1 up to 7 DPI. Specifically, we detected an earlier 
accumulation of M1 subset in the injury site that reached a peak at 3 
DPI and decreased at 7 DPI (data not shown). On the other hand, a 
significant amount of M2 cells in the injury site peaked at 7 DPI (data 
not shown). This suggests the presence of an early migration of M1 
macrophages that partially decreased in favor of an M2 subset later on. 
Interestingly, PCL Mino T0 treatment (Fig. 3.5 A; b, c) significantly 
reduced the amount of M1 macrophages detected in the epicenter of 
the lesion at 7 DPI compared to untreated INJ mice (Fig. 3.5 A; a, c). 
This was also confirmed by a reduction of both IL-1β and TNFα (two 
well-known M1 markers) detected in the epicenter of PCL Mino treated 
mice at 3 DPI by respectively mRNA and ELISA techniques (Fig. 3.5 B; 
a, b). Furthermore, TNFα levels in the injury site after PCL Mino T0 
treatment remained comparable to the uninjured rostral portion 
(cervical tract) of the same mice analyzed in the epicenter (Fig. 3.5 B, 
b). Noteworthy, an M2 subset persisted in PCL Mino mice treated 
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immediately after SCI as demonstrated by the 
CD11bpos/CX3CR1high/Ly6Clow population detected in the epicenter of the 
lesion at 7 DPI (Fig. 3.5 A; a, b, d). Accordingly with a pro-regenerative 
milieu, mRNA evaluation in PCL Mino T0 treated mice demonstrated a 
significant augmented M2 transcripts of both Arg-I and YM1 at 3 DPI 
compared to untreated injured mice (Fig. 3.5 B; c, d). These data 
suggest that M2 phenotype cells were longer available compared to M1, 
thus fostering healing processes (Fig. 3.5 A, B). Contrarily, persistent 
M1 (TNFα mRNA) and M2 (Arg-I and YM1 mRNA) subsets were found in 
PCL Mino T7 treated mice evaluated 3 days after treatment (10 DPI) 
(data not shown).  
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Figure 3.5 M1 recruited macrophage population is reduced after an early 
PCL Mino treatment in SCI mouse model. (A) Representative FACS dot plot 
analysis of M1/M2 macrophagic cells present in the injured site of untreated 
injured (a) or PCL Mino treated (b) SCI mice and gated respectively as 
CD11bpos/CX3CR1-GFPlow/Ly6Chigh (M1, red) or CD11bpos/CX3CR1-
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GFPhigh/Ly6Clow (M2, blue) at 7 DPI. The percentage of M1 positive gated cells 
is significantly reduced in PCL Mino T0 treated mice compared to injured mice 
(c), whereas M2 subset is not significantly changed (d). (B) The quantitative 
analysis of mRNA or protein levels of M1 (IL1β, a and TNFα, b) or M2 markers 
(Arg-1, c and YM1, d) at 3 DPI confirms that PCL Mino T0 treatment is able to 
preserve and promote an M2 phenotype (c,d) and to reduce a pro-
inflammatory M1 macrophage population (a,b) when compared to untreated 
injured mice (INJ) (a, b, c, d). Mean±SD is reported, (*) p≤0.05, (**) 
p≤0.01.  
 
 
 
2.3.6 Evaluation of CCL2 levels in the injury site of PCL 
Mino treated SCI mice 
 
In order to evaluate potential chemoattractant stimuli that induce 
macrophages infiltration into the injury site, we investigated a specific 
chemokine CCL2 that is involved in proinflammatory M1 macrophages 
recruitment from the blood stream (Shechter 2013). In the ex vivo 
injured tissue, we observed a significant reduction of both mRNA and 
protein levels of CCL2 after PCL Mino T0 treatment (respectively 82.2 ± 
65.3 relative mRNA expression, mean±SD; 47.0±2.1 pg/mL, 
mean±SD) compared to untreated mice (respectively 138.0±81.4 
relative mRNA expression, mean±SD; 60.0±8.2 pg/mL, mean±SD) at 3 
DPI (Fig. 3.6 A; a, b).  Furthermore, no significant change for CCL2 
mRNA were measured after PCL Mino T7 treatment (data not shown), 
confirming that only a prompt anti-inflammatory treatment after SCI 
has a significant healing efficacy. 
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To confirm that a reduced migration of M1 monocyte/macrophages 
occurred after PCL Mino T0 treatment, we performed an in vitro 
chemotaxis assay. Specifically, macrophages were recruited from the 
peritoneal cavity and stimulated by TNFα+IFNγ (M1 polarization). The 
migration toward a reservoir containing conditioned media of: i) 
unstimulated microglia; ii) LPS+PCL pre-stimulated microglia; or iii) 
LPS+PCL Mino pre-stimulated microglia was assessed by COM (COM, 
Centre of Mass represents the spatial averaged point of all migrated 
cells) (Fig. 3.6 B; f). Noteworthy, conditioned media from LPS+PCL 
Mino treated microglia (Fig. 3.6 B; c, d) (COM 0.94±0.55 mm, 
mean±SD) was able to significantly slow down the migration of M1 
macrophages compared to LPS+PCL treatment (Fig. 3.6 B; b, d) (COM 
5.32±2.0 mm, mean±SD), here considered as a control. At variance, 
conditioned media from untreated microglia induced a limited M1 
macrophages migration (Fig. 3.6 B; a, d) (COM 0.22±0.08 mm, 
mean±SD). To further confirm that CCL2 was involved in the 
chemotactic response, we measured the CCL2 levels in the conditioned 
media by ELISA, and we found that PCL Mino treatment of LPS 
stimulated microglia significantly reduced the paracrine CCL2 release 
(860.9 ± 143.9 pg/mL, mean±SD) when compared to the treatment 
with LPS+empty PCL (1268.0 ± 407.3 pg/mL, mean±SD) (Fig. 3.6 B e). 
These results demonstrate that a reduced recall of pro-inflammatory 
macrophages via CCL2 occurs when Minocycline-containing PCL were 
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added, and that untreated microglia can orchestrate and exacerbate an 
additional inflammatory response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 (A) CCL2 mRNA and protein levels in untreated injured or PCL 
Mino T0 treated injured mice evaluated at 3DPI (a,b). A significant decrease 
of both mRNA and protein levels was detected in PCL Mino T0 group compared 
to untreated injured mice (a,b). Mean±SD is reported. (*)p< 0.05. (B) An 
early treatment with PCL Mino inhibits CCL2 mediated M1 recruited 
macrophage migration. In vitro chemotactic assay: M1 stimulated 
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macrophages migration was tested using conditioned media of untreated (non-
activated), LPS+PCL or LPS+PCL Mino treated microglia such as represented 
by the cartoon (f). Poor migration of M1 stimulated recruited macrophages 
occurs toward unconditioned medium or conditioned medium from non-
activated microglia (CTR, a, d). An increased migration has been observed 
toward conditioned medium from activated microglia treated with PCL (b, d). 
Treatment of activated microglia with PCL Mino decrease the migration of M1 
stimulated macrophages, as shown by representative migration plot (c) and 
quantitative evaluation of center of mass (COM) (d). Conditioned media of 
both LPS ±PCL or LPS±PCL Mino treated microglia were evaluated for CCL2 
protein levels showing a significant reduced amount of CCL2 in PCL Mino 
treated group (e). Mean±SD is reported. (*) p≤0.05. 
 
2.3.7 Evaluation of neuropathological outcome after 
PCL Mino treatment in SCI mice 
 
 
Motor function outcome after SCI is tightly correlated with white matter 
(myelin) sparing (Sundberg et al.; 2010) We thus analyzed the lesion 
size by using whole mount myelin staining with Light Sheet 
Fluorescence Microscopy (LSFM). LSFM is a recently developed 
technology (Dodt et al.; 2007) that allows the reconstruction of the 
three dimensional distribution of the fluorescent signals in a whole 
spinal cord, without the need of physical sectioning. This method 
provides a general overview of the expression of particular fluorescent 
markers inside the spinal cord, and allows an accurate quantification of 
the fluorescent signals. LSFM analysis showed a well-organized and 
preserved white matter in the epicenter of the lesion of PCL Mino 
treated mice (Fig. 7; b, c). This was confirmed by a more preserved 
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connection and continuity in the myelin staining in the cord detected by 
quantitative evaluation of the fluoromyelin labeling (Fig. 3.7; d). 
Differently, an extended lesion size was revealed in the epicenter of the 
lesion in untreated injured mice, suggesting an increased spread of the 
damage (Fig. 3.7; a, c, d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 An early treatment with PCL Mino preserves white matter in the 
injury site of SCI mouse model. Representative longitudinal section of spinal 
cord of untreated injured (INJ, a) or PCL Mino T0 treated injured (b) mice at 
63 DPI stained with fluoromyelin (myelin, green). Boxed regions represent the 
a b 
c 
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injury site. The LSFM analysis shows a more preserved myelin labeling in the 
injury site of PCL Mino T0 treated mice compared to untreated injured mice 
(a), as confirmed by the three-dimensional reconstruction (c) and by the 
quantification of the percentage of myelin volume preserved in the epicenter 
of the lesion (d). Scale bar=1 mm. Mean±SD is reported. (*) p≤0.05.  
 
 
 
2.3.8 Discussion and Conclusions 
 
The real contribution of the inflammatory response related to the 
activated state of microglia/macrophages during the progression of SCI 
is still debated. In this study, we used minocycline-loaded PCL NPs to 
pharmacologically restrain the inflammatory response associated with 
the microglia/macrophage activation. Many independent groups 
demonstrated that a range of doses of minocycline administered 
intraperitoneally (IP) or intravenously (IV) at different times from the 
injury (Festoff et al.; 2006, Teng et al.; 2004, Yune et al.; 2007) were 
able to ameliorate the behavioral outcome. Furthermore, it has been 
shown that minocycline treatment reduces the pro-inflammatory 
response associated with the activation of microglia/macrophages 
(Wells et al.; 2003). However, minocycline can act on many pathways 
(cytochrome C release, MAP kinase, oxidative stress) and cells within 
the nervous system (Teng et al.; 2004, Yune et al.; 2007). For these 
reasons, the direct effect on microglia remains purely speculative. 
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A controlled drug release through polymeric NPs as here proposed is 
also an innovative strategy to improve the knowledge of the role played 
by microglia during SCI repair overcoming the difficulties so far 
reported, namely: i) the unfeasibility to pharmacologically treat 
microglia in a selective way during SCI repair, ii) a limited drug efficacy 
potentially due to the widespread diffusion of the drug when 
administered by conventional delivery strategies (IP or IV), iii) a genetic 
manipulation approach that could include compensatory effects leading 
to misinterpretation of the involved mechanism (Wieghofer et al.; 
2015). On the basis of previous evaluations, it has been demonstrated 
that PCL NPs were selectively taken up by microglia exploiting the 
peculiar phagocytic activity of these cells. Furthermore, minocycline 
delivered by PCL was able to effectively deactivate microglia and reduce 
proinflammatory cytokine release. To extend the previous findings, this 
smart delivery tool has been used to analyze and clarify the temporal 
and spatial involvement of the inflammatory microglia response during 
SCI. First of all, it has been demonstrated that minocycline is able to 
directly act on microglial cells reducing their inflammatory response. In 
fact, given the minocycline delivery approaches previously proposed (IP 
and IV) (Festoff et al.; 2006, Teng et al.; 2004, Yune et al.; 2007), the 
direct target associated with the therapeutic response to the treatment 
has remained so far unknown and only speculative. Noteworthy, it has 
been demonstrated also that a very early PCL Mino selective treatment 
is able to significantly ameliorate the deterioration of the locomotor 
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performance after SCI. Specifically, we found that PCL Mino treatment 
administered in the early phase of the injury is able to efficiently 
modulate resident microglial cells, reducing the pro-inflammatory milieu 
for several days (up to 7 days after the primary injury). By FACS 
analysis, it has been demonstrated that minocycline loaded 
nanoparticles are almost exclusively taken up by microglial cells 1 DPI. 
Indeed, resident microglia, corresponding to the first pro-inflammatory 
cells activated in the spinal cord (Thawer et al.; 2013, Cohen et al.; 
2014, Raposo et al.; 2014, Beck et al.; 2012), are stimulated 
immediately after SCI and only when mice were treated immediately 
after injury with PCL Mino, is a significant improvement of behavioral 
outcome observed. This suggests that a dramatic effect is associated 
with the pro-inflammatory activation of the microglial cells in a very 
short time after the injury that, if not promptly deactivated, 
exacerbates the tissue damage. Noteworthy, macrophage recruitment is 
reduced after the early anti-inflammatory treatment by Minocycline, 
revealing that a selective modulation of the resident microglia has a key 
role in the recruitment of peripheral macrophages as demonstrated by a 
significant reduction of CD11bpos/CD45high cells in the epicenter of the 
injury. Recently, it has been demonstrated that M1 and M2 recruited 
macrophages reach the damaged site by distinct routes of migration 
(Shechter et al.; 2013). Specifically, M1 phenotype is recruited via 
spinal cord leptomeninges, whereas M2 commitment occurs through the 
passage of the choroid plexus (Shechter et al.; 2013). Furthermore, M1 
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and M2 show different waves of activation, with an early M1 migration 
in the injury site in the first days followed by M2 recruitment several 
days after SCI (Shechter et al.; 2013). A significant reduction of this M1 
pro-inflammatory phenotype (CD11bpos/ CX3CR1low/Ly6Chigh cells) in the 
epicenter of PCL Mino T0 treated mice has been observed by FACS 
analysis, whereas M2 phenotype (CD11bpos/ CX3CR1high/ Ly6Clow cells) 
remains in situ. In line with these results, reduced levels of both IL-1β 
mRNA and TNFα protein (M1 markers) were found at 3 DPI in PCL Mino 
T0 treated mice, concomitantly to an increase of both Arg-I and YM1 
mRNA (M2 markers), confirming a predominant pro-regenerative 
environment at this time-point. A reduced CCL2 level (a cytokine 
directly involved in the M1 recruitment) (Shechter et al.; 2013) has 
been observed in the injured site, suggesting that a reduced 
recruitment of M1 pro-inflammatory macrophages occurred in PCL Mino 
treated mice. Supporting this, we demonstrated by an in vitro 
chemotaxis assay that the migration of M1 pre-stimulated peripheral 
macrophages is significantly reduced toward PCL Mino treated compared 
to untreated microglia. The pro-regenerative environment established 
after PCL Mino T0 treatment could also explain the significant 
preservation of white matter in the injury site of treated mice (Doring et 
al.; 2015, Evans et al.; 2014, Guerrero et al.;  2012, Ma et al.; 2015). 
Indeed, thanks to the accurate evaluation of the entire volume of the 
injured site by using LSFM, a milder tissue damage has been observed 
in PCL Mino treated mice, represented by a significant preserved myelin 
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staining, compared to untreated animals. In conclusion, this thesis 
demonstrates that early activated microglia after SCI are an important 
mechanistic driver of SCI associated secondary injury. Furthermore, 
microglia inhibitory treatment delivered immediately after injury 
induces a significant long lasting recovery up to 63 days post SCI, 
confirming the relevant pro-inflammatory imprinting given by the 
activated microglia in the earliest stage of the degeneration in SCI. In 
addition, the pharmacological delivery by polymeric NPs presents 
important features, namely a selective drug delivery and a maximized 
pharmacological activity (anti-inflammatory effect) compared to other 
administration routes such as direct parenchymal or IP minocycline 
injection. In fact, we observed that an IP Minocycline treatment with a 
dosage frequently proposed in the literature (Wells et al.; 2003, Stirling 
et al.; 2004) was not able to significantly affect behavioral recovery 
after SCI in mice. Whereas a significant outcome improvement with 
only one timely administration of the drug loaded nanovector into the 
injured tissue was observed. In conclusion, the modulation of the pro-
inflammatory injured environment can promote reparative mechanisms 
and ameliorate the outcome after SCI. Indeed, the selective delivery of 
drugs through tailored biomaterials, as showed in this work, is a 
promising and innovative approach that may represent a breakthrough 
in manipulating microglia activation with potential beneficial impact on 
SCI. 
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1. OVERVIEW 
 
Improved pharmacological approaches for limiting the progressive 
tissue degeneration and neuronal dysfunction after an acute spinal cord 
injury are needed. The main focus of this thesis was the 
characterization of a pharmacological nanoparticle delivery tool able to 
treat selectively microglia/macrophages cells, key players in the 
inflammatory reaction that strongly characterized the SCI progression. 
Indeed, microglia are the first activated inflammatory cells in the site of 
spinal trauma, able to release pro-inflammatory stimuli and to attract 
macrophages from the blood stream. Recent findings have highlighted a 
dual role (detrimental or beneficial) related to different activated 
phenotypes of microglia/macrophages after the primary SCI: 
proinflammatory cells (M1) or anti-inflammatory/reparative cells (M2). 
Detrimental effects have been associated with the M1 cells such as 
production of many proinflammatory mediators including cytokines 
(IL1β, IL-6, and TNFα), reactive oxygen species, and inducible nitric 
oxide synthase. M1 phenotype results already activated in an early 
stage after the primary injury (minutes) with a sustained prolonged 
effect up to months. On the other hand, M2 cells exert protective effects 
in terms of tissue repair and resolution of inflammation with a 
temporally limited effect (some days after injury). It is well 
characterized that M1 subset is the most prominent activated 
phenotype during the progression of the trauma, suggesting that a lack 
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in resolving the inflammation is one of the major drivers in worsening of 
the secondary injury of SCI. This suggests that a long-term deactivation 
of microglial cells after the acute phase could be a promising strategy to 
counteract the detrimental contributing effect of a prolonged 
inflammatory response associated SCI. 
For this study, polymeric PCL NPs have been used and we demonstrated 
by in vitro and in vivo paradigms that PCL NPs are promising for the 
treatment of this specific cell population because they are internalized 
mostly by the activated form of microglia/macrophages. In particular, 
we proved that PCL NPs are captured exclusively by activated microglial 
cells in a short time (24-48 hours), thanks to their phagocytic activity of 
foreign bodies. PCL NPs are biocompatible and show a complete 
degradation by lysosomal activity after 6 days after microglial uptake. 
Polymeric nanoparticles, such as PCL NPs, are able to load drugs. 
Previously, different NPs were used and tested in SCI (Rossi et al.; 
2013) and have been used to deliver compounds directly in microglial 
cells (e.g. Qdot nanocrystal, Minami et al.; 2012) but they present low 
specificity to activated microglia and great limitation with the capability 
to link chemically compounds, restricting this approach to a scantly 
number of drugs. This property makes PCL NPs an ideal 
pharmacological carrier for the selective treatment of activated 
microglia/macrophages with anti-inflammatory drugs. Among them, 
minocycline is one of the most promising drug with a direct active effect 
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on microglial cells. Their anti-inflammatory effects are mostly 
associated with the suppression of microglia/macrophages proliferation 
and activation. 
PCL Mino were tested in an in vivo inflammatory context (hydrogel 
intraparenchymal injection) and demonstrated to be able to modulate 
the activation and the proliferation of microglia/macrophages around 
the injection site, up to 15 days tested, turning them from a round 
shape phagocytic-like phenotype with high CD68 level to a more 
arborized resting phenotype with low CD68 staining.  
These results demonstrate that these polymeric NPs can supply 
optimized specific targeting of activated microglia/macrophages, in vivo, 
and can release an anti-inflammatory drug (minocycline) in situ. This 
represents a proof of concept of the possibility to exploit this new drug 
delivery tool for specifically modulating activated 
microglia/macrophages and the associated proinflammatory events in a 
SCI context. 
To better understand the importance of inflammation and in particular 
the specific role of activated microglia/macrophages during SCI 
progression, we perform spinal cord intraparenchymal injection of PCL 
Mino in SCI mice. The in situ delivery approach as here proposed is able 
to improve and maximize the therapeutic efficacy of minocycline, by 
reducing the drug dose used in therapy and minimizing side effects. In 
addition, an in situ treatment is able to overcome BSCB limitations, 
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which occurs with other traditional route of administration. SCI 
inflammation is a temporally well-defined process, which could have 
beneficial or detrimental effect in different time of SCI progression. A 
specific modulation of pro-inflammatory cells (microglia/macrophages) 
could be useful to understand the spatial and temporal changes of 
inflammatory response associated to these cells population and their 
implication in injury progression. 
In this prospective, we tested different times of PCL Mino treatment in 
SCI mice, starting immediately after mechanical trauma (T0), up to 7 
days post injury (T7). 
We demonstrate that minocycline-loaded NPs treatment is able to 
modulate the inflammatory milieu specifically targeting activated 
microglia and leads to a significant and persistent amelioration of the 
behavioral outcome only when acutely administered (T0) after SCI. This 
amelioration of behavioral outcome is observed up to 63 DPI, 
confirming the relevant role of activated microglial cells in the first 
phases of secondary injury. 
We therefore show that an early modulation of the pro-inflammatory 
microglia by minocycline-loaded NPs is able to skew toward a reparative 
environment the injured tissue, preserving M2 microglia/macrophages 
phenotype while decreasing M1. Furthermore, we provide a mechanistic 
link between early microglia activation and M1 macrophages 
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recruitment via CCL2 that can be mitigated by acute delivery of 
minocycline-loaded NPs following SCI.  
 
2. GENERAL CONCLUSIONS 
SCI inflammation is one of the most important deleterious mechanisms 
involved in the secondary injury. In particular, microglia and 
macrophages are the most involved cells in this process but their 
specific role have never been elucidated because of the difficulties to 
selectively treat them. 
In this study we used PCL NPs loaded with a well-known anti-
inflammatory drug (minocycline) to understand the specific role played 
by these cells in the inflammatory process. Our results indicate that 
resident microglia, the first pro-inflammatory activated cells in the 
spinal cord after SCI, are strongly associated with the exacerbation of 
inflammatory reaction and the subsequent macrophages recruitment, 
playing a crucial role in the orchestration of the SCI inflammatory 
response. Indeed, we demonstrated that a selective microglia treatment 
with minocycline-loaded PCL NPs, only when administered immediately 
after injury before macrophages infiltration, reduces the pro-
inflammatory response, maintains a pro-regenerative milieu and 
ameliorates the behavioral outcome up to 63 days post injury.  
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These results demonstrate that the selective delivery of drugs through 
tailored biomaterials, as showed in this work, is a promising and 
innovative approach that may represent a breakthrough in manipulating 
microglia activation with potential beneficial impact on SCI. Moreover, 
these data suggest that the identification of the best time to act against 
inflammatory response has a great importance in designing therapeutic 
strategies to counteract inflammation after SCI. 
In addition, other diseases may also respond to such treatment. In fact 
many central nervous system diseases show microglia/macrophage 
inflammatory response, such as multiple sclerosis, Alzheimer's disease, 
Parkinson disease, amyotrophic lateral sclerosis, prion's disease, and 
epilepsy. Furthermore, this delivery strategy may be considered for 
other potential drugs such as molecules potentially able to induce a shift 
from M1 to M2 phenotype, leading to beneficial effects after the 
inflammatory response. Moreover, the approach here proposed, which 
is able to treat selectively inflammatory cells using biodegradable 
nanoparticles with a well-known drug (minocycline) used in different 
human pathologies (antibiotic activity), opens a new translational 
avenue to the inflammatory and pain treatment in SCI patients. 
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3. FUTURE PERSPECTIVES 
Many preclinical studies have been proposed to find potential 
treatments for SCI. Unfortunately, many of them showed no relevant 
efficacy when translated to clinical trials (Rabchevsky et al.; 2011, 
Hawryluk et al.; 2008). A possible reason could be that most strategies 
proposed have used treatments directed toward a single 
pathophysiological mechanism and only few attempts to find effective 
combination therapies (neuroprotective and neuroregenerative) were 
carried out to improve the outcome (Kwon et al.; 2011, Tetzlaff  et al.; 
2011). Other reasons could be associated with the confined 
pharmacological treatment of a conventional drug administration, 
mainly due to the low concentration achieved in CNS (for BSCB 
restrictions) and/or potential unacceptable side effects of prolonged 
treatments. Consequently, new efforts are directed to develop 
innovative strategies to combine different treatments and drug delivery 
tools, to overcome BSCB or to perform effective drug delivery directly in 
SC parenchyma. A combined approach by using smart biomaterials 
(e.g., multipolymeric approach using NPs) could represent today’s new 
frontiers of a tailored delivery solution to control and progressively 
release different drugs in either CSF or SC parenchyma. Several recent 
studies have investigated these aspects trying to combine the 
advantages of biomaterials delivery systems for multitherapeutic 
treatments: methylprednisolone (Kim et al.; 2009), antibodies 
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(Stanwick et al.; 2012) and growth factors (Piotrowicz et al.; 2006) 
were incorporated in NPs and then loaded into hydrogels to provide a 
sustained release into the final target tissue, aiming at increasing 
medical recovery chances.  
In this perspective, an early modulation of pro-inflammatory microglia 
as obtained in this work could be combined with other 
neuroregenerative treatments, in order to define a multi-therapeutic 
approach able to counteract the different mechanisms that characterize 
secondary injury. 
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